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ABSTRACT
Current scientific literature has shown that: 1) NO is a pro-ovulatory agent
and inhibition of its production inhibits ovulation, and 2) NO has strong antisteroidogenic activity, especially on estradiol (E 2) production by granulosa cells.
The experiments described in this dissertation were designed to answer the
following questions involving effects of NO on ovarian physiology: 1) is the
inhibitory effect of nitric oxide synthase (NOS) inhibitors on ovulation irreversible
(follicular atresia) or temporary (delayed ovulation)? and 2) what is the
relationship between NO and hCG-induced preovulatory luteinization?
Accordingly, cycling mares were subjected to treatment with NOS
inhibitors (L-NAME or aminoguanidine) during estrus. Results showed that
administration of NOS inhibitors temporarily inhibited hCG-induced ovulation for
up to 5 d. Using a similar experimental approach, Holstein cows treated with
L-NAME had delayed ovulation and an attenuated post-ovulation rise in plasma
progesterone (P4) concentration. In a subsequent experiment, analyses of
follicular fluid from mares in estrus showed that NO concentrations were
increased after hCG administration. Furthermore, equine and bovine granulosa
cell cultures treated with NOS inhibitors showed that inhibition of NOS activity in
vitro luteinization as evidenced by decreased P4.E2 ratios. Pharmacokinetic and
hemodynamic parameters associated with L-NAME administration in horses
demonstrated that L-NAME has a short half life (3.6 min) as opposed to its major
metabolite L-NNA (19.5 h).
The results of these experiments demonstrated that: 1) administration of
NOS inhibitors delayed ovulation in mares and cows; 2) intrafollicular production
of NO was up-regulated following hCG administration; 3) inhibition of NO
prevented preovulatory follicular luteinization and in vitro luteinization of
granulosa cells; 4) both nonspecific and iNOS-specific inhibitors caused
significant effects both in vivo and in vitro and 5) L-NAME has a short half life in
horses and L-NNA is a major metabolite with a relatively long half life. Finally,
these

results will contribute to designing pharmacological therapies for

manipulating ovarian function for experimental or therapeutic purposes. Future
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studies investigating the involvement of NO with preovulatory luteinization will
likely contribute to the understanding of ovarian dysfunction, such as cystic
ovarian syndrome or unruptured luteinized follicles. These conditions affect both
animals and humans.
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CHAPTER 1
LITERATURE REVIEW/INTRODUCTION
HISTORICAL PERSPECTIVE
The name Alfred Nobel likely sounds familiar to many people worldwide,
but few probably would remember or know who Ascanio Sobrero (1812-1888)
was. Sobrero, an Italian chemist, was born in Casale Monferrato and initiated his
studies in medicine but changed to chemistry. He worked as a chemistry teacher
at the University of Turin and at the Application School for Engineers. In 1846
Sobrero discovered a powerful chemical obtained from the addition of glycerin
into a cooled mixture of nitric and sulfuric acids. The chemical was the nitric acid
triester of glycerol called glyceryl trinitrate; however, it is commonly referred to as
nitroglycerin. The liquid was as powerful as it was unstable and the slightest
motion would trigger its explosion. Sobrero, after being indirectly responsible for
several explosion-induced injuries (some that were fatal) to the people working in
his laboratory, including himself, deemed nitroglycerin too dangerous to be safely
handled and abandoned any further research on that chemical (Sohlman and
Schuck, 1929). Curiously, he found that a small amount of nitroglycerin in contact
with oral mucosa would cause headaches that would last for hours.
Alfred Bernhard Nobel (1833-1896) was born in Stockholm, Sweden but
obtained his education in St. Petersburg, Russia. After his return to Sweden, he
became interested in researching ways to stabilize and handle nitroglycerin. The
work was done in his father’s nitroglycerin factory and it was not until after many
incidents (explosions) that Nobel, serendipitously, found a way to handle,
transport and use nitroglycerin. One day, a small amount of nitroglycerin dropped
from the bench where Nobel and his workers were working and, to their surprise,
nothing happened. Astonishingly, Nobel noticed that the highly volatile explosive
fell into a box containing a fine porous powder called kieselguhr (Sohlman and
Schuck, 1929). Kieselguhr is an unconsolidated form of diatomite or silicacomposed shells of microscopic unicellular aquatic plants (algae). Kieselguhr is
heat resistant and has been used as an insulator. Because it has abrasive
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properties, kieselguhr is used as a component in toothpaste and in metal
polishes. In the chemical industry, it is also used as a filter to clarify syrups and
sugar and as a filling material in paper, paints, ceramics, soap and detergents.
The mixture of nitroglycerin and silica was pasty and malleable. Nobel called his
discovery dynamite for which he received a patent in 1867. This discovery was
the landmark of a successful career as an entrepreneur and the foundation of his
wealth (Sohlman and Schuck, 1929; Fant, 1991).
Alfred Nobel, a pacifist by nature, naively did not predict that his invention
would do more than be used in road constructions. Disappointed for the potential
use of dynamite in wars, Nobel left in his will a 9 million dollar funding to award
outstanding developments and discoveries that would benefit humanity and
foster peace around the world. Thus was created the Nobel Prize, the most
honored award in the world in the areas of Physics, Chemistry, Physiology and
Medicine, Literature, and Peace (Fant, 1991).
Alfred Nobel constantly had health problems during his entire life and late
in his life he suffered from angina pectoris, a heart condition marked by
paroxysms of intense chest pains. In 1867, a British physician named Brunton
found that organic nitrates could be used to ameliorate the painful signs of
angina pectoris. Later in 1879, William Murrel started to use nitroglycerin for
angina pectoris. Alfred Nobel was surprised when in 1890 his physician
prescribed nitroglycerin to treat his heart problem. Nobel refused to be treated
with such a chemical and confided to a friend:
“...isn't the irony of fate that I have been prescribed nitroglycerin, to be
taken internally! They call it Trinitrin, so as not to scare the chemist and
the public...” Alfred Nobel, 1892.
Despite his initial reluctance, Nobel finally agreed to follow his doctor’s
recommendations before his death in 1896.
One hundred years later, in 1977, a pharmacologist at the University of
Texas at Houston, Ferid Murad noted that nitroglycerin had the ability to cause
the release of nitric oxide (NO) in the body (Katsuki et al., 1977). A year later, it
was reported that biosynthesis of nitrite and nitrate occur in humans, regardless

2
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of whether nitrate ingestion was low or high (Tannenbaum et al., 1978; Green et
a/., 1981). Later, in 1980, another researcher at the State University of New York,
Robert Furchgott, reported that endothelial cells played an important role in the
vasodilatation and relaxation of arteries induced by acetylcholine and other
muscarinic agents (Furchgott and Zawadzki, 1980). The vascular relaxation was
shown to be mediated by a highly labile and diffusible agent derived from the
endothelium that, being unidentified at that time, was called endothelium-derived
relaxing factor (EDRF).
Finally, in 1987, Louis Ignarro, a pharmacologist at the University of
California, identified NO as being the long-sought EDRF produced and released
by arteries and veins (Ignarro etal., 1987). It then became easily understood how
the NO-releasing nitrate (nitroglycerin) invented by Ascanio Sobrero would bring
relief to people suffering from angina pectoris. Nitroglycerin causes relaxation of
smooth muscle, therefore causing systemic vasodilatation of both venous and
arterial vascular beds (Dinerman et al., 1993). In the venous vascular system,
nytroglycerin dilates post-capillary vessels and large caliber vessels that promote
peripheral pooling of blood (Palmer et al., 1987; Palmer et al., 1988). The net
result is a decreased venous return to the heart, causing a net reduction of the
end-diastolic pressure in the left ventricle (preload) that contributes to lowering
systemic

blood

pressure.

Dilatation

of

peripheral

arteries

induced

by

nitroglycerin-derived NO reduces systemic vascular resistance and arterial
pressure (afterioad) that leads to lower systemic blood pressure. Both
nitroglycerin-derived NO effects on venous and arterial vessels result in
decreased myocardial oxygen consumption. Because of all these effects,
nitroglycerin is able to reduce systolic, diastolic and mean arterial blood
pressures.
The discovery that NO was the EDRF (Ignarro et al., 1987; Palmer et al.,
1987) was received enthusiastically by the scientific community and triggered a
great deal of research worldwide to unravel the myriad of physiological and
pathological processes that NO could possibly be involved in. As a result, NO
has been implicated as a major cell-signaling molecule involved in processes

3
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such as vascular tone (Palmer et al., 1988), neurotransmission and immune
responses associated with viral (Evans et al., 1994), bacterial (Stuehr et al.,
1985) and parasitic aggression (Evans et al., 1993a; Garcia et al., 1999). As a
result, it was discovered that NO not only activates guanylate cyclase but also
has a role in regulating the function of enzymes of the cytochrome P450
(CYP450).
Accordingly, NO was implicated in several biological processes in virtually
any tissue in the body and is probably the most versatile known mediator of
biological processes in the body. Nitric oxide was found to participate in major
physiological and pathophysiological processes such as vascular dilatation,
control of basal systemic blood pressure, immune responses to infectious agents
and parasites (Burgner et al., 1999). Memory and learning centers in the central
nervous system are also thought to be modulated by NO. Nitric oxide was
acclaimed in 1992 the “Molecule of the Year” by D. E. Koshland Jr., Editor for the
scientific journal Science, in recognition of thousands of articles that had been
published on the biology and biochemistry of NO (Koshland, 1992). The
recognition of the importance of NO research culminated when, finally, Murad,
Furchgott and Ignarro were rewarded in 1998 and received the Nobel Prize for
their independent work showing that NO was, in fact, EORF. Ascanio Sobrero
would probably be gladdened to know that his invention after all is being used to
treat medical conditions and more importantly, to know that nitroglycerin was
pivotal in inciting the work that resulted in identifying NO as one of the most
versatile cell-signaling molecule.
Along with scientists working in vascular and neuroendocrinology areas,
reproductive biologists also launched intensive research investigating possible
NO-mediated phenomena in the male and female reproductive system. The
outcome of this intensive investigation by several laboratories was that NO was
found to

participate

in several processes regulating

male

reproductive physiology through mechanisms involving the

and female
hypothalamic-

hypophyseal-gonadal axes (McCann and Rettori, 1996b) and other sex organs,
such as the penis (Burnett, 1992; Penson et al., 1997), accessory sex glands
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(Farnsworth, 1999; Grozdanovic and Goessi, 1999), uterus (Rosselli et al.,
1998), uterine tubes (Rosselli et al., 1994b; Rosselli et al., 1996), cervix
(Buhimschi etal., 1996; Tschugguel etal., 1999) and vagina (Al-Hijji etal., 2000).
NITRIC OXIDE BIOSYNTHESIS
Nitric oxide (nitrogen monoxide) is a simple gas molecule, lipophilic, highly
diffusible and with an ultra-short half life when in an aerobic environment. The
NO molecule is composed of one atom of nitrogen and one atom of oxygen
bound by a double bond. The oxygen and the nitrogen atoms have two pair and
one pair of non-bonding electrons, respectively. The NO molecule does not have
a net charge despite its odd number of electrons, which results in it having an
atomic number only different from O 2. It has, however, a molecular polarity
represented by a negative charge on the oxygen atom and a positive charge on
the nitrogen atom.
The presence of an extra electron in the outer shell of the nitrogen atom
makes this molecule a free radical. A free radical is a single, unpaired electron
that is found in the valence or outer shell of an atom. Free radical molecules are
highly reactive because they always seek to find another electron to complete the
space in the outer shell. These molecules dynamically respond to changes in the
surrounding magnetic field, and thus, are named paramagnetic (molecules that
contain unpaired electrons). Accordingly, the NO molecule simply and constantly
seeks to fulfill the octet rule to become a lower energy species. The seemingly
ubiquitous involvement of NO in most biological actions in diverse tissues is due
greatly to its paramagnetism (Stamler et al., 1992). Paramagnetism is not an
exclusive characteristic of molecules with an odd number of electrons like NO.
Diamagnetic molecules (with an even number of electrons) can also have
paramagnetic properties as they may have two orbitals with unpaired electrons.
For example, the dioxygen molecule (0 2) has two unpaired electrons in two
different orbitals. Paramagnetism makes NO inherently unstable because
paramagnetic molecules tend to react with surrounding molecules to become
stable. NO is, therefore, a free radical.

5

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

There are two primary ways that NO molecules become stable: 1) reacting
with oxygen species and 2) reacting with transition metal ions. Reaction with O 2
in aqueous solutions produces relatively unreactive and stable products, such as
nitrate (NO3) and nitrite (NO2) ions. Conversely, a very reactive and toxic
product is generated from the reaction of NO with superoxide (O 2 ), the
peroxynitrite (O NO O ), which in turn rapidly generates additional highly reactive
and seemingly toxic intermediates (Beckman et al., 1990; Beckman and Crow,
1993). Peroxynitrite is not a free radical but is highly reactive and participates in
several reactions, including oxidation of sulfhydryls and lipids, and nitration of
tyrosine groups in proteins. Peroxynitrite also rapidly reacts with carbon dioxide
to produce the highly reactive nitrosoperoxycarbonate anion adduct, which has
been implicated as a critical mediator of oxidative injury derived from the reaction
of NO and O 2*.
For most metal ions in biological systems the orbitals are only partially
occupied and therefore available for pairing with elements having an unpaired
electron. NO reacts also with transition metal ions to become stable. Iron is a
suitable candidate for binding with NO because it is the most ubiquitous metal ion
in mammalian cells and participates in important biological processes involving
oxidation-reduction reactions. Iron has been shown to be essential for cell
survival for virtually any organism (Aisen et al., 2001) The amount of energy that
separates the five orbitals that contain the five (Fe+3) or six (Fe+2) electrons on
the iron atom is relatively small. These characteristics make iron an important
target for binding to and reacting with NO. The two main forms of iron in cells are
heme and non-heme iron, which bind to NO. Heme-containing proteins such as
hemoglobin, myoglobin and CYP450 enzymes are

0 2 -binding

substrates. The

NO molecule is very similar structurally to O2 and therefore is also highly reactive
in the presence of these proteins. Iron is also found in non-heme proteins, such
as the iron-sulfur protein clusters that are essential for the transfer of electrons in
the mitochondrial electron transfer chain.

6
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NITRIC OXIDE SYNTHASE ENZYMOLOGY
NO is formed from the amino acid substrate L-arginine in the presence of
O 2 and NADPH. The reaction is governed by a group of enzymes known
collectively as nitric oxide synthases (NOS). Nitric oxide synthases catalyze the
5-electron oxidation of the terminal guanidine nitrogen of the amino acid
L-arginine into NO and citrulline in the presence of 0 2 and NADPH-derived
electrons. It has not been reported whether the citrulline molecule formed is in
l-

or d / l - form (Alderton et al., 2001). The regulation and biological activation of

NOS have been shown to be either calcium (Ca2*)/calmodulin (CaM)-dependent
or independent (Moncada et al., 1991). The Ca2+- and CaM-dependent isoforms
are

constitutively

expressed;

whereas,

the

expression

of the

calcium-

independent isoform is induced. This complexity of NOS regulation accounts for
the multitude of biological actions of NO, which include, in addition to the control
of vascular tone, acute and inflammatory reactions. Two constitutive isoforms
were originally identified in the brain and endothelial cells and were designated
neuronal (nNOS) and endothelial (eNOS) isoforms, respectively; the inducible
isoform (iNOS) was associated mainly with macrophages (Abu-Soud et al.,
1995).
Three genes encoding for the two constitutive (Bredt et al., 1991) and one
inducible NO isoforms have been cloned (Charles etal., 1993; Baek etal., 1993).
There is a high degree of homology among the NOS isoforms (50-60%) and an
even higher degree of genetic conservation for the same isoform when examined
in different species (85% for iNOS and 95% for nNOS and eNOS; Geller et al.,
1993). A numerical nomenclature for the NOS isoforms has been proposed:
NOS-1, NOS-2 and NOS-3 for nNOS, eNOS and iNOS, respectively. The
numerical sequence of this classification refers to the order the genes for each
isoform were cloned. The numerical nomenclature has several advantages
because all three isoforms have been found to be expressed in tissues other
than those originally described (Forstermann etal., 1994).
Moreover, both constitutive isoforms can be induced in some tissues and,
similarly, the inducible isoform can be constitutively expressed in others
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(Forstermann et al., 1998; Aiderton et al., 2001). For example, the constitutive
nNOS isoform expression can be induced by heat, electrical stimulation, light
exposure and formalin (Forstermann et al., 1998). The expression of the other,
constitutive isoform, eNOS, can be up-regulated by shear stress, exercise
training,

hypoxia,

growth

factors

and

down-regulated

by

hypertension,

lipopolysaccharide and increases in cyclic AMP (Forstermann etal., 1998).
However, in this dissertation I will use the terminology suggested by the
International Union of Pharmacology Committee on Receptor Nomenclature and
Drug Classification, which recommends: nNOS for the isoform originally found in
neuronal tissue; eNOS for the isoform originally found in endothelial cells; and
iNOS for the isoform originally found in macrophages after being induced by
stimuli such as endotoxin, liposaccharides, cytokines and microbes (Moncada et
al., 1997).
The complex and diverse action of NO as a cell-signaling molecule
derives from the similarly complex molecular regulation of the NOS isoforms
(Bredt et al., 1992). This regulation is critical to controlling the production and
release of NO

in mechanisms involving homeostasis and response to

immunopathological stimuli. In general small amounts (picomoles) of NO are
associated with expression of constitutive isoforms, whereas, relatively large
amounts (nanomoles) of NO are released following the expression of iNOS.
Prosthetic groups for NOS isoforms include flavin adenine dinucleotide (FAD),
flavin

mononucleotide

(FMN)

and

heme,

whereas

the

co-factor

is

tetrahydrobiopterin (BH4). Tetrahydrobiopterin is an essential cofactor for the
NOS isoforms ability to bind L-arginine (Gross and Levi, 1992). In the absence of
BH4, NOS isoforms transfer electrons to oxygen to produce the toxic free radical
0 2‘ (Pou etal., 1992).
In addition to the substrate L-arginine, the reduced form of nicotine
adenine dinucleotide phosphate (NADPH) and 0 2 also serve as substrates for
NOS catalytic activity and subsequent NO production (Griffith and Stuehr, 1995).
The activity of NOS is significantly enhanced in the presence of reduced thiols,
such as P-mercaptoethanol or glutathione. The complex Ca2+/CaM reversibly

8
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activates the constitutive isoforms nNOS and eNOS; whereas, the iNOS binds
tightly and irreversibly to CaM and, therefore, its activation is Ca2+-independent.
However, CaM binding is required for activity of all NOS isoforms (Su et al.,
1995). Once activated, NOS isoforms use NADPH to catalyze the 5-electron
oxidation of L-arginine to form citrulline and NO in the presence of O 2 . The
electrons required for this two-step reaction flow from NADPH to the FAD, then to
the FMN, and lastly to the heme iron atom. The binding of CaM to NOS regulates
the flow of electrons from the FMN to the heme iron atom, making this region a
site for the Ca2+-dependent regulation of the constitutive NOS isoforms.
Three well-defined domains are necessary for the catalytic activity of NOS
isoforms. Arranged from the COOH-terminus to the NH2-terminus are a
flavoprotein reductase domain, a CaM recognition sequence binding domain and
an oxygenase domain. The reductase domain contains the FAD and FMN
moieties and shares extensive genetic homology with enzymes of the CYP450
reductase group. This domain transfers electrons from NADPH to the oxygenase
domain. The oxygenase domain is highly conserved between isoforms and
across species (amino acid homology sequence ranging from 56% to 87%). This
domain is the one that actually catalyzes the conversion of L-arginine into
citrulline and NO. It is also the oxygenase domain that contains the binding sites
for the heme, tetrahydrobiopterin and arginine. All NOS isoforms contain a CaM
recognition sequence between the oxygenase and the reductase domains. This
sequence is also highly conserved among species (100%, 94% and 91%
homology for nNOS, eNOS and iNOS, respectively) but less conserved among
isoforms (32 to 60% homology reported for humans; Cho et al., 1992).
The characteristics of the enzymology of the NOS isoforms determine the
biological functions of NO derived from each of these NOS isoforms (Table 1.1).
Transcriptional, pre-translational and post-translational regulations of catalytic
activity of NOS isoforms differ from each other. Isoform-specific domains
determine the localization of NOS inside the cellular compartment and are
directly related to the specificity of NOS expression.

9
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Table 1.1

Characteristics of the enzymology of the nitric oxide synthase isoforms
nNOS

iNOS

eNOS

Numerical nomenclature

NOS-1

NOS-2

NOS-3

Expression

primarily constitutive

primarily induced

primarily constitutive

Originally found

brain tissue

macrophage

vascular endothelium

Subcellular localization

soluble and particulate

soluble and particulate

primarily particulate

Primary biological function

neurotransmitter

cytoxicity (host defense)

vascular tone

Number of amino acids

1433

1153

1203

Subunit size (kDa)

160

130

135-140

Ca2+ dependence

yes; reversible

no

yes; reversible

Calmodulin dependence

yes; reversible

yes; tightly bound

yes; reversible

BH4 affinity

100-400 nM

30-100 nm

~

Splice variants

yes

yes

yes

100

nm

The nNOS isoform is expressed in the central and peripheral nervous
system as well as in skeletal muscles. In the central nervous system (CNS),
nNOS catalytic activity is related to long-term regulation of synaptic transmission,
acting as a neuromodulator of important neurologic functions such as sexual
behavior (Hull etal., 1994), learning and memory (Rose, 2000).
In the

peripheral nervous system

(PNS)

NO

acts mainly as

a

neurotransmitter in nitrergic nerves, participating in smooth muscle control,
gastrointestinal motility and

neuroendocrine functions. Although originally

described only as a constitutive isoform that is developmentally regulated, nNOS
expression can be up-regulated (induced) by certain pathophysiological stimuli
such as nerve injury, cerebral ischemia (Coert et al., 1999) and other
inflammatory conditions of the nervous system (Samdani et al., 1997).
Thus, production of nNOS-derived NO above physiologic concentrations
mediates neuronal injury during acute periods of cerebral vascular dysfunction as
well as neurodegeneration in more chronic conditions such as Parkinson’s
disease (Przedborski et al., 1996), Huntington’s disease (Bredt, 1996) and
amyotrophic lateral sclerosis (Sasaki et al., 2001). Because the nervous system
is extremely susceptible to cell injury upon an insult, nNOS-reguiated production
of NO must be at the site of biological action. The primary form of nNOS
activation and regulation is through the binding of CaM to the nNOS that occurs
in response to increases in the intracellular concentrations of Ca*2 (Bredt and
Snyder, 1990; Christopherson and Bredt, 1997).
The nNOS has a unique regulatory region in its sequence, which is a 300
amino acid sequence at the NH 2-terminus (Wang et al, 1999). This domain
contains a PDZ (protein-recognition regions) motif that binds to several other
proteins and directs nNOS to sites of signal transduction. The PDZ recognition
region makes nNOS longer than the other NOS isoforms. In neuronal tissues, the
influx of Ca2+ triggered by NMDA receptors induces nNOS catalytic activity. The
activation of nNOS occurs through the binding of the nNOS PDZ binding motif
with PDS-93 and PDS-95. Then, the complex PDZ-PDS-93-PDS-95 binds to the
NMDA receptors. The NH2-terminus of nNOS also contains a binding site for the
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widely and highly expressed 89-amino acid protein called PIN (protein inhibitor of
NOS). The binding of PIN with nNOS causes inhibition of nNOS catalytic activity
by promoting monomerization of nNOS.
The constitutive isoforms (nNOS and eNOS) have a much higher
requirement for activation than iNOS. In addition, nNOS and eNOS have 40-50
amino acid inserts in the middle of the FMN-binding sub-domain, which has been
described as an auto-inhibitory loop. It has been shown that the function of this
“loop” is to destabilize CaM binding at low concentrations of Ca2* and by
inhibiting electron transfer from FMN to the heme in the absence of Ca2+ and
CaM. Phosphorylation also regulates the activation of nNOS and eNOS. For
example, phosphorylation of eNOS at Ser1179 increases NO production, whereas
phosphorylation of nNOS at Ser847 decreases the production of NO. More
recently, the molecular chaperone heat shock protein 90 has been reported to
regulate eNOS catalytic activity by allosteric modulation.
O f the three isoforms, eNOS is the only one that is acylated by both
satured fatty acids myristate and palmitate (Michel
phenomenon

accounts

for

eNOS

being

et al.,

primarily

1997). This

membrane-bound.

Palmitoylation is a dynamic and reversible process regulated by agonists such as
bradykinin, which modifies intracellular concentrations of Caz* and serves to
stabilize the association of eNOS with the plasma membrane. Palmitoylation of
eNOS is reversible and it may be related to regulation of eNOS activation. In
contrast, myristoylation is an irreversible process that is also essential for eNOS
targeting to the caveloae of the plasma membrane (Busconi and Mitchel, 1993).
Caveloae are small invaginations in the plasma membrane characterized by the
presence of caveolin, a transmembrane protein that has been well characterized
in endothelial cells and myocytes (Anderson, 1993;Parton, 1996).

The

oxygenase domain of eNOS binds to caveolin maintaining the inactivation of
eNOS (Michel et al., 1993). Calcium and CaM regulate

this binding and CaM

competitively displaces caveolin out of the oxygenase domain resulting in eNOS
catalytic activation. When

intracellular concentrations of Ca2+ decrease,

calmodulin disassociates from eNOS, the eNOS-caveolin complex reforms and,
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ultimately, inactivates eNOS (Michel and Feron, 1997). Because the binding of
caveolin and CaM are mutually exclusive, it is unlikely that the iNOS isoform
catalytic activity is regulated by caveolin because iNOS binds irreversibly to CaM.
The only inducible NOS isoform so far identified irreversibly binds CaM at
very low intracellular Ca2+ concentrations, and is therefore not subjected to
activation in the presence of variations in intracellular Ca2+ concentrations. Found
primarily in the cytoplasm, iNOS activity is primarily transcriptionally regulated by
cytokines rather than changes in intracellular Ca2+ concentrations (Ghosh et al.,
1996). Kalicrin, a proinflammatory protein, appears to inhibit the dimerization of
iNOS in the CNS (Cho et al., 1995), suggesting a neuroprotective role during
inflammation in neuronal tissues.
Expression of NOS splice variants is another way of post-transcriptional
regulation and has been better documented in nNOS isoforms (Huber et al.,
1998). Very little information is available on iNOS splice variants and no eNOS
splice variants have been reported to date. The biological significance of NOS
splice variants remains elusive, but may be related to tissue-specific activity. For
example, some nNOS splice variants are found only in certain specific tissues,
denoting specific physiological roles yet to be elucidated.
NITRIC OXIDE BIOLOGICAL ACTIONS
Guanvlate Cvclase
The first described mechanism of NO in biological systems was its effect
on increasing the intracellular concentration of cyclic guanosine monophosphate
(GMP) in endothelial and smooth muscle cells. The pathway of this effect
involves the reaction of NO with the ferrous iron (Fe2+) moiety in the heme
prosthetic group of the soluble guanylate cyclase in smooth muscle cells (Murad,
1994). Guanylate cyclase catalyzes the formation of cyclic GMP from guanosine
triphosphate. The resulting cyclic GMP from the interaction of NO with guanylate
cyclase has, in addition to inducing vascular relaxation, many regulatory roles
such as inhibition of platelet aggregation and adhesion (Radomski et al., 1987),
inhibition of leukocyte adhesion (Kubes et al., 1991) and changes in vascular
permeability (Kubes and Granger,

1992).

NO-induced

cyclic GMP also
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synergistically interacts with prostacyclin to promote inhibition of platelet
aggregation (Sinzinger et al., 1992).
Cvclooxvaenases
Cyclooxygenases (COX) belong to the CYP450 superfamily of enzymes.
They catalyze the conversion of arachidonic acid into prostacyclins and
thromboxane A2. It has been reported that NO up-regulates COX activation, thus,
contributing to the production of proinflammatory prostaglandins. Therefore, NOS
inhibitors could have another anti-inflammatory effect in addition to inhibiting proinflammatory NO, that is, the indirect inhibition of prostaglandins. The COX
pathway, like the L-arginine-NO pathway, has constitutive and inducible isoforms
(DeWitt and Smith, 1988). One isoform (COX-1) is constitutively expressed in
virtually every cell except mature erythrocytes. COX-1

is thought to be

responsible for the production of prostaglandins necessary for maintaining
homeostasis (Seibert and Masferrer, 1994). Inflammatory stimuli are responsible
for the expression of another isoform (COX-2) that accounts for the supraphysiological production of prostaglandins in inflamed tissues (Gierse et al.,
1995).
The COX pathway shares several similarities with the L-arginine pathway.
This stimulated researchers to further investigate whether a more direct
relationship would exist between these important pathways. Both COX-1 and
COX-2 are expressed in endothelial cells serving to produce prostacyclins, which
are potent vasodilators and inhibitors of platelet aggregation like NO (Hla and
Neilson, 1992; Kubes et al., 1991). Cytokines have also been found to induce
expression of COX-2 and iNOS in diverse tissues.
Dexamethasone, a glucocorticoid with immunosuppressive and anti
inflammatory effects, inhibits the de novo synthesis of iNOS (Baydoun et al.,
1993) but not eNOS (Radomski et al., 1990). Similarly, dexamethasone has also
been known as a potent inhibitor of prostaglandins (Smith, 1992), and
subsequently evidence was found for post-transcriptional regulation of cytokineinduced COX-2 transcript isoforms.
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Stimulation of a murine macrophage cell line by Escherichia coli
lipopolysaccharide caused an increase in the basal release of NO 2' and PGE2 ,
denoting that the NO and COX pathways were activated. Two known NOS
inhibitors, NG-monomethyl-L-arginine (L-NMA) and aminoguanidine (AG) inhibited
the production of both NO2- and PGE2. Furthermore, addition of sodium
nitroprusside (SNP), a NO donor, increased the production of arachidonic acidstimulated PGE 2 by murine recombinant COX-1 and COX-2 (Salvemini et al.,
1993). It seems, however, that this synchronous regulation of iNOS and COX-2 is
more evident during acute inflammation than during chronic stages of
inflammatory processes, when dissociation between iNOS and COX-2 is
detected (Vane et al., 1994). The NO-induced activation of the cyclooxygenase
pathway appears to be cyclic GMP-independent (Salvemini et al., 1993; Tetsuka
et al., 1994). While co-regulation of eNOS and COX-1 may be associated with
maintenance of homeostasis (e.g., vasodilator tone) the dual expression of iNOS
and COX-2 plays an important role in the pathogenesis of cerebral ischemia
injury (Nogawa et al., 1998). Activation of COX-2 by NO is likely to be a result of
a direct stimulation of NO on COX-2 (Salvemini et al., 1993).
Reactive Oxygen Species
The true nature of the antimicrobial and cytotoxic effects of NO is not
known, but likely results from oxidative injury caused by production of NOderived reactive oxygen species (ROS). This NO-stimulated antimicrobial
mechanism of defense requires high concentrations of iNOS-derived NO.
Infections in humans and experimental models are positively correlated with an
increase in systemic NO production as determined by increased concentrations
of NO2' and NO 3* in plasma and urine (Evans et al., 1993b). The reaction of
reactive oxygen and NO-derived nitrogen intermediates results in a diverse group
of chemicals with powerful ability to cause cellular injury.
Peroxynitrite is perhaps the most powerful of these agents with
antimicrobial activity and is formed from the reaction of NO with O 2'. Although
ONOO' is not a free radical per se, it is highly reactive, participating in the
oxidation of sulfhydrils, lipids and nitration of tyrosine groups in proteins (Radi et
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al., 1991). Peroxynitrite is stable at alkaline pH and its conjugate acid
(peroxynitrous acid; NOOH) is highly reactive. Conversely, peroxynitrous acid
can decompose to form relatively unreactive NO3* at physiological pH. Hydroxyl
radicals that are formed from the reaction of NO with H2O 2 are potent oxidants,
expressing antimicrobial activity mainly in the presence of iron species (Pacelli et
al., 1995).
Although NO reacts with 0 2' to form ONOO', which is potentially
neurotoxic, it can also react with a variety of metal complexes to form high-affinity
nitroso complexes (Lancaster et al., 1992) that promote neuroprotection
(Garthwaite et al.,

1988). Accordingly, neuroprotection evoked by down-

regulation of N-methyl-D-aspartate (NMDA) receptors, may not only be triggered
by NO itself (Hoyt et al., 1992), but also indirectly through the formation of redox
NO-related species (Lipton, 1996), probably involving reactions with cysteine
sulfhydryls.
NO also reacts with Cu-Fe proteins and Fe-S clusters to generate reactive
O 2 and highly toxic hydroxyl radicals (Anggdrd, 1994). Glycolytic activity is also
regulated by the binding of NO with thiol groups of important enzymes such as
glyceraldehyde-3-phosphate dehydrogenase (Mohr et al.,

1996).

Specific

antimicrobial action of NO-derived reactive nitrogen intermediates appears to be
through deamination of DNA (Wink et al., 1991) and oxidative damage to DNA
strands (Juedes and Wogan, 1996). Cytotoxic activities of NO derivatives involve
inhibition of cellular metabolic enzymes (Ischiropoulos and Al-Mehdi, 1995),
membrane receptors (Lipton, 1996; Fang, 1997) and signal transduction
mechanisms (Murad, 1994). A great part of these complexes results from the
reaction of NO with oxyhemoglobin and Fe-S-containing proteins present in the
tricarboxilic acid.
NITRIC OXIDE DONORS
One approach to investigating the biological actions of NO in vitro or in
vivo would be to administer the pure NO gas to experimental units; however,
although this approach seems ideal, it is not feasible in light of the inconveniently
short half life of NO. An alternative method would be the administration of
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compounds that spontaneously or enzymatically release NO, called NO
generators and commonly known as NO donors. Fortunately, several NO donors
(terminology recommended by the

International Union of Pharmacology

Nomenclature in Nitric Oxide Research) such as nitroglycerin and sodium
nitroprusside have been used for many years to treat cardiovascular diseases,
long before they were known to work through the release of NO to effect a
biological action therapeutically (Needleman eta!., 1972; Ignarro et al., 1981). In
addition, novel NO donors were developed and used in NO research, and there
are currently several groups of NO donors including the organic nitrates and
nitrites,

inorganic

nitroso compounds,

sydnonimines,

S-nitrosothiols

and

diazeniumdiolates. In general, most of the NO donors generate NO at
physiological pH spontaneously or enzymatically (Singh et al., 1996).
Diazeniumdiolates are compounds that contain the anionic N2O 2 functional
group attached to various carrier molecules (e.g., spermine NONOate) and have
the advantage of generating NO as the compound degrades. Diazeniumdiolates
spontaneously generate bioactive NO in an aqueous environment and have a
wide range of half lives that facilitate their use in diverse experimental settings.
Another advantage is that diazeniumdioaltes generate NO at a rate independent
of the tissue involved or medium characteristics. Spermine NONOate has a half
life of 73 min at 37°C in physiological saline solution.
Sodium nitroprusside [SNP; sodium pentacyanonitrosyl ferrate (II)] is an
iron nitrosyl compound where the iron atom is in the ferrous state and NO is
formally bound as NO*. Although the effects of SNP on the cardiovascular
system are well known, its mechanism of NO release is not. It is probable that in
biological systems both spontaneous and enzymatic release of NO occurs. Either
way, it is known that the generation of NO from SNP requires irradiation with light
or one electron reduction. It has been suggested that a membrane-bound
enzyme may be associated with the generation of NO from SNP. The
requirement for NADPH or NADH for NO generation has been suggested but not
demonstrated. Cyanide is released following SNP reduction and formation of
S-nitrosyl compounds.
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NITRIC OXIDE SYNTHASE INHIBITORS
The first step of the reaction that generates NO from the amino acid
L-arginine involves the formation of NG-hydroxy-L-arginine (Stuehr et al., 1991).
Therefore, the L-arginine/NO pathway can be inhibited by several L-arginine
analogues (Abu-Soud et al., 1994). The first known NOS inhibitor was a
compound

found

to

inhibit the

L-arginine-induced

cytoxicity

in

murine

macrophages, before it was even known that L-arginine was a substrate for NO
generation (Hibbs et al., 1987). This compound, NG-monomethyl-L-arginine (LNMA) was shown to be a competitive inhibitor of the formation of NO and it was
one of the first NOS inhibitors to be used in NO research (Hibbs et al., 1988).
Later on, many other analogues of L-arginine were developed to competitively
inhibit both constitutive and inducible NOS isoforms. It has been reported that
NG-NG-dimethyl-L-arginine (L-ADMA) and L-NMA are NOS inhibitors naturally
found in human plasma and urine, suggesting that plasma or urine quantification
of these inhibitors may be an indicator of imbalances in NO biosynthesis related
to disease (Flicking et al., 1993). Another class of drugs that inhibit NOS action
includes non-amino acid compounds that chemically resemble the guanidinium
moiety of L-arginine.
Recently it was reported that a novel compound (BN-80933) was
developed to inhibit both nNOS and lipid peroxydation in order to promote
neuroprotection (Chabrier et al., 1999). The rationale was based on the fact that
excessive NO production in the brain as well as excessive reactive oxygen
species stimulated lipid peroxydation. The methyl ester of NG-nitro-L-arginine
(L-NAME) was shown to inhibit acetylcholine-induced relaxation of aortic rings
and since then L-NAME has been used in physiological studies. NG-nitro-Larginine methyl ester is far more soluble than its free acid, NG-nitro-L-arginine
(L-NNA) and, therefore, suits physiological experimentation involving in vivo
administration to animals or in vitro-cultured cells.
The efficacy of L-NAME as an NOS inhibitor is questionable, because
L-NAME inhibitory effects are more pronounced in the presence of cellular
esterases that readily hydrolyze L-NAME into L-NNA, a more potent NOS
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inhibitor. N6 -nitro- L-arginine methyl ester has a short half life and the inhibitory
effects on NOS activity are probably a result of L-NNA action. The hydrolysis rate
leading to formation of L-NA from L-NAME may vary from tissue to tissue and
even between the same cell lines cultured under different media. The mechanism
of transport of L-NAME is unknown, however, perhaps it can be extrapolated
from studies with other amino acid esters that L-NAME is quickly transported
inside the cells and subsequently hydrolyzed to its free acid, which becomes
“trapped” inside the cells. Administration of L-NAME to cell cultures should
produce approximately 90% NOS inhibition, particularly nNOS and eNOS. LNAME can be administered intravenously to animals and hydrolysis of L-NAME
to L-NNA should be expected. This explains why administration of L-NAME, an
agent with a short half live is followed by a prolonged inhibition of NOS, probably
attributable to L-NNA.
Aminoguanidine

(AG)

has been

reported to

inhibit NOS

activity.

Aminoguanidine is a poor inhibitor of constitutively expressed NOS isoforms and
at high concentrations the inhibitory effect on NOS activity is preferentially toward
iNOS. Thus, AG has been reported to be a selective inhibitor of iNOS (Corbett et
al., 1992). First synthesized from the reduction of nitroguanidine in 1892, AG is
structurally related to the amino acid L-arginine. Chemically, AG is a nucleophilic
compound containing two guanidine nitrogens that shares many properties with
hydrazines and is, thus, often classified as a hydrazine. Three chemical forms of
AG, the hydrochloride, the hemisulfate and bicarbonate salts, are commercially
available. The most soluble form is the hydrochloride that is freely soluble in
aqueous solutions and culture media.
Although AG was first known as an explosive, its effects on systemic
blood pressure and respiratory function have been known for years. The first
important biological effect of AG was reported in 1952, when it was found that
AG inhibited diamine oxidase (histaminase), which catalyzes the oxidative
deamination

of

histamine

and

putrescine

(Schuler,

1952).

Thus,

the

administration of AG to animals could potentially lead to histamine accumulation
in the body (Nilsson, 1999). Later on, another important biological effect of AG
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was discovered. The administration of AG inhibited the nonenzymatic formation
of advanced glycosylation end products (AGE; Brownlee et al., 1986). Advanced
glycosylation end products are formed by glycosylation of cellular or extracellular
protein constituents and their accumulation has been associated with diabetic
complications. AGE effects at the tissue and cellular level have been reviewed
(Singh e t a i, 2001).
Researchers are intensively investigating AG as a pharmacological agent
for treatment of complicated diabetes. Results of a Phase III trial using
pimagedine (the generic name for aminoguanidine) in humans suggest that
inhibition of AGE formation in Type-I diabetic patients may slow diabetes-induced
nephropathy (Friedman, 1999; Sugimoto et al., 1999; Singh et al., 2001).
Moreover, human subjects with Type I diabetes that were treated with AG had a
reduced

progression

of

retinopathy

along

with

lowered

plasma

lipid

concentrations (Singh et al., 2001). Similar results were reported for diabetic
dogs that were treated daily with AG for 5 years. AG-treated dogs did not
develop retinopathy as control diabetic dogs did; however, this AG-induced effect
was independent of inhibition of AGE formation (Kem and Engerman, 2001). The
biochemical mechanism by which AG prevented the onset of retinopathy in
diabetic dogs remains unclear. Another biological effect of importance is the
ability of AG to stabilize S-adenosylmethionine decarboxylase, an enzyme
involved in the metabolism of polyamines. The use of AG in experiments
investigating the biology of NO should be exercised with care because of several
other AG-mediated biological effects unrelated to NO-related mechanisms.
Hemoglobin as a Nitric Oxide Scavenger
The oxidation of NO to NO 3' by hemoglobin is thought to be the major
pathway for elimination of NO from the body (Wennmalm et al., 1992).
Accordingly, hemoglobin has been used as a NO scavenger in in vitro
experimental models to elucidate the biological role of NO in a number of
physiological and pathophysiological processes. Originally the binding of NO with
hemoglobin was considered uncooperative (Moore and Gibson, 1976), but recent
work has suggested that the NO-hemoglobin reaction in a physiological milieu
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may serve to secure and deliver it as needed (Stamler et al., 1997; Gow and
Stamler, 1998). In this aspect, NO was found to bind preferentially to unoccupied
heme sites in the hemoglobin molecule in a cooperative manner, to nytrosylate
hemoglobin thiols or to react with available O 2*. Superoxide dismutase in
erythrocytes reacts with 0 2~ and generates NO. The NO produced reacts with
hemoglobin to form nitrosohemoglobin and nitrosylated hemes that ultimately
maintain NO in a bioactive state (Gow et al, 1999).
The use of hemoglobin is a very effective means to scavenge NO in vitro
because NO concentrations are usually much greater than that found in a
physiological milieu (Eich et al., 1996). Thus, hemoglobin is an important tool to
study the biochemistry of NO associated with its physiological actions, as it has
been shown in several studies investigating NO regulation in vasodilation
(Feelisch and Noack, 1987), neural receptors (McMahon and Ponomareva,
1996), granulosa cell steroidogenesis (Van Voorhis et al., 1994) and in vitro
bovine embryo development (Lim and Hansel, 1998).
NITRIC OXIDE AND REPRODUCTION
Soon after the discovery of convincing evidence that NO was the EDRF
(Furchgott and Zawadski, 1980; Ignarro et al., 1981; Palmer et al., 1987),
researchers started to investigate the biology of NO and found that NO was
involved in multiple biological functions responsible for normal homeostasis of
important systems, such as the gastrointestinal (Kubes, 1993; Moore and
Seahorn, 1997) and respiratory (Jorens et al., 1993; De Sanctis et al., 1999), in
addition to the well-described control of vasodilator tone (Calver et al., 1993).
The biology of NO turned out to be more complex and ubiquitous than previously
thought, and NO was reported to modulate or participate in pathophysiological
mechanisms of disease in diverse systems (Moncada etal., 1991). Researchers’
attention then turned to investigating the biological effects of NO in the
reproductive system (Adams et al., 1992; Rosselli et al., 1994a).
Researchers in several laboratories found NO to be involved in regulatory
processes of the reproductive system, including many biological processes in the
hypothalamic-hypophyseal-gonadal axis (McCann and Rettori, 1996b; Rosselli et
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al., 1998; Dixit and Parvizi, 2001). Cerebral NO (produced by the NOergic
neurons) caused the release of gonadotropin releasing hormone (GnRH) from
the hypothalamus. Results from initial investigations on NO and release of
luteinizing hormone (LH) were apparently conflicting because evidence was
found that supported both stimulatory (Rettori eta!., 1992; Bonavera e /a /., 1993;
Canteros et al., 1995) and inhibitory (Seilicovich et al., 1995; McCann and
Rettori, 1996a) effects on LH release.
A conciliatory hypothesis was suggested when these initially discrepancy
results were interpreted to mean that NO was responsible for the pulsatile
release of LH, causing initiation and termination of neural impulses in the
hypothalamus (Aguan et al., 1996; McCann and Rettori, 1996b). initiation of the
LH pulse generator was a result of NO-stimulated up-regulation of PGE 2
(Bonavera et al., 1994). It was postulated that NOergic neurons were activated
by norepinephrine-stimulated a -1 receptors, resulting in increased intracellular
Ca2+ concentrations and further activation of CaM to stimulate NOS catalytic
activity. Typically, NO production would be expected to decrease intracellular
concentrations Ca2*, as happens with Ca2> concentrations of endothelial cells
expressing NOS activity. However, it was proposed that in the brain NO would
increase Ca2+ concentrations, a phenomenom previously detected in pancreatic
acinar cells that showed a biphasic response to NO stimulation, increasing Ca2+
concentrations at low NO concentration and lowering at high concentrations of
NO (Xu et al., 1994). Because of increased Ca2* concentrations, activation of
phospholipase A2 catlytic activity caused

the conversion of membrane

phospholipids to form arachidonic acid. The COX pathway was then activated
resulting in PGE 2 formation and GnRH release (McCann and Rettori, 1996b).
The pulse was shown to terminate through the NO-activation of two different
mechanisms. The NO released by norepinephrine, entered an ultra short loop
negative feed-back mechanism to terminate the pulsatile release of LH by
inhibiting the norepinephrine release at the noradrenergic terminals that,
ultimately, resulted in a sequential termination of the norepinephrine, GnRH and
LH pulsatile pulses (Seilicovich eta/., 1995).
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Nitric oxide also stimulated the release of the gamma amino butyric acid
(GABA), which previously has been shown to inhibit the response of GnRH to
SNP treatment to median basal hypothalamic explants, adding one more
pathway of NO-induced inhibiton of GnRH-induced LH pulsatile release (McCann
and Rettori, 1996a). Interestingly, the release of the follicle-stimulating hormone
(FSH) was not affected either by NO donors or NOS inhibitors, thus, adding
additional evidence to the hypothesis that supports the existence of an FSHreleasing hormone (FSHRH) that is regulated independently from GnRH release
(Rettori etal., 1993).
It has been suggested that there are two types of GnRH secreting
neurons: one group of neurons with axons terminating in the hypophyseal portal
vascular micro-system and another group of neurons with axons extending to
areas in the hypothalamus that control sexual behavior (Mani et al., 1994). As
GnRH has been implicated in the control of mating behavior in rats, further
experiments suggested that lordosis behavior in female rats was directly linked to
NO stimulation. Accordingly, administration of SNP stimulated the lordosis
behavior, whereas administration of NOS inhibitors inhibited the display of
lordosis (Mani etal., 1994).
The release of hypophyseal hormones also appears to be under NO
control. The presence of NOS isoforms has been identified in gonadotropes.
Furthermore, studies using isolated cultures of hypophyseal explants showed
that secretions of LH and FSH are reduced as a result of the removal of
hypothalamic regulation, whereas prolactin is released in large quantities
because of the absence of hypothalamic-derived prolactin-inhibitory factors.
Addition of NO donors to hypophyseal explants stimulated LH while decreasing
the output of prolactin. Because cyclic GMP has been found to stimulate both LH
and FSH release, it was later found that NOS inhibitors also inhibited the release
of these hormones induced by GnRH. It was concluded that NO would be acting
through cyclic GMP, a known activator of protein kinase G (Yu et al., 1997).
Other studies have shown that the administration of NOS inhibitors inhibited the
preovulatory LH surge in rats, suggesting additional evidence for NO-mediated
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LH release in cycling animals (Bonaventura et a/., 1993; Aguan etal., 1996). Upregulation of nNOS activity has been shown by immunohistochemistry to
coincide with the LH surge in ovulating rats (Lamar eta l., 1999).
NO has also been implicated in the regulation of oxytocin and GABA
release from the neurohypophysis via the regulatory neuroendocrine peptide
neurokinin A (De Laurentiis et al., 2000). Results from other studies have shown
that NO inhibition of neuronal excitability in oxytocin and vasopressin neurons
involves pre- and post-synaptic potentiation of synaptic activity in GABAcontaining neurons in the supraoptic nucleus (Lutz-Bucher and Koch, 1994;
Stem and Ludwig, 2001).
Nitric Oxide and Male Reproductive Phvsioloov
Human testicular nNOS activity was reported to be relatively lower than
that of vas deferens, prostate and seminal vesicle (Ehren et al., 1994). Further
research involving NO mechanisms of regulation of penile function and
dysfunction was the first area of NO research that resulted in the discovery of a
clinical treatment for a reproductive dysfunction. Studies using isolated strips of
rabbit corpus cavernosum exposed to electrical field stimulation resulted in
production of NO (Ignarro et al., 1990). This finding suggested that NO was a
mediator of penile erection via a noncholinergic nonadrenergic neuroregulation
(Burnett ef al., 1992).
Immunohistochemistry studies performed in the mouse (GonzalezCadavid et al., 2000), rat (Burnett et al., 1995) and human (Burnett et al., 1993)
determined the presence of nNOS protein disseminated throughout the penile
innervation and extending into the pelvic ganglion (where their neuronal bodies
are located). Expression of nNOS and NO production in the penis was intimately
associated with rat penile erection (Chang et al., 1996) and declined with age
(Carrier et al., 1997). However, long-term treatment with androgens restored
penile erection in old rats without affecting NOS expression (Garban etal., 1995).
Furthermore, the presence of eNOS was also found in endothelial cells of
arteries supplying the mouse penis (Burnett et al., 1996). It was then postulated
that NO would activate the soluble guanylate cyclase in the smooth muscle of the
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corpus cavemosum to form cyclic GMP. Increased concentrations of cyclic GMP
would then cause vasorelaxation, allowing arterial blood to enter the penis to
cause erection (Burnett et al., 1993). This knowledge led researchers to develop
a phosphodiesterase inhibitor (sildenafil) that when taken orally (Viagra®) would
inhibit the phosphodiesterase isoform (PDE5) that metabolizes cyclic GMP
(Boolell et al., 1996). The resulting accumulation of cyclic GMP would facilitate
the triggering of vascular and vascular-associated neural reflexes responsible for
penile erection. Sildenafil is used for treatment of erectilte dysfucntion but
requires prior sexual stimulation. Quality and duration of erection depend on the
presence of integer vascular-neuro-muscular structure to support penile erection
(Glossmann etal., 1999).
The testes are a site for NOS expression and a target for NO action
(Ehren et al., 1994; Burnett et al, 1995). Leydig cells are in close proximity to
endothelial cells and macrophages (Hutson, 1992), which are a source of
cytokines

that

modulate

testicular

steroidogenesis.

Cytokine-modulated

steroidogenesis may involve NO-mediated cell signaling as the presence of
nNOS and eNOS activity has been detected in Sertoli cells, Leydig cells and
endothelial cells of human testes (Davidoff et al., 1995; Zini et al., 1996). Even
the expression of iNOS induced by cytokines has been reported to occur in
cultured Sertoli cells (Stephan et al., 1995) and Leydig cells as well (Tatsumi et
al., 1997). Although the soluble guanylate cyclase and cyclic GMP have been
found to be co-localized within the cytoplasm of Leydig cells and immature
spermatids (Davidoff et al., 1995), NO participation in the modulation of
steroidogenesis might involve mechanisms independent of cyclic GMP activation
(Del Punta et al., 1996). The NO effect on testicular steroidogenesis is inhibitory
and possibly reflects the well known ability of NO to bind with CYP450 enzymes
(Adams et al., 1994). When the mechanism of NO-induced inhibition was studied
in a murine Leydig tumor cell line and in rat Leydig cell steroidogenesis, it was
found that NO was inhibiting one of the rate-limiting enzymes, the CYP450 sidechain cleavage enzyme (Del Punta et al., 1996), which catalyzes the formation of
pregnenolone from cholesterol. In a subsequent study, administration of a NOS
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substrate to intact male rats decreased both LH and testosterone concentrations
(Gaytdn et al., 1997). This effect had been previously reported to be reversed by
the NOS inhibitor, L-NAME (Adams etal., 1994).
Sperm cell function also appears to be mediated via NO-mediated
mechanisms (Hellstrom et al., 1994; Rosselli et al., 1995). The role of NO on
sperm cell motility has been found to be inhibitory under high concentrations of
NO (Rosselli et al., 1995), whereas low concentrations of NO may be beneficial
for promoting sperm cell motility (Hellstrom et al., 1994; Lewis et al., 1996). In a
subsequent study, NO was reported to modulate the progesterone-induced
acrosomal exocytosis in mouse spermatozoa, therefore, suggesting a role for NO
in sperm cell capacitation (Herrero et al., 1995). Furthermore, it was found that
NOS activity was highly expressed in sea urchin sperm cells after activation by
the acrosome reaction. The resulting NO production at the site of fertilization led
to nitrosation reactions within the egg before the Ca2*-induced egg activation
(Kuo et al., 2000). Moreover, microinjection of SNAP or recombinant NOS
recapitulated the events preceding and occurring during egg activation, whereas,
microinjection of oxyhemoglobin prevented egg activation after fertilization (Kuo
et al.,

2 0 0 0 ).

Nitric Oxide and Female Reproductive Physiology
The female reproductive model has posed an attractive model to study
both physiological and pathophysiological regulatory mechanisms for their wellknown constant and dynamic state of cyclic and hormonally regulated changes.
Because the discovery of NO as a cell-signaling molecule was related to its role
as an EDRF (Ignarro et al., 1987), initial work evaluating what role NO would
have in the female reproductive system was directed to vascular physiology
studies. Until 1992, very few articles had been published on the biological effects
of NO in the female reproductive system. At that time, most of the NO research
on the reproductive system was concentrated on investigating NO-mediated
effects in the uterine vasculature of pregnant and non-pregnant animals (Weiner
etal., 1992; Matsumoto etal., 1992; Kimura etal., 1992). However, in 1993, one
group reported that addition of aminoguanidine to primary cultures of interleukin-
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1 -beta-treated

rat ovarian dispersates prevented the documented interleukin-1 -

beta-induced morphologic and cytotoxic changes (Ben-Shlomo et al., 1994).
Because these changes were thought to reflect tissue-remodeling events
associated with ovulation, it was postulated that NO would have a role in
ovulation (Ellman et al., 1993). The results of that study suggested that the NO
effects on cytotoxicity were shown to be mediated by cyclic GMP.
In 1994, several researchers reported the results of studies suggesting a
role for NO in mediating events in the female reproductive system. In one study,
administration of L-NAME to bovine uterine tube segments (ampulla and
isthmus) enhanced the ET-1 -induced contraction of uterine tube rings suggesting
a role for NO-mediated uterine tube function (Rosselli et al., 1994b; Bryant et al.,
1995). Later in the year, the same group reported that concentrations of N 0 2'
and NO 3* in human plasma increased during the follicular phase of ovarian cycles
that was correlated with a concomitant increase in estradiol (E2) plasma
concentrations suggesting a role for NO in follicular development in humans
(Rosselli etal, 1994a).
Because women after menopause are at risk for cardiovascular disease
and estrogen replacement therapy may have cardioprotective properties, the
authors of that study examined the serum concentrations of NO metabolites
(NO2' and NO3 ) at specific stages of follicular development during natural and
gonadotropin-stimulated cycles (Imthum et al., 1997). A correlation was found
between NO metabolites and serum E2 concentrations during the progression of
follicle development; however, elevated serum E2 concentrations during the postovulatory period when serum progesterone (P4) concentrations were also
elevated were not correlated with serum NO metabolites. These results
suggested an up-regulation of the NO pathway during the human follicular phase.
Using a more mechanistic approach, researchers demonstrated that NO
was implicated in the autocrine regulation of granulosa cell steroidogenesis and
that this effect was not mediated by the cyclic GMP pathway (Van Vhorris et al.,
1994). It was found that NO caused a dose-dependent decrease in both E2 and
P4 secretion by human granulosa cells. Results of that study suggested that NO
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directly inhibited CYP450 aromatase activity and it was one of the first studies to
propose a more specific site of NO action in addition to the well established
relationship between NO and cyclic GMP. Although the participation of NO in
reproductive physiological processes is irrefutable, the specific control and
expression of NO production during reproductive biological events are yet to be
fully elucidated. The ubiquitous nature of this gas cell-signaling molecule is
perhaps a clue as to how diverse and complex NO biology is, a phenomenon
comparable

to

the

seemingly

ubiquitous

and

complex

expression

of

prostaglandins.
Molecular Mechanisms of Mammalian Ovulation
Ovulation is a process that is represented by the rupture of the follicle wall
to release an oocyte that has completed or is completing the process of cellular
and nuclear maturation, a sine qua non condition for fertilization. The luteinizing
hormone (LH) surge initiates a cascade of molecular and biochemical events
occurring in the follicle wall and oocyte that enable the follicle to release the
oocyte. These LH-induced events take place during a period that is relatively
constant and species-specific. Administration of human chorionic gonadotropin
(hCG) typically reproduces LH-stimulated events and is, therefore, used to
induce ovulation in domestic animals in reproductive experimental models.
The events leading to ovulation can be grouped into three distinct, but
closely related, processes: vascular changes in the ovary and preovulatory
follicles; endocrinological shift in the granulosa-thecal cell complex that initiates
the process of preovulatory luteinization (increased P4 :E2 ratio) and structural
degradation of the follicle and ovarian surface necessary for rupture and release
of the oocyte. Along with these processes, there is the resumption of oocyte
maturation, which was arrested in prophase I of the first meiotic division. Similarly
impressive is the rapid morphological and functional transformation of the
granulosa-theca cell complex into luteal cells. The preovulatory period and the
ovulation itself have been compared with an inflammatory-like event (Espey,
1980), whereas, the post-ovulation period (luteal formation) has been compared
with a wound-repair process (Silvester and Luck, 1999). Interestingly, Leopold
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and Mironoff (1894) had already noted that rapid preovulatory follicular
development and ovulation in the human ovary were processes accompanied by
inflammation and that ovarian congestion was a natural condition present in the
ovary bearing the preovulatory follicle.

Vascular changes
Perhaps the increase in vascularity is one of the first notable changes
observed in the preovulatory follicle following LH stimulation. The apparent
venous congestion in follicles before ovulation has been observed in ovaries of
frogs (Grohe, 1863), cats (Thomson, 1919), ewes (Marshall, 1904), monkeys
Heape, 1897) and women (Leopold and Mironoff, 1894). Subsequently, the
hyperemia and venous congestion of preovulatory follicles were attributed to
gonadotropins (Zondek et al., 1945). Ovarian blood flow increases after hCG
stimulation (Murdoch et al., 1983) and hyperemia-associated vascular changes
are predominantly seen in preovulatory follicles. Interestingly, the area of the
preovulatory follicle destined to rupture during ovulation is devoid of vascular
changes (Brannstrom etal., 1998).
The LH surge also induces migration of leukocytes to the preovulatory
follicle (Brannnstrom et al., 1994). Whereas neutrophils are the predominant cell
type in sheep (Cavender and Murdoch, 1988) and cows, eosinophils are most
common in equine preovulatory follicles Kerban et al.,

1999).

In rats,

macrophages and neutrophilic granulocytes account for the bulk of leukocytes
detected before ovulation (Brdnnstrdm, 1993). It has been postulated that
leukocyte migration may serve as a source of cytokines and proteolytic enzymes
needed for degradation of the follicle and ovarian surface before ovulation
(Adashi, 1989; Andreani et al., 1991). Leukocyte supplementation significantly
increased the LH-induced ovulation rate in perfused rat ovaries as compared with
LH-stimulation alone (Hellbergh etal., 1991). In another study (BrSnnstrdm etal.,
1995),

systemic administration

of neutrophil-depleting

antibodies to rats

decreased the rate of LH-induced ovulation. However, severe systemic leukocyte
depletion induced by cyclosphosphamide or depletion of neutrophils by
vinblastine did not alter the expected ovulation rate in gonadotropin-stimulated
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immature rats (Chun et al., 1993). Likewise, systemic eosinopenia induced by
prednisolone did not affect the ovulation rate in ewes nor affected post-ovulation
luteal formation and, thus, adding evidence to question the role of leukocytes in
mammalian ovulation (Murdoch and Steadman, 1991). The depletion of
leukocytes in the periovulatory period may be compensated by the presence of
theca fibroblasts as an important source of proteolytic enzymes.
Nevertheless, leukocyte-derived vasoactive agents have been implicated
as playing an important role in mammalian ovulation. Growth factors such as the
vascular endothelial-permeability growth factor, one of the most important
inducers of angiogenesis (Carmeliet et al., 1996) and a mitogen for vascular
endothelium, has been identified in rodent ovaries (Shweiki et al., 1993). It is
significantly expressed following ovulatory stimulus by LH or hCG administration
(Koos et al, 1995; Christenson and Stouffer, 1997). Other growth factors, such as
epidermal growth factor, transforming growth factor-a and insulin-like growth
factor have also stimulated granulosa cell proliferation and angiogenesis. Tumor
necrosis factor-a stimulated the NOS and cyclic GMP pathway in bovine theca
cells stimulated with LH (Brunswig-Spickenheier and Mukhopadhyay, 1997).
Growth hormone (GH) has also been implicated in follicular dynamics in humans
(Blumenfeld and Amit, 1996) and, more recently, administration of equine growth
hormone to anestrous mares increased the hCG-induced ovulation rate
compared to hCG alone (Cochran, 2000).
The importance of interleukin-1 (3 (IL-1(3) for ovulation has been suggested
in rats (Brannstrom et al., 1993) and rabbits (Takehara et al., 1994). The
mechanism of IL-1P on ovulation may involve prostaglandin production (Kokia et
al., 1992), induction of formation of hyaluronic acid and proteoglycan synthesis
(Kokia et al., 1993), cumulus expansion during oocyte maturation (Chen et al.,
1993), induction of plasminogen activator and gelatinase activities (Hurwitz et al.
1993; Hurwitz et al., 1997), and activation of the NOS pathway (Ben-Sholomo et
al., 1994; Bonello et al., 1996). Furthermore, another interleukin (IL-8 ) has been
found to mediate hCG-stimulated ovulation in rabbits, primarily by inducing
neutrophil accumulation and activation (Ujioka etal., 1998).
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Prostaglandins are also considered essential for ovulation, especially in
regard to vascular changes (hyperemia, edema) and the process of follicular
rupture and, to a lesser extent, the preovulatory luteinization phenomenon.
Administration of hCG induces the expression of cyclooxygenases (COX),
resulting in production of prostaglandins F2a and E2 and lipooxygenases (LOX),
resulting in production of peptidic and nonpeptidic leukotrienes (Espey et al.,
1989; Tanaka et al., 1989; Yoshimura et al., 1991; Higuchi ef al., 1995).
Administration of indomethacin, a COX inhibitor, or nordihydroguaiaretic acid, a
LOX inhibitor, significantly decreased ovulation rates in rats and rabbits but did
not impede the hCG-induced luteinization of granulosa and theca cells. Inhibitors
of the LOX pathway inhibited ovulation in rats in vivo (Reich et al., 1983) and in
vitro perfused ovaries (Mikuni et al., 1998). Furthermore, indomethacin reduced
the LH-induced hyperemia in rabbits (Lee and Novy, 1978) and in ewes
(Murdoch et al., 1983). In the rat, hCG-stimulated vascular changes, such as
increase

in

vascular

permeability

were

also

significantly

inhibited

by

administration of COX and LOX inhibitors (Abisogun etal., 1988).
More recently, the expression of cyclooxygenase 2 (the inducible isoform)
has been identified in granulosa cells of rats, cows, horses and humans. The
time of expression of COX-2 mRNA in relation to hCG stimulation varies among
these species (rats, 4 h; cows. 16 h; mares, 30-32 h); however, ovulation in these
three species occurs invariably 10 h after COX-2 expression (Sirois et al., 1992;
Sirois, 1994; Liu et al., 1997; Sirois and D o r6 ,1997). It has been suggested that
COX-2 expression may be a determinant of hCG-induced ovulation and accounts
for species-specific differences in the length of estrus among these species
(Sirois and Dore, 1997).
Platelet-activating factor (PAF) is a very potent mediator of inflammation,
modulating changes in vascular permeability and systemic blood pressure.
Administration of PAF antagonists decreased hCG-induced ovulation rates in rats
(Abisogun etal., 1989) and mice (Kikukawa etal., 1991).
Bradykinin is a nonapeptide generated in inflamed tissues and is
generated from the proteolytic cleavage of plasma kininogens by kallikrein.
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Bradykinin is a potent vasoactive agent that augments local vasodilation in
inflammed tissues, increased vascular permeability and cell proliferation. Espey
et al. (1986) demonstrated the presence of bradykinin in gonadotropin-stimulated
rat ovaries. Furthermore, evidence exists suggesting that bradykinin and other
kinins modulate ovulation in rabbits (Yoshimura et al., 1988) and in rats
(Hellbergh et al., 1991) probably by stimulating the production of prostaglandins
in preovulatory follicles.
Histamine is a well-known vasoactive substance derived from the
enzymatic decarboxylation of histidine. It is mainly stored in the metachromatic
granula of mast cells and basophils. The participation of histamine in the
ovulatory process has been suggested (Szego and Gitin, 1964). Subsequently,
reports suggested that administration of antihistaminic drugs inhibited ovulation
in vivo and in vitro, whereas administration of histamine caused ovulation.
Histamine induced increased hyperemia in the preovulatory follicle wall after
gonadotropin stimulation (Espey, 1980). However, a pivotal role for histamine is
yet to be demonstrated, as several studies have questioned a role for histamine
in ovulation in mares (Watson and Sertich, 1991), sheep (Halterman and
Murdoch, 1986) and rabbits (Kitai etal., 1985).
Angiotensin II regulates blood pressure and fluid homeostasis. The same
enzyme that converts angiotensin I to angiotensin II also acts as a kininase to
degrade bradykinin. There is evidence indicating a primary role for angiotensin II
in ovarian steroidogenesis and ovulation. Prorenin forms the enzyme that
converts angiotensinogen into angiotensin I. Prorenin is present in ovarian
follicles and its concentration increases after an ovulatory stimulus. The
expression of the angiotensin II receptor varies with species and stages of
follicular development. An ovulatory stimulus increases the ovarian reninangiotensin system activity in the ovary. The specific role of angiotensin II in
ovulation has not been clearly identified. Angiotensin II induced ovulation in
perfused rabbit ovaries by stimulating prostaglandin production (Yoshimura etal.,
1993) whereas administration of the angiotensin II antagonist saralasin inhibited
ovulation in perfused rat ovaries (Peterson et al., 1993). However, other reports
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questioned the importance of angiotensin for ovulation when the use of the
converting enzyme inhibitor captopril failed to find significant effects in ovulation
or ovarian steroidogenesis in rats (Daud et al., 1990).
The LH surge is associated with an increase in generation of reactive
oxygen species in the preovulatory follicle. When the scavenging enzyme
superoxide dismutase (SOO) was added to perfused rabbit ovaries, LH-induced
ovulation was significantly decreased (Miyasaki et al., 1991). This is in
agreement with one study that found that hCG supplementation depleted
ascorbic acid in the perfused rat preovulatory follicle and a similar effect was
noted when menadione (a generator of oxygen free radicals) was added to the
perfusion medium (Guamaccia et al., 2000).

Proteolysis
Although LH-induced events necessary for ovulation to occur take place
before follicular rupture, the process of ovulation, strictly, refers to follicular
rupture and final expulsion of the oocyte. Follicle rupture requires the degradation
of otherwise healthy ovarian tissue. Degradation of a specific area of the follicle
and ovarian surface where ovulation will occur is a precise process, if one
considers that follicles continue to increase their diameter until ovulation takes
place. The process of degradation involves intense proteolytic activities in
the extracellular matrix and collagen fibers present primarily in the theca
externa and tunica albuginea (Brannnstrom et al., 1988). The main proteolytic
enzymes are plasminogen-activating factor (PLAF), kallykreins and coilagenases
(metalloproteinases; Tsafriri etal., 1989).
Quiescent

fibroblasts

become

fully

active

after

the

LH

surge.

Plasminogen-activating factor is a serine protease that is secreted from
fibroblasts in association with coilagenases. Several studies have identified the
presence of PLAF in the granulosa cell layer and theca externa. The appearance
of PLAF activity has been linked to steroid and eicosanoid modulation. Kallikreins
are also serine proteases that are present in inflamed tissues. Besides producing
kinins (vasoactive substances like bradykinin), they also convert procollagenase
into collagenase (active form).
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The importance of collagenolytic activity for ovulation comes from studies
showing that inhibitors of collagenase prevented ovulation. Coilagenases are
enzymes that are members of a group of enzymes collectively known as matrix
metalloproteinases (MMPs) that also include gelatinases, stromelysins and
membrane-type matrix MMPs. Inhibitors of MMPs inhibited ovulation. It has been
speculated that interstitial collagenase and collagenase-3 may be responsible for
the initial degradation of the follicle wall before ovulation. Gelatinases A and B
are noted for their ability to cleave gelatin and type IV collagen, which are
components of basement membranes. One study reported that equine ovarian
stromal cells cultured in vitro were able to produce gelatinases A and B along
with tissue inhibitors of MMPs (Song etal., 1999).
In summary, although the literature contains conflicting reports on the
mechanisms of activation and modulation of PLAF, kallykrein and collagenase, it
is generally accepted that their activation is temporally related as, apparently, is
their modulation by prostaglandins and steroids (primarily P4). Furthermore, it has
been postulated that accumulation of ligands in the ovary after the LH surge may
initiate an action potential to the fibroblasts to generate signal transduction
mechanisms that self perpetuate and propagate, resulting in intense proteolytic
activity until ovulation takes place.

Ovarian steroids
After the LH surge, granulosa and theca cells collectively start to produce
more P4 than E2 and androgens. Results of several studies support the concept
of a steroidogenesis shift that increase the P4:E2 ratio in response to endogenous
LH or administration of hCG. Decreases in CYP450 side chain cleavage enzyme,
CYP450 aromatase and steroidogenic acute regulatory protein expression
accounts for increased production of P4 (Bao et al., 1998). The highly significant
increase in P4 concentrations in the follicular fluid after the LH surge incited
diverse experimental approaches to establish the importance of this steroid for
ovulation. Epostane is an inhibitor of 3(3-hydroxysteroid dehydrogenase (3(3HSD) that prevents the formation of pregnenolone into P4 (Tanaka et al., 1991).
Administration of epostane inhibited follicular steroidogenesis and ovulation in
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rats that could be reversed by exogenous P4 (Snyder et al., 1984). The P4
antagonist mifepristone (RU486) inhibited the mid-cycle gonadotropin surge and
delayed ovulation in humans. Inhibition of LH release and 3f3-HSD activity appear
to be mediated by RU486. Aminoglutethimide (another anti-steroid agent)
administration inhibited ovulation in some studies but had no effect in others.
Overall, administration of exogenous P4 reversed the inhibitory effect of anti
steroid agents. The detailed mechanism of P4 action in the ovulatory process
remains to be determined. Participation of P4 in activation of collagenase and
consequent proteolytic activity has been suggested as well as its role as an anti
inflammatory agent in the follicular milieu.
Nitric Oxide and Ovulation
There is unanimous agreement among researchers involved in NO
research that NO is essential for normal follicular maturation and ovulation to
occur. Shukovski and Tsafriri (1994) first reported the in vivo effects of NO
inhibition on ovulation rate of rabbits.

Following that report, effects of NO on

ovulation have been reported in mice (Powers et al., 1995; Klein et al., 1998;
Jablonka and Olson, 1998; Drazen et al., 1999; Jablonka-Shariff et al., 1999b),
rats (Shukovski and Tsafriri, 1994; Bonello et al., 1996; Jackrisson et al., 1996,
Faletti etal., 1999; Nakamura etal., 1999) rabbits (Kugu etal., 1995; Hesla etal.,
1997; Yamauchi et al., 1997) and mares (Pinto et al, 2000).
Mice made genetically deficient (knockout) for nNOS (Klein et al., 1998),
eNOS (Jablonka-Shariff and Olson, 1998) and iNOS (Jablonka-Shariff et al.,
1999b) clearly demonstrated that all three NOS isoforms play important ovulation
mediator roles, at least in mice. The effects of NOS gene disruption observed in
mice include abnormalities of estrous cyclicity, oocyte maturation, ovulation and
oocyte tubal transport that, ultimately, lead to lower pregnancy and litter size
rates. These same NOS-deficiency-induced reproductive abnormalities are
mimicked by chronic inhibition of NO production (Dunnam et al., 1999) and by
temporary administration of NOS inhibitors to cycling animals (Shukovski and
Tsafriri, 1994; Powers etal., 1995; Hesla etal., 1997; Faletti etal., 1999).
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Evaluation of NOS inhibition on ovulation rates of ovaries perfused in vitro
has also yielded results comparable to those derived from in vivo studies
(Bonello etal., 1996; Hesla etal., 1997; Yamauchi etal., 1997). Furthermore, the
in vivo administration of a NO donor significantly counteracted the NOS
inhibition-induced inhibition of ovulation (Shukovski and Tsafriri, 1994) or
mimicked hCG-like ovulation rates (Powers etal., 1995).
Although mainly eNOS and iNOS have been found to play a significant
role on ovulation, scientists still debate which NOS isoform is more relevant to
the ovulatory process. The participation of iNOS in ovulation has been
substantiated by studies showing its immunolocalization and even up-regulation
after a hormonal ovulatory stimulus (Dunnam et al., 1996; Faletti et al., 1999).
Expression of iNOS activity during early follicular development has been found to
influence follicle survival via inhibition of apoptotic mechanisms leading to atresia
(Chun et al., 1995; Matsumi et al., 1998; Matsumi et al., 2000). Moreover, the
administration of drugs showing a relative specificity for iNOS, such as AG,
resulted in significant inhibition of ovulation. (Shukovski and Tsafriri, 1994;
Yamauchi etal., 1997).
In an interesting study, the expression of eNOS and iNOS activity in
gonadotropin-stimulated rats was measured following the conversion of labeled
l-[ 14C] arginine into [14C]citrulline as described by Bredt and Snyder (1989). It
was found that both NOS isoforms were up-regulated following ovarian
stimulation with equine chorionic gonadotropin (eCG) and reached the highest
activity 10 h after hCG (administered 48 h after eCG administration). However,
iNOS was the only isoform that significantly increased after hCG administration
denoting a specific and defined role of iNOS in ovulation in rats. Moreover, the
temporal expression of iNOS activity as it was determined in that study coincides
with the hCG-stimulated ontogeny of prostaglandins (Sirois etal., 1992).
Therefore, both eNOS and iNOS were up-regulated in response to eCG
administration and only iNOS activity was further increased following hCG
administration. These results are an example of a constitutive isoform being
induced to perform a physiological function (follicle growth and ovulation).
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Conversely, evidence that favors eNOS as a primary NOS isoform for
follicle development and ovulation comes from studies using eNOS- and iNOSknockout mice (Jablonka-Shariff et al., 1999b). Ovulation rates and ovarian
steroidogenesis were significantly decreased in mice genetically engineered to
lack the genes encoding for eNOS and iNOS as compared with wild-type mice.
Interestingly, mice lacking the gene for the nNOS isoform also displayed infertility
and abnormal ovarian physiology (Klein etal., 1997).
Nitric Oxide and Ovarian Steroidogenesis
Recent studies suggest the existence of a nitric oxide-generating system
in the ovaries of quail (Van Nassauw et al., 1999), small laboratory animals (Van
Voorhis etal., 1995; Chatterjee etal., 1996; Zackrisson etal., 1996; Hesla etal.,
1997), cows (Basini etal., 1998), humans (Van Voorhis etal., 1994) and horses.
Expression of eNOS and iNOS, but not nNOS was determined in the ovaries of
rats (Van Voorhis et al., 1995) and that expression was up-regulated by the
administration of gonadotropins. Other studies also demonstrated that the
immunolocalization and the degree of expression of NOS isoforms varied
according to the stage of the estrous cycle (Zackrisson et al., 1996; JablonkaShariff and Olson, 1997).
Van Voorhis et al. (1994) noted that when NOS inhibitors were added to a
human granulosa cell culture, E2 production by the granulosa cells was
significantly increased, whereas no change resulted in P4 production. The
addition of a NO generator, S-Nitroso-L-acetyl penicillamine (S-NAP), caused a
significant inhibition of both E2 and P4 production; however, the E2 production
was inhibited more than P4 production. Similar findings of NO-induced inhibition
of follicular steroidogenesis have been reported in rats (Dave et al., 1997;
Dunnam et al., 1999), rabbits (Yamauchi et al., 1997) and cultured bovine
granulosa cells (Basini etal., 1998).
It appears that the NO-mediated inhibitory effect on steroidogenesis
follows a cyclic GMP-independent pathway (Snyder et al.,

1996). The

independence of the activation of guanylate cyclase was evident when the
addition of cyclic GMP

analogues did not reproduce the inhibition on
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steroidogenesis as NO did (Snyder et at, 1996). The steroidogenesis pathway is
regulated by CYP450 enzymes that are responsible for rate-limiting steps of
steroid production including aromatization of androgens to form estrogens (Peter
and Dubuis, 2000). Long-term regulation of steroidogenesis is intimately related
with the precise molecular regulation of CYP450 enzymes (Peter and Dubuis,

2000).
The CYP450 enzymes are heme-containing molecules. Because one of
the primary mechanisms of NO biological action is through the binding with heme
groups, studies were carried out to determine the mechanism(s) of NO-induced
inhibition of steroidogenesis. NO was found to inhibit CYP450 aromatase gene
expression as evidenced by a 26% decrease in CYP450 aromatase mRNA in
human granulosa cells as determined by northern analysis after 16 h of
incubation with a NO donor (Van Voorhis et at, 1994; Snyder et at, 1996).
However, the effect of adding a NO donor to cultured granulosa cells promoted a
rapid onset of inhibition of E2 production by the granulosa cells that could not be
solely accounted for by the decrease in mRNA expression. It was then
hypothesized that NO was probably directly inhibiting the CYP450 aromatase
catalytic activity.
Using microsomes derived from human placentae, it was verified that NO
decreased as much as 80% of microsomal aromatase activity. A LineweaverBurke plot of the data showed that the NO inhibition of CYP450 aromatase was
non-competitive. Although the mechanism of NO inhibition of CYP450 aromatase
has not been clearly elucidated, it was speculated that NO-induced nitrosylation
of aromatase cysteine groups could be part of this mechanism, independent of
NO-binding with heme groups as it was originally hypothesized (Van Voorhis et
a t, 1994). Accordingly, binding of CYP450 aromatase heme groups with CO did
not inhibit the enzyme activity. The hypothesis of NO-stimulated nitrosylation of a
cysteine adjacent to the heme aromatase (Snyder et at, 1996) is reinforced by
the fact that there are several cysteine groups in the CYP450 aromatase enzyme
including one essential cysteine at amino acid 437 in human CYP450 aromatase.
The importance of this cysteine for CYP450 aromatase function has been
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confirmed by in vitro mutational analysis (Ito et al., 1993). Apparently this
cysteine is required for normal fertility as one report describes the complete
absence of CYP450 aromatase activity in an infertile human patient bearing a
missense mutation in amino acid position 437 (Conte etal., 1994).
Studies using rat granulosa cells found that the NO donors SNAP and
SNP significantly decreased P4 production, whereas exposure of cultured
granulosa cells to the NOS inhibitor L-NAME, but not AG, reversed the SNAPinduced inhibition of P4 production (Ahsan et al., 1997; Dave et al., 1997).
Inhibition of P4 was determined in cultured ovarian dispersates treated with SNP,
but no significant effects were found after treatment of granulosa cells with AG
(Ahsan et al., 1997). However, a direct comparison between NO donor effects
and NOS inhibitor effects on P4 in this study (Ahsan et al., 1997) is difficult
because different cell preparations were used for SNP-treated wells (ovarian
dispersates) and AG-treated wells (granulosa cells). Neither SNAP nor L-NAME
affected granulosa cell viability as determined by the Trypan Blue dye exclusion.
In agreement with Van Voorhis et al. (1994) were the results of a study using
porcine granulosa cells for 24 h, which showed that the NO-stimulated inhibition
of granulosa cell steroidogenesis was independent of guanylate cyclase
activation (Masuda et al., 1997). Hanke et al. (1998) arrived at the same
conclusion after showing that NO inhibited aldosterone synthesis by inhibiting the
CYP450 side chain cleavage, through a guanylate cyclase-independent effect.
Using a different approach from Van Voorhis et al. (1994) and Snyder et
al. (1996), Japanese researchers showed that neither NO catabolites nor a
peroxynitrite-releasing

compound

(3-morpholynosydnonimine-hydrochloride;

SIN-1) inhibited the CYP450 aromatase activity of human granulosa cells. It was
concluded that the inhibitory action of NO donors on CYP450 aromatase activity
must be related to the release of NO itself and independent of activation of
guanylate cyclase (Kagabu et al., 1999). In contrast, Ishimaru et al. (2001)
suggested that NO-stimulated inhibition of steroidogenesis in immature rat
granulosa cells was involved the cyclic GMP pathway. These authors had
previously reported that cyclic GMP inhibited the FHS-stimulated production of E2
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by rat granulosa cells (LaPolt and Hong, 1995) and investigated, in a subsequent
experiment, the role of NO on this phenomenon. Accordingly, increased levels of
cyclic GMP accompanied NO-mediated inhibition of E2 production by rat
granulosa cells. Moreover, treatment of rat granulosa cells with a cyclic GMP
analogue resembled the NO-induced inhibition on E2 production, in addition, they
showed that NO inhibited accumulation of FSH-induced cyclic AMP, denoting
that NO can act distally to the FSH receptor. It was concluded that, as opposed
to previous reports (Van Voorhis et al., 1994; Snyder et a i, 1996; Masuda et al.,
1997; Kagabu et al., 1999), that mechanisms of NO-induced inhibition of
granulosa cell steroidogenesis may involve cyclic GMP antagonism on cyclic
AMP-stimulated steroidogenesis (LaPolt and Hong, 1995; Ishimaru etal., 2001).
Inhibitory effects of gossypol appear to be mediated by up-regulation of
the NO-generating system in porcine granulosa cells (Vranova et al., 1999).
Because reduction in bovine fertility has been associated with deficiency in
selenium (Allison and Laven, 2000), culturing bovine granulosa cells with
selenium were shown to increase the FSH-stimuiated E2 production while
decreasing the production of NO (Basini and Tamanini, 2000). The same group
had previously reported that NO donors inhibited steroidogenesis in bovine
granulosa cells from both small (< 5mm) and large ovarian follicles (>

8 mm)

that

were cultured for up to 72 h (Basini et al., 1998).
The role of cytokines in granulosa cell steroidogenesis is yet to be clearly
elucidated as studies that have exposed granulosa cells to interleukin-1 (3 (IL-1f3),
interleukin-6 ,
necrosis-a

granulocyte-macrophage

have

reported

colony-stimulating

inhibitory (Andreani et al.,

factor
1991),

or

tumor

stimulatory

(Brannstrbm et al., 1993; Tobai and Nishiya, 2001) or no effects at all (Shakil and
Whitehead, 1994). The NO modulation of granulosa cell steroidogenesis may
also involve the activation of iNOS, as interieukin-lp stimulated NO production in
rat cultured granulosa-thecal cells (Ellman et al., 1993; Ben-Shlomo et al., 1994)
and PGE in human granulosa cells (Hurwitz et al., 1995). In another study,
effects of IL-1P on NO and prostaglandin synthesis were seen only in ovarian
dispersate cells, but not in cultured rat granulosa cells (Ahsan et al., 1997). IL-1(3
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treatment decreased the production of P4 by ovarian dispersates in response to
forskolin stimulation. This is in contrast with other studies that showed that IL-1p
facilitated ovulation by increasing P4 in rat ovaries perfused in vitro (BrannstrOm
etal., 1993; Bonelloefa/., 1996).
Nitric Oxide in Ovarian Follicular Fluid
Only recently the presence of NO in ovarian follicular fluid has begun to be
investigated and the scarce literature on this matter shows discrepant
observations. The discrepant observations are most likely a result of different
methodologies employed and, more importantly, a consequence of inherent
constraints associated with the human in vitro fertilization (IVF) model. Human
intrafollicular NO concentrations, as evidenced by N02* and NO 3' analyses, have
been detected in follicular fluid of women undergoing in vitro fertilization (IVF)
procedures (Arnteby et al., 1996; Sugino et al., 1996;Tao et al., 1997; Manau et
al., 1999; Barroso et al., 1999; Manau et al., 2000; Lee et al., 2000; Reis et al.,
2000; Barrionuevo et al., 2000). A negative correlation between human IVF
outcome and concentrations of NO metabolites in donor follicles has been
reported (Barroso etal., 1999; Barrionuevo etal., 2000). Furthermore, one study
found no correlation between intrafollicular NO concentrations and ovarian
response markers such as oocyte maturation, oocyte quality and pregnancy
outcome (Lee et al., 2000; Manau et al., 2000). While two studies failed to show
a significant correlation between NO and follicle size (Sugino et al., 1996; Tao et
al., 1997), another study reported a significant correlation between NO and
follicle size and between NO and E2 concentrations (Anteby et al., 1996).
To date, only one study reported the concentrations of NO metabolites in
animals, using bovine ovaries obtained from a slaughterhouse (Basini et al.,
1998). Intrafollicular NO concentrations from small follicles were significantly
higher than those determined in larger follicles. Granulosa cells obtained from
these follicles were cultured for up to 144 h and exposed to a NO donor (SNAP),
which decreased the production of both E2 and P4 (Basini et al., 1998).
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Nitric Oxide and Physiology of Vagina. Cervix and Uterus
NOS isoforms have been identified in the vagina, cervix and uterus of
mice (Grozdanovic etal., 1994; Boquet etal., 1998), rats (Chatterjee etal., 1996;
Dong et al., 1998; Al-Hijji et al., 2001), rabbits (Batra and Al-Hijji, 1998; Al-Hijji et
al., 2000), sows (Majewski et al., 1995; Wu et al., 1998), cows (Majewski et al.,
1995; Rosselli et al., 1996) and humans (Hoyle et al., 1996). The temporal
pattern of expression of these NOS isoforms probably reflect hormonal and
tissue-remodeling events characteristic of the estrous cycle and also changes
associated with the pregnancy status (Buhimschi et al., 1995). Although the
presence of NOS isoforms in the genital tract is unquestionable, as is their
impact on uterine function in non-pregnant and pregnant animals, a clear and
complete biological characterization of these functions is yet to be fully
elucidated. For example, this particulate form of eNOS had greater activity than
the cytosolic isoform in the uterus of nonpregnant sheep (Figueroa and
Massman, 1995) and pregnant rabbit (Sladek et al., 1993). However, in
nonpregnant sheep NOS activity was highly sensitive to Ca2+ modulation,
whereas in the pregnant rabbit NOS activity was significantly insensitive to Ca2+
oscillations. In another study using nonpregnant rabbits (Batra and Al-Hijji, 1998),
the cytosolic form of iNOS was more predominant than the particulate one, and
both were highly Ca2+ dependent. Cyclic changes associated with tissue
remodeling of the genital tract are intimately dependent on control by ovarian
steroids (Al-Hijji et al., 2001). Accordingly, E2 (Zancan et al., 1999) and P4 (AlHijji et al., 2000; Rupnow et al., 2001) have been found to modulate NOS activity
in the genital tract in nonpregnant and pregnant females. Expression of nNOS
and eNOS are differentially regulated by E2 in the sheep uterus (Zhang et al.,
1999). Expression of nNOS by E2 may regulate myometrial activity and glucose
metabolism in the uterus, whereas the E2-mediated regulation of eNOS
expression may be related with the control of uterine blood flow.
The role of NOS isoform activities in the vagina seems to be to control the
blood supply and relaxation of smooth muscle, which denote important functions
for sexual excitement, copulation and functioning as a birth canal (Berman et al.,

42

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1998). Al-Hijji et al. (2000) reported NOS activity in the rabbit vagina that was
nearly 4-fold higher than in the uterus, pointing to a tissue-specific NOS
regulation under the influence of the same hormonal milieu. Expression of iNOS
just before and after labor has been implicated in the human cervical ripening
process (Bansal etal., 1997; Tschugguel etal., 1999).
In the nonpregnant uterus NOS activity may be associated with local
events that are primarily under the control of steroids. The vagina, cervix and
uterus undergo notable physiologic changes during estrus that are preparatory
for copulation, gamete and early conceptus transport, and establishment of
pregnancy. These changes depend on proper control of blood flow, endometrial
glandular secretion and myometrial activity.
In summary, P4, while maintaining uterine quiescence in cooperation with
uterine catalytic expression of NOS isoforms, acts to decrease the expression of
NOS isoforms in cervical tissues. Upon the initiation of events leading to labor,
uterine NOS activity decreases whereas cervical NOS isoforms up-regulate,
facilitating cervical softening (ripening) and dilation (Buhimschi et al., 1997). It
seems that eNOS is mainly decreased in the uterus, whereas, iNOS and nNOS
are up-regulated in the cervix as parturition approaches (Yallampalli et al., 1993).
These hypotheses are supported by results of studies using an antiprogesterone
agent (onapristone) that mimicked the changes in eNOS and iNOS expressions
in uteri and cervices of rats during labor (Ali et al., 1997).
Nitric Oxide and Luteal Function
Luteinization is a process that starts before ovulation is completed in
response to the LH surge. In the horse, the initiation of luteinization is evidenced
by an increase in follicular concentrations of P4 and decreased E 2 production by
the granulosa cell. Histologically, there is an increase in pyknotic cells in theca
intema, whereas, granulosa cell double in thickness after hCG stimulus. These
histological changes are accompanied by severe edema, hyperemia and
hemorrhages of theca intema and theca externa. After ovulation, angiogenesis is
accelerated and neovascularization invade the former avascular granulosaderived luteal cells. The corpus luteum becomes a potent endocrine gland, being
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highly vascularized and with a growth rate only comparable to fast-growing
tumors.
Van Voorhis et al (1994) reported the presence of NOS isoforms in human
granulosa cells from women undergoing infertility treatments. It was noted that
the addition of NOS inhibitors to the cell culture system resulted in a higher
steroid production by granulosa cells, whereas addition of NO donor agents
significantly suppressed steroid production. It was then concluded that NO ahs a
strong anti-steroidogenic activity. Later, Olson et al., (1996) reported the
presence of eNOS and, to a lesser extent, iNOS in rat luteal cells. Inhibition of
NOS activity as evidenced by lower nitrite concentrations in the culture medium
was achieved by treatment with AG or L-NAME. Addition of SNP to cultured
luteal cells inhibited both E2 and P4 productions by rat luteal cells (Olson et al.,
1996).
Similar results have also been reported for human ovaries confirming the
presence of NOS isoforms in luteal cells (Vega et al., 1998) and a role for NO in
luteal regression has been suggested (Friden et al., 2000). In rabbits,
prostaglandin F2q (PGF2a) up-regulated the expression of NOS isoforms that was
followed by a marked decreased in P4 production (Gobbetti et al., 1999). These
authors subsequently reported that NO modulation in luteal cells was mediated
by PKC/PKA signal transduction pathways (Boiti et al., 2000). Intra-luteal
administration of L-NAME resulted in extended lifespan of the corpus luteum that
prolonged diestrus in Holstein heifers, suggesting a role for NO on luteal
regression in cows (Jaroszewski and Hansel, 2000).

Nitric oxide and embryonic development
The role of NO on embryonic development is not clear. Administration of a
NO donor agent to a bovine embryo culture system inhibited embryonic
development (Lim and Hansel, 1998) but a similar result was noted when NO
production was inhibited in a mouse embryo culture system (Gouge et al., 1998).
The addition of hemoglobin, a NO scavenger, significantly promoted bovine
embryonic development (Lim et al.,

1999). In a more elaborated study

investigating the role of NO in mouse oocyte maturation and embryonic
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development, it was found that low doses of SNP promoted oocyte maturation,
increased the percentage of embryos reaching blastocyst stage and enhanced
trophoblast outgrowth (Sengoku et al., 2001). The latter result denotes a role for
NO in the implantation process as it has been previously suggested for rats
(Biswas etal., 1998).
HYPOTHESES
I decided to investigate the role of NO in equine and bovine follicular
dynamics and steroidogenesis seeking to answer questions that had not been
addressed before: 1) does the systemic inhibition of NO cause permanent
inhibition of ovulation, leading to follicular atresia, or only delay ovulation, once
NO inhibition subsides?; 2) How does the anti-steroidogenic activity of NO relate
to its participation in the ovulatory process?; 3) is NO involved in the process of
hCG-induced preovulatory follicular luteinization in vivo?; 4) is NO involved in the
process of in vitro functional luteinization?; and 5) what are the pharmacokinetics
and hemodynamics of L-NAME, a potent nonspecific NOS inhibitor, in horses?
The hypotheses for the present study were:
1) The systemic administration of NOS inhibitors will block hCGinduced ovulation in mares and cows.
2) The systemic administration of hCG to mares in estrus will upregulate the NO pathway in the equine preovulatory follicle.
3) Cultured equine and bovine granulosa cells treated with NOS
inhibitors will have lower P^E 2 ratios (an indicator of functional
luteinization.
4) The systemic administration of bolus injection of L-NAME will cause
transient systemic and pulmonary hypertension due to its short half
life.
The primary goals of this study were to use large animals such as mares
and

cows,

which

can

be

routinely

examined

by

transrectal

ovarian

ultrasonography, to determine how parameters of follicular dynamics such as
follicular growth and ovulation would be affected by administration of NOS
inhibitors. Analyses of follicular concentrations of P4, E2 and NO, before hCG and
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36 h after hCG administration will provide information on whether the NO
pathway is up-regulatory following an ovulatory stimulus or not. Furthermore,
analyses of P4:E2 ratios of granulosa cells treated with NOS inhibitors and a NO
donor agent will show how NO relates to the phenomenon of in vitro luteinization.
Finally, I sought to characterize the pharmacokinetic and cardiovascular
parameters associated with an intravenous bolus administration of L-NAME.
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CHAPTER 2
EFFECTS OF NITRIC OXIDE SYNTHASE INHIBITORS ON
OVULATION IN hCG-STIMULATED MARES
INTRODUCTION
During the past three decades researchers have investigated the
regulation of follicular dynamics and ovulation (Espey and Lipner, 1994; Tsafriri
and Reich, 1999). In addition to hypophyseal and ovarian steroid hormones, it is
now known that growth factors (Koos, 1995), proteolytic enzymes (BrSnnstrdm et
al., 1988; Tsafriri et al., 1989) and cytokines (BrSnnstrOm et al., 1994; Ujioka et
al., 1998) play a significant role in overall ovarian function. It has been
hypothesized that imbalances in any of these factors may lead to ovarian
dysfunction. Nitric oxide (NO) has emerged as one of the most recently
discovered modulators of ovarian function (Van Voorhis et al., 1994; Rosselli
et al., 1998). Nitric oxide is a small molecule that is the product of the enzymatic
conversion of L-arginine to citruliine. The reaction is catalyzed by the enzyme
nitric oxide synthase (NOS). To date, three different genes have been cloned
encoding for different NOS isoforms. Two isoforms, neuronal NOS (nNOS) and
endothelial NOS (eNOS), are mainly constitutively expressed, whereas the
expression

of

a

third

isoform

(iNOS)

is

induced

by

cytokines

and

lipopolysaccharides (Moncada et al., 1991). The action of NO is autocrine and
paracrine in nature as a result of its high diffusion rate in cell membranes, high
solubility and ultra short half life (Moncada et al., 1991; Rosselli et al., 1998).
Nitric oxide isoforms have been found in ovarian cells of rats (Van Voorhis
et al., 1995; Zackrisson et al., 1996; Jablonka-Shariff and Olson, 1997), rabbits
(Hesla et al., 1997), horses (Pinto et al., unpublished) and humans (Van Voorhis
et al., 1994). The expression of ovarian NOS seems to be under gonadotropin
regulation (Van Voorhis et al., 1995; Chatteqee et al., 1996; Zackrisson et al.,
1996; Srivastava etal., 1997 Jablonka-Shariff and Olson, 1997; Nakamura etal.,
1999). In addition, iNOS and eNOS expression appear to modulate follicular
steroidogenesis and the ovulation process, as suggested by studies investigating
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specific and non-specific inhibition of these isoforms (Bonello et al., 1996;
Shukovski and Tsafriri, 1994; Ahsan etal., 1997,).
The addition of iNOS and eNOS inhibitors into human granulosa cell
cultures increased E2 secretion by granulosa cells and had little or no effect on P4
secretion (Van Voorhis et al., 1994). When NO generator agents were added into
the granulosa cell culture, E2 and P4 secretion by granulosa cells decreased
considerably (Van Voorhis et al., 1994). Similar findings were reported by Basini
et al. (1998) working with bovine granulosa cells exposed to a NO generator.
In other studies, inhibition of iNOS and eNOS performed in vivo (Hesla et
al., 1997) or using ex vivo ovarian perfusion (Yamauchi et al., 1997) invariably
resulted in a significant reduction in the ovulation rate in rabbits treated with
human chorionic gonadotropin (hCG). When NO generators were used
concomitantly with NOS inhibitors, ovulation rates were similar to that of controls
(Shukovski and Tsafriri, 1994). In some studies, administration of NO generators
alone to rabbits and rats caused ovulation to occur at a time similar to animals
treated with hCG (Yamauchi ef al., 1997; Mitsube etal., 1999).
Ovulation and pregnancy rates in mice genetically engineered by a
knockout procedure to be deficient in iNOS or eNOS were lower than those of
wild-type animals (Jablonka-Shariff and Olson, 1998). In that study, impairment
of ovulation was also accompanied by a higher than normal incidence of oocyte
meiotic abnormalities. In a subsequent study, iNOS and eNOS knockout mice
displayed irregular estrous cycles, disruption of normal E2 and P4 plasma profiles,
a reduced number of developing follicles in the ovaries and lower ovulation rates
(Jablonka-Shariff et al., 1999b). Abnormalities of the estrous cycles were more
evident in eNOS-knockout than in iNOS-knockout mice.
In studies performed in laboratory animals, subjects are euthanatized to
examine the reproductive tract at specific times after hCG administration.
Because ovaries are only examined postmortem, the specific fate of individual
follicles is not known. Unfortunately, when this investigative approach is used
and an animal is categorized as having lower ovulation rates, it is uncertain
whether the ability of the remaining follicles to ovulate would be blocked
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permanently (leading to anovulation followed by atresia) or temporarily blocked
resulting in delayed ovulation. Thus, the results of those studies do not provide
information on the fate of unruptured follicles if the ovarian reproductive cycles
were allowed to proceed.
To answer these questions, horse and pony mares, a species with a
prolonged estrus (5 to 7 days) and a long ovulatory phase (36 to 48 h after hCG
induction), were used to evaluate what effects administration of NOS inhibitors
might have on follicular dynamics and on ovulation pattern. The two possible
fates of ovarian follicles, ovulation or anovulation (followed by either regression
or luteinization of the unruptured follicle), are routinely evaluated in mares using
palpation per rectum and transrectal ultrasonography. In the present study,
aminoguanidine (AG), a relatively specific iNOS inhibitor, and NG-nitro-L-arginine
methyl ester (L-NAME), a nonspecific NOS inhibitor, were administered to mares
in estrus and the effects of NOS inhibitor administration on follicular growth rate
and ovulation pattern were documented. The hypothesis was that administration
of NOS inhibitors would delay hCG-induced ovulation in estrous mares.
MATERIALS AND METHODS
Experimental Animals and Agents
Mares used in this study were treated according to a protocol approved by
the Institutional Animal Care and Use Committee of the School of Veterinary
Medicine, Louisiana State University, in accordance with NIH guidelines for the
care and use of animals for research. Forty cycling mares in good body condition
(2 0

horse and

20

pony mares) of varying ages were allotted by breed type across

the treatment groups.
Aminoguanidine hemisulfate (AG) and NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME) were purchased from Sigma Chemical Company
(St. Louis, MO).
Experimental Design and Procedures
Palpation per rectum and ovarian ultrasonography were performed twice
daily to assess follicular development from the beginning of estrus until ovulation
was detected. When an ovarian follicle was at least 27 mm in diameter, but less
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than 35 mm, mares were subjected to one of the following treatments twice daily
as follows: saline solution 0.9% (n = 20, w/v, iv, q 12 h), L-NAME (n = 10, 148
pmol/kg, iv, q 12 h or AG (n = 10,406 pmol/kg, iv, q 12 h). The L-NAME and AG
solutions were prepared using saline solution, 10% (w/v) and 30% (w/v)
concentrations, respectively. The AG treatment was started 24 h before the hCG
administration, whereas, L-NAME treatment was begun only 12 h before the hCG
administration. This schedule was based on the fact that inhibition of iNOS by AG
in horses likely starts 12 h after administration (Hunter et al, 1999), whereas,
L-NAME inhibitory action was evident during the first hour after iv administration
(Kubes and Granger, 1992). In the control group, 10 mares received a matched
volume of saline solution (Control I) for the AG group (starting 24 h before hCG
administration) and 10 mares received a matched volume (control II) for the
L-NAME group (starting 12 h before hCG administration). Because horses
typically have a long period from hCG administration to ovulation, all treatments
(saline solution, L-NAME and AG) continued until 24 h after hCG administration,
so that L-NAME and AG-treated animals received a total of 4 and 5
administrations, respectively, as did their matched controls.
After treatment was initiated and when a follicle > 30 mm in diameter was
present on one of the ovaries, mares were administered hCG (2,500 iu, iv) to
induce ovulation. Mares continued to be examined twice daily to document
follicular development and time of ovulation. The degree of endometrial edema
observed ultrasonographically during estrus was classified (score of

1

= minimal,

2 = moderate, 3 = strong, 4 = very strong) and a recorded mean score was
calculated for each mare during the time treatments were administered (until 24 h
post-hCG) and analyzed for detection of effects of treatment on endometrial
edema.
Blood samples were taken daily by jugular venipuncture from the
beginning of the treatment until 2 days after ovulation and once a week thereafter
to document the pattern of P4 secretion. Plasma samples were stored at -70 °C
until assayed for P4 as previously described (Thompson etal., 1983).
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Some mares (Control group, n =

6;

L-NAME treated group, n = 3; AG

treated group, n = 4) participating in this study were part of a breeding program
and the resulting pregnancy rates were recorded using transrectal uterine
ultrasonography performed

at d

14 and d 25

post-ovulation. Breeding

management consisted of mating mares in estrus to a proven stallion every other
day until ovulation was detected.
Statistical Analyses
Experimental data are expressed as mean ± SEM. Time of ovulation after
hCG administration was analyzed among treatment groups by the Kruskai-Wallis
ANOVA on ranks test (Shott, 1990). Pair-wise comparisons were made using the
Mann-Whitney rank sum test after being adjusted by the Bonferroni method
(Shott, 1990). The follicle growth rate from 12 h before hCG administration until
ovulation detection was analyzed using one-way ANOVA. When appropriate,
post-hoc

comparisons

were

made

using

Tukey’s

test

(Shott,

1990).

Concentrations of plasma P4 were analyzed by ANOVA. A P value < 0.05 was
considered significant for all tests.
RESULTS
Side effects associated with L-NAME administration were not noted in any
of the treated mares. However, six lactating pony mares receiving AG became
anorectic and sick during or shortly after the end of AG treatment. These sick
mares were treated with fluids but three died within 5 d after being identified as
sick. The remaining three pony mares recovered uneventfully. Necropsy of these
animals confirmed the provisional diagnosis of hepatic lipidosis.
The relationship between systemic administration of AG and incidence of
hepatic lipidosis is yet to be clarified. In mice, oral administration of AG caused
the formation of a Schiff base of AG with pyridoxal phosphate resulting in lower
concentrations of free pyridoxal phosphate in the liver than of control mice
(Taguchi etal., 1998). Pyridoxal phosphate, the coenzyme form of vitamin B6 , is
essential for many biochemical reactions in the body. The potential depletion of
hepatic pyridoxal phosphate in pony mares treated with AG resulting in impaired
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liver function remains to be further investigated. These six animals were not
included in the present study.
All mares ovulated in this experiment. Anovulation followed by luteinization
or atresia of preovulatory follicles was not detected in any of the mares used in
this study. The L-NAME- and AG-treated groups each had one mare that had
double ovulation during estrus. The time to ovulation after hCG administration in
the treatment groups were as follows: saline solution, 41.4 ± 2.5 h; L-NAME, 87.6
± 9.5 h; AG, 61.2 ± 6.9 h;. There was no significant difference between the
groups treated with AG or L-NAME (P = 0.06), however, these groups were
different from the control group (P < 0.05; Figure 2.1).
The follicle size documented at the last ovarian ultrasonographic
examination before ovulation did not differ among treatment groups (saline
solution, 41.4 ± 1 .0 mm; L-NAME, 38.7 ± 2.7 mm; AG, 35.5 ± 1.9 mm; P > 0.10,
Figure 2.2). Similarly, the net follicular growth (change in size) from 12 h before
hCG administration until the last examination before ovulation was not
significantly different among the treatment groups (saline solution, 9.4 ± 0.9 mm;
L-NAME, 11.9 ± 2.7 mm; AG, 7.3 ± 1.5 mm; P > 0.10, Figure 2.3), however, the
pattern of follicle growth was different (saline solution, Figure 2.4; L-NAME,
Figure 2.5; AG, Figure 2.6). The follicular growth rate (defined as the net follicular
growth divided by the number of days counted from

12

h before the

administration of hCG until the detection of ovulation) was 3.9 ± 0.4 mm/day, 2.3
± 0.4 mm/day and 2.0 ± 0.3 mm/day for saline solution treated group, L-NAME
treated group and AG treated group, respectively. The L-NAME- and AG-treated
mares had significantly lower follicular growth rates than did control mares
(P < 0.05; Figure 2.7). Mares treated with L-NAME or AG remained in estrus
longer than mares treated with a control saline solution (P < 0.05; Figure 2.8)
Four mares in the L-NAME group had follicles that did not show any
change in diameter for 5 days and then resumed rapid follicular growth (12 to 23
mm increase in follicle diameter) approximately 36 h before ovulation. In the AG
treated group three mares displayed protracted follicle evacuation that took 24 to
36 h to complete. The prolonged evacuations of the follicular fluid from these
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slowly ovulating follicles were assessed by successive measurements of the
follicle diameters performed at 12-h intervals. Nevertheless, all 42 ovulations in
the present study resulted in apparently normal appearing corpora lutea, as
assessed

by

characteristic

luteal

echogenicity

upon

ultrasonography

examination. No differences were detected in the plasma concentrations of P4 of
treated and control mares during estrus (P > 0.10), similarly, no differences were
detected in plasma P4 concentrations during diestrus (P > 0 . 1 0 ).
Mean uterine edema score were different in the L-NAME treatment group
(1.3 ± 0.2) when compared with control mares (2.0 ± 0.1; P < 0.05), but no
difference was detected when compared with the mean score from AG-treated
mares (1.9 ± 0.2; P > 0.05).
Pregnancy rates were 100% (6 / 6 ), 33.3% (1/3) and 75% (3/4) for control,
L-NAME and AG treatment groups, respectively. The objective was to report that
mares treated with L-NAME or AG could get pregnant, but conclusions on how
NOS inhibitors affect normal fertility could not be drawn from this study. Thus,
statistical analysis for pregnancy rates was not performed.
DISCUSSION
The main objective of this study was to investigate the effects of NOS
inhibition on the follicular dynamics of mares in estrus. These results clearly
demonstrate that L-NAME and AG significantly delayed ovulation in hCGstimulated mares. Moreover, this is the first report to document the follicular
dynamics associated with NOS inhibitors administered continuously throughout
estrus in live animals. Previous studies in mice (Jablonka-Shariff et al., 1999),
rats (Bonello et al., 1996; Jablonka-Shariff et al., 1999) and rabbits (Hesla etal.,
1997, Yamauchi et al., 1997) have shown that inhibition NOS inhibited ovulation.
In these studies, ovulation rates and the quality of ovulated oocytes of animals
treated with NOS inhibitors were significantly decreased.
The previous studies were conducted in small laboratory animals and
repetitive ovarian examination could not be performed. Experimental subjects
had to be euthanatized according to a time schedule to determine the effects of
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Figure 2.1 Time to ovulation (mean ± SEM) after hCG administration to mares in
estrus. Note that mares treated with NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME; n = 1 0 ) or aminoguanidine hemisulfate (AG; n = 10) had
a mean time to ovulation greater than 48 h, whereas control mares (n = 20) had a
mean time to ovulation within 48 h post-hCG administration. Bars with different
letters are significantly different; P < 0.05.
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Figure 2.2 Follicle diameter (mean 1 SEM) recorded during the last transrecta!
ovarian ultrasonography exam before ovulation was detected, did not differ
among mares treated with saline solution (Control; n - 20), NG-nitro-L-arginine
methyl ester hydrochloride (L-NAME; n = 10) or aminoguanidine hemisulfate
(AG; n = 10). (P > 0.10).
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Figure 2.3 Net follicular growth (mean ± SEM) of preovulatory follicles from
mares in estrus treated with saline solution (Control; n = 20), NG-nitro-L-arginine
methyl ester hydrochloride (L-NAME; n = 10) or aminoguanidine hemisulfate
(AG; n = 10). (P > 0.10).
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Figure 2.4 Representative pattern of follicular growth during estrus in mares
treated with saline solution (Control). Follicles of control mares generally
increased in diameter throughout the estrus period.
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Figure 2.5 Representative pattern of follicular growth during estrus in mares
treated with NG-nitro-L-arginine methyl ester hydrochloride (L-NAME). Note that
there is a marked inhibition of follicular growth that reinitiates abruptly 24 h before
ovulation.
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Figure 2.6 Representative pattern of follicular growth during estrus in mares
treated with aminoguanidine (AG). Note the apparent slowing of follicular growth
rate as the mare progresses toward ovulation.
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Figure 2.7 Follicular growth rate (mean ± SEM) was expressed as the net
follicular growth from beginning of treatment until the last transrectal ovarian
ultrasonography examination before detection of ovulation divided by the number
of days of that period. Mares treated with NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME; n =10) or aminoguanidine hemisulfate (AG; n = 10) had
a lower follicular growth rate than control mares (n = 20). Bars with different
letters are significantly different; P < 0.05.
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Figure 2.8 Total number of days (mean ± SEM) in estrus of mares treated with
saline solution (Control; n = 20), NG-nitro-L-arginine methyl ester hydrochloride
(L-NAME; n = 10) or aminoguanidine hemisulfate (AG; n = 10). Note that mares
receiving L-NAME or AG remained in estrus longer. Bars with different letters are
significantly different; P < 0.05.
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NOS inhibition on follicular dynamics. Furthermore, in these previous studies,
assessment of the number of follicles ovulated was performed when normal
ovulation was expected to occur in relation to hCG administration. Thus, the fate
of unruptured follicles found on the ovaries after euthanasia could not be
determined. However, in one study, examination of diestrus ovaries from eNOS
“knockout" mice revealed luteinized follicles and follicles undergoing atresia
(Jablonka-Shariff et al., 1999b). In contrast, in the present study horse and pony
mares receiving AG or L-NAME during estrus had their ovulation only temporarily
blocked as assessed by transrectal ovarian ultrasonography. In fact, regression
and atresia of the preovulatory follicle was not found in any of the treated mares.
The fact that some mares did not ovulate until 5 d after hCG administration
suggested that inhibition of NO production, while inhibiting follicular growth and
ovulation, maintained the potential for follicle development and subsequent
ovulation. It is noteworthy that all mares participating in the present study
ovulated.
The phenomenon of delayed ovulation noted in the present study probably
resulted from local effects of NOS inhibition in the ovary, because all mares
received hCG to induce ovulation, bypassing the potential central effect of NOS
inhibition on luteinizing hormone (LH) release (Traystman et al., 1995; McCann
and Rettori, 1996b). In the rabbit ovary, NO has been implicated in mediating
vascular changes, prostaglandin production and inhibition of steroidogenesis
(Yamauchi et al., 1997). Ovarian vascular changes include vasodilatation of
intraovarian arterioles and altered microvascular permeability leading to edema
formation (Hughes et al., 1990; Powers et al., 1995; Anteby et al, 1996; Kerban
et al., 1999). In addition, NO is involved in the blood-follicle barrier, which is
disrupted after hCG stimulation or administration of NO generators (Powers et
al., 1995; Powers et al., 1996). The equine preovulatory follicle undergoes a
marked hyperemia after hCG administration (Kerban et al., 1999), such that it is
possible to pinpoint the oocyte location in a dissected follicle without
magnification. This is probably due to the presence of enhanced vascularization
in the theca intema over the area that corresponds to the site of the cumulus, an

62

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

observation already made by Thomson (1919) when working with preovulatory
human follicles. Nitric oxide may have a direct effect on these vascular changes
in addition to the suggested role of prostaglandins on follicular vasculature
(Espey, 1980).
The induction of the inducible isoform of cyciooxygenase (COX-2) in
response to an hCG ovulatory stimulus has been shown in rats (Sirois et al.,
1992), cows (Sirois, 1994; Liu e ta l., 1997) and horses (Sirois and Dor6 , 1997).
Enhanced prostaglandin production was detected in preovulatory follicles of
rabbits and the authors of that study proposed that this was, at least in part,
stimulated by NO (Yamauchi et al., 1997). It has also been suggested that NO
mediates hCG-induced prostaglandin E2 production in rat oocyte-cumulus
complexes (Jawerbaum et al., 1997). The interrelationship between iNOS and
COX-2 has been investigated in other tissues (Salvemini etal., 1993; Posadas et
al., 2000). It seems that both inducible pathways (COX-2 and iNOS) play mutual
modulatory roles in an inflammatory response (Posadas et al., 2000). It is
possible that this interrelationship also occurs in the rat ovary, especially after
hCG administration (Faletti etal., 1999).
These NO mechanisms of action suggest that NO may act to signal or
modulate the inflammatory-like events associated with follicle maturation and
ovulation. The biochemical and cellular events leading to ovulation have been
compared to an inflammatory process (Espey, 1980), with this model being
further substantiated in recent years (Cavender and Murdoch, 1988; Espey,
1992; Espey, 1994). The equine preovulatory follicle displays a series of cellular
and vascular changes after hCG stimulation that include extensive remodeling of
the granulosa cell layer, degeneration of the theca cell layer, eosinophilia,
follicle wall hyperemia, vasodilatation of follicle wall vessels, edema and
hemorrhage (Kerban et al., 1999). However, the extent to which NO affects
these periovulatory events is yet to be determined. It has been suggested
that several events related to the phenomenon of inflammation appear to be
mediated or modulated by NO, such as an increased ovarian blood flow after
gonadotropin stimulation (Anteby etal., 1996; Powers etal., 1995), modulation of
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microvascular permeability (Kubes and Granger, 1992), edema formation (lalenti
et al., 1992) and prostaglandin production (Yamauchi et al., 1997; Faletti et al.,
1999). Thus, NO may be an important folliclular mediator of molecular
mechanisms preceding ovulation.
In the present study, ovulation was significantly delayed in mares
receiving AG, thus suggesting a role for iNOS-derived NO in ovulation in mares.
The expression of COX-2 and consequently prostaglandin production in the
equine follicle has been shown to be significant at 33 h post hCG (Kerban et al.,
1999). A half life of 11.04 h has been reported for AG in the circulation of the
horse (Hunter et al., 1999). In the present study, the last treatment administration
was 24 h post-hCG in all 3 treatment groups and plasma concentrations of AG
after 36 h were likely not great enough to interfere with the hCG-induced follicular
production of prostaglandins. Whether administration of AG beyond 24 h posthCG would have caused a more pronounced delay in ovulation is not known at
this time.
In three AG-treated mares follicle evacuation was not completed until 36 h
after the first ultrasound examination that showed initial signs of follicle
evacuation. This prolonged follicle evacuation differs from the normal rapid
pattern of follicle evacuation (varying from seconds up to 7 min) previously
described (Townson and Ginther, 1989). This protracted follicle evacuation could
be explained by an incomplete rupture of the follicle wall, indicating that the
proteolytic cascade was not fully functional. Interactions involving NO and
proteolytic enzymes during the ovulatory process are another aspect of ovarian
physiology yet to be studied.
Other mechanisms of action of AG in addition to iNOS inhibition are
possible. First, AG inhibits diamine oxidase (DAO), an enzyme that catalyzes the
oxidative deamination of histamine and putrescine (Schuler et al, 1952). The AG
dose used in this study (406 umol/kg) was sufficient to cause inhibition of DAO
in guinea pigs, cats and humans (Nilsson, 1999). Inhibition of DAO could
potentially lead to an increase in histamine concentration, resulting in a
histamine-induced increased hyperemia in the preovulatory follicle wall after
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gonadotropin stimulation (Espey, 1980). The histamine-induced increased follicle
wall hyperemia could have a facilitating role in ovulation (Szego and Gitin, 1964;
Schmidt et al., 1986), however, this contrasts with the delayed ovulation noted in
mares receiving AG. W e speculate that the inhibition of NOS by AG overrode any
increase in histamine or its action in the ovary, or that a compensatory
methylation catalyzed by histamine methyltransferase (another pathway for
histamine catabolism) was able to metabolize any excess of histamine. Thus, the
present study provides indirect evidence to support previous studies that
questioned a role for histamine in ovulation in mares (Watson and Sertich, 1991),
sheep (Halterman and Murdoch, 1996) and rabbits (Kitai etal., 1985). The extent
of an AG-induced increase in ovarian histamine concentrations in the mare has
not yet been reported.
Another potential action of AG is stabilization of the active site of the
enzyme S-adenosylmethionine decarboxylase that is a key enzyme in the
synthesis of polyamines such as spermine and spermidine (Stjernborg and
Persson, 1993). The significance of polyamine excess or depletion on ovarian
physiology is presently unknown. Studies utilizing AG as an iNOS inhibitor should
consider all additional potential effects of AG not related to NOS inhibition. It is
recommended that further studies investigating the effect of the iNOS inhibition
on ovarian physiology utilize a more specific iNOS inhibitor than AG.
The extent of the participation of each NOS isoform in the ovulatory
process has not yet been unequivocally determined. In one study, it was
concluded that both iNOS and eNOS contributed to an increase in NO production
after hCG administration in rats (Jablonka-Shariff and Olson, 1997). Other
studies in mice and rats provided evidence that animals treated with nonspecific
inhibitors, or eNOS-knockout animals, showed a greater blockade of ovulation
than did iNOS-knockout animals or after treatment with iNOS inhibitors
(Jablonka-Shariff et al., 1999b; Mitsube et al., 1999). Moreover, in one study,
ovulation rates in control and AG-treated in rat ovaries perfused in vitro were not
significantly different, as opposed to lower rates of ovulation detected in
L-NAME-treated ovaries (Mitsube etal., 1999). On the contrary, a lower inhibition
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of ovulation rates in rats treated with NG-methyl-L-arginine (a nonspecific
inhibitor) as opposed to a stronger inhibition induced by administration of AG has
been reported (Shukosvi and Tsafriri, 1994).
Delayed ovulation in L-NAME and AG-treated mares was accompanied by
a clear slowing of follicular growth. In general, follicles had a decreased growth
rate and some follicles did not show any increase at all during the estrus period.
For four mares in the L-NAME group, follicle growth stopped during treatments
and remained unchanged in size for 5 days when, unexpectedly, follicle growth
resumed 24 to 36 h before ovulation. Remarkably, some follicles in these mares
increased more than 15 mm in diameter in a 24-h period 4 days after hCG
administration, increasing their diameter from 33 mm to 50 mm before ovulation.
This marked increase in follicle diameter within a 24-h period by follicles that had
not shown any significant change in follicle diameter in the previous 5 days
during estrus is noteworthy but still remains unexplained.
A decrease in uterine edema was also observed mainly in mares receiving
L-NAME. This was subjectively assessed by the degree of endometrial folding
observed during ultrasonographic examination. The decrease in uterine edema
was evident 12 h after the first L-NAME administration. This in agreement with
previous studies that found L-NAME blocked the formation of estradiol-induced
uterine edema in rats (Rao et al., 1995). In sheep, a local uterine intraarterial
administration of L-NAME antagonized the increase in uterine blood flow induced
by E2 administration (Van Buren etal., 1992).
The importance of the results reported in this paper is two-fold. First, this
study attests to the presence of a NO-mediated mechanism on follicular growth
and ovulation in mares; secondly, it raises the possibility that delaying ovulation
might be an additional breeding management strategy in brood mares. Because
mares have a long estrus, synchronization of ovulation poses a problem for the
equine industry. Estrous cycles are generally manipulated using drugs that
create an artificial luteal period (progestins) or shorten the luteal period
(prostaglandins). Ovulation is usually induced with hCG or a gonadotropinreleasing hormone analogue. Nevertheless, a high degree of variability among
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mares and within estrous cycles causes economic losses in equine embryo
transfer/artificial insemination programs when ovulation is not successfully
synchronized.
Delaying ovulation could be an aid in synchronizing mares for timed
artificial insemination or preparation of recipients for embryo transfer or oocyte
transfer (or gamete intrafallopian transfer). Delaying ovulation could also be used
for management of natural mating in stud farms. The use of agents that delay
ovulation in association with ones that stimulate it would better accommodate the
booking of mares for a specific stud. It is important to note that in the present
study all treatments were conducted with hCG-stimulated mares. Therefore, it is
plausible to consider that the delay of ovulation in the present study could have
been enhanced if hCG would not have been used. Experiments with more
elaborate treatment schedules (doses, frequencies, etc) using safe and highly
effective NOS inhibitors will help to determine whether delaying ovulation can be
used reliably in the equine breeding industry. Although breeding mares was not a
primary goal of this study, some mares treated with L-NAME or AG became
pregnant and delivered healthy foals. However, the effects of NOS inhibitors and
delaying ovulation on the fertility of the mare need to be further investigated in a
subsequent study.
In conclusion, the present study demonstrates that administration of wellknown NOS inhibitors to mares in estrus until 24 h after hCG administration
caused a temporary delay in ovulation up to 5 days after hCG stimulation. The
characteristic estrous uterine edema was significantly inhibited in L-NAMEtreated mares. The specific mechanism(s) by which administration of NOS
inhibitors caused delayed ovulation remains speculative. Based on recent
research, mechanisms accounting for this phenomenon could include: effects on
ovarian and follicular blood flow (Bonello et al., 1996; Anteby et al., 1996),
modulation of the blood-follicle barrier (Powers et al., 1995), modulation of
follicular apoptosis (Chun et al., 1995; Matsumi et al., 2000) and follicular
prostaglandin and steroid production (Ahsan e ta l, 1997; Faletti etal., 1999).
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CHAPTER 3
CONCENTRATIONS OF NITRIC OXIDE IN EQUINE
PREOVULATORY FOLLICLES BEFORE AND AFTER
ADMINISTRATION OF HUMAN CHORIONIC GONADOTROPIN
INTRODUCTION
Nitric oxide (NO) has emerged in recent years as a novel cell-signaling
molecule implicated in several physiological and pathophysiological mechanisms
(Moncada et al., 1991). After NO was identified as being the endothelial-derived
relaxing factor (Ignarro et al., 1987), researchers soon started to characterize the
ubiquitous nature of this important molecule in many other systems (Moncada
et al., 1991), including the reproductive system (McCann and Rettori, 1996b;
Rosselli et al., 1998; Tsafriri and Reich, 1999). Nitric oxide is produced from the
amino acid L-arginine, a reaction catalyzed by a family of enzymes collectively
known as nitric oxide synthases (NOS). Three isoforms of NO have been
identified.

Two isoforms, endothelial (eNOS) and neuronal (nNOS) are

constitutively expressed and have calcium-dependent regulation. The third
isoform (iNOS) is induced in response to host defense and immune-mediated
mechanisms. These isoforms are responsible for the diversity of NOS expression
in various tissues in the body and for the complexity of NO regulation in many
physiological and pathophysiological processes (Moncada etal., 1991).
Nitric oxide has been implicated in several processes involving the
hypothalamic-hypohyseal-gonadal axis such as sexual behavior (Mani et al.,
1994), LH release (Rettori ef al., 1993), penile erection (Burnett et al., 1992;
Melis et al., 1994), cervical ripening (Denison et al., 1999), ovulation and
granulosa cell steroidogenesis (Tsafriri and Reich, 1999). The participation of NO
in the ovulatory process was suggested by studies in mice (Powers et al., 1996;
Jablonka-Shariff and Olson, 1998), rats (Shukovski and Tsafriri, 1994; JablonkaShariff ef al., 1999; Faletti etal., 1999; Mitsube etal., 1999), rabbits (Hesla etal.,
1997; Yamauchi et al., 1997) and horses (Pinto et al., 2000) using various
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protocols that administered NOS inhibitors or NO-generating drugs (NO donors)
to animals or to in vitro perfused ovaries.
In one study, intraperitoneal administration of aminoguanidine (AG), a
relatively specific inhibitor of iNOS, concomitantly with human chorionic
gonadotropin (hCG) to gonadotropin-stimulated immature rats resulted in a 54%
inhibition of ovulation when compared with rats treated with saline solution
(Shukovski and Tsafriri, 1994). This inhibitory effect of AG on the ovulation rate
was reversed by administration of sodium nitroprusside (SNP, an NO donor).
This group reported that administration of the nonspecific NOS inhibitor
NG-monomethyl-L-arginine (L-NMA) significantly reduced the ovulation rate, but
less so than AG (Shukovski and Tsafriri, 1994).
An opposing finding was reported in the same species (Mitsube et al,
1999). It was noted that the addition of L-NMA to perfused rat ovaries reduced
the ovulation rate, whereas, the addition of AG to the perfusate did not change
the ovulation rate. In another study, administration of NG-nitro-L-arginine methyl
ester hydrochloride (L-NAME, a non specific NOS inhibitor) to rabbits resulted in
a 63% reduction in the normal ovulation rate (Hesla et al., 1997). Recent work
from our laboratory suggests that systemic administration of L-NAME or AG to
estrous mares temporarily inhibited

hCG-induced

ovulation

(Chapter

1 ).

Ovulation was delayed in L-NAME-treated mares for up to 5 days after hCG
administration, however, permanent inhibition of ovulation (leading to follicle
regression and atresia) was not detected. The mechanisms of NO-induced
ovulation have been proposed to be via vascular effects in the preovulatory ovary
(Powers et al., 1995; Bonello et al., 1996), up-regulation of hCG-induced
prostaglandin production (Yamauchi et al., 1997; Faletti et al., 1999) and
modulation of ovarian steroidogenesis (Bonello et al., 1996; Ahsan ef al., 1997;
Yamauchi etal., 1997).
The diversity of NO-mediated modulation of cellular processes has been
attributed to the fact that NO acts not only through the activation of soluble
guanylate cyclase, but also by binding to enzymes of the cytochrome P450
(CYP450) family, such as cyclocxygenase (Salvemini et al., 1993) and CYP450
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aromatase (Snyder et al., 1996), regulatory enzymes for the production of
prostaglandins and E2, respectively. Binding of NO to cyclooxygenase activates
the

complex

(Salvemini

et al.,

1993)

and

may

explain

the

reported

interrelationship between NO and the hCG-induced intrafollicular production of
prostaglandins (Sirois and Dore, 1997; Yamauchi et al., 1997; Faletti et al.,
1999). Conversely, binding of NO to CYP450 aromatase enzyme inhibits its
action (Snyder et al., 1996). This may be one mechanism regulating the
diminished CYP450 aromatase activity noted after hCG administration, thereby,
decreasing E2 production (Voss and Fortune, 1993; Boerboom et al., 1999;
Chaffin and Stouffer, 2000). If we consider the evidence that NO is involved in
the ovulatory process along with the fact that the equine granulosa and theca
interna cells start to luteinize before ovulation in response to an ovulatory
stimulus (Collins et al., 1997; Kerban et al., 1999), then one might propose that
NO may modulate, at least in part, the process of luteinization in the preovulatory
follicle.
The present study was performed to determine the pattern of NO,
progesterone (P4) and E2 concentrations in follicles of estrous mares sampled
before and 36 h after hCG administration. It was hypothesized that the
administration of hCG would result in a higher intrafollicular concentration of NO
in control mares sampled at 36 h post hCG when compared with control follicles
sampled before hCG administration. In addition, the increased NO concentration
of control follicles at 36 h after hCG would likely parallel the hCG-induced
increased P4 :E2 ratio (a marker of hCG-induced preovulatory luteinization)
expected to occur in these same follicles. Our final aim was to determine the
effects of AG, a specific iNOS inhibitor, and L-NAME, a nonspecific NOS inhibitor
on the concentration of NO and steroids in the follicular fluid.
MATERIALS AND METHODS
Experimental Animals and Agents
During the spring and summer of 1999 and 2000, 40 normally cycling
mares

(2 0

pony and

20

light horse mares), as determined by palpation per

rectum and ovarian ultrasonography, in good health, were used in this study. All
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mares were treated according to a protocol approved by the Institutional Animal
Care and Use Committee of the School of Veterinary Medicine, Louisiana State
University, in accordance with NIH guidelines for the care and use of animals for
research.
NG-nitro-L-arginine

methyl

ester

hydrochloride

(L-NAME)

and

aminoguanidine hemisulfate (AG) were obtained from a commercial source
(Sigma, St. Louis, MO).
Experimental Design
The study was carried out in the spring and summer of 1999 and 2000.
Mares were teased daily with a stallion and those displaying behavioral estrus
were examined by transrectal uterine/ovarian ultrasonography twice daily. When
an ovarian follicle was at least 27 mm in diameter, but less than 35 mm, mares
were subjected to one of the following treatments: saline solution 0.9% (n = 20,
w/v, iv, q 12 h), L-NAME (n = 10, 148 pmol/kg, iv, q 12 h) or AG (n = 10, 406
pmol/kg, iv, q 12 h). The L-NAME and AG were dissolved in saline solution, 10%
(w/v) and 30% (w/v) solutions, respectively. The L-NAME treatment started 12 h
before the hCG injection, whereas, the AG treatment started 24 h before hCG
administration. This schedule was based on the fact that the nonspecific
inhibition of NOS by L-NAME starts during the first hour after iv administration
(Mills et al., 1999), whereas, the inhibitory action of AG in horses starts 12 h after
intravenous administration (Hunter et al., 1999). In the control group, 10 mares
received a matched volume of saline solution, starting 12 h before hCG
administration, for the L-NAME (Control L-NAME) and 10 mares received a
matched volume of saline solution, starting 24 h before hCG administration, for
the AG group (Control AG). The L-NAME, AG, Control L-NAME and Control AG
groups were each divided in two groups whereby each mare underwent
preovulatory follicle aspiration one time, either before hCG administration or 36 h
after hCG administration (Table 3.1).
Experimental Procedures
Follicular aspiration was performed using a 60-cm, 17-gauge needle and a
guided ultrasound scanner (Sonovet 600, Universal Ultrasound, NY, NY)
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equipped with a 7.5 MHz transvaginal sector transducer. Immediately before
aspiration mares were sedated with detomidine hydrochloride (0.5 mg/kg, iv) and
butorphanol (0.02 mg/kg, iv). Care was taken to stabilize the ovaries by palpation
per rectum before the follicle was punctured to minimize infiltration of follicular
fluid with blood. Once the needle was advanced inside the follicle, the follicular
fluid was aspirated using a 60 ml syringe connected to an extension set coupled
to the aspiration needle. Immediately after aspiration, the follicular fluid was
centrifuged (2000 x g, 4°C) for 10 min, divided into multiple aliquots and stored at
-70°C until assayed for NO, P4 and E2. Blood samples were taken daily by jugular
venipuncture into heparinized tubes and the harvested plasma was also stored at
- 70°C until assayed for P4 and E2.
Hormonal and Nitric Oxide Analyses
Follicular fluids and plasma without extraction were analyzed for P4 and E2
using radioimmunoassay procedures previously described (Thompson et al.,
1983). Intra-assay coefficients of variation for P4 and E2 analyses were 7.2% and
6.5%, respectively. The inter-assay coefficients of variation were 9.8% and
11.5%, respectively.
Table 3.1 Number of mares randomly allotted to each treatment group along
with respective time-matched control mares. NG-nitro-L-arginine methyl ester
(L-NAME) hydrochloride is a nonspecific inhibitor of nitric oxide synthase and
aminoguanidine (AG) is a relatively specific inhibitor of the inducible nitric oxide
synthase isoform.

Treatment
L-NAME
Control L-NAME

No. of mares
per group
10
10

AG
Control AG

10

Total

40

No. of mares
aspirated before
hCG
5
5

5
5

10

20

No. of mares
aspirated 36 h
after hCG
5
5

5
5
20
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Concentrations of NO in the follicular fluids were determined using a
chemiluminescence detector (Nitric Oxide Analyzer NOA™, Model 280, Sievers
Instruments, Inc., Boulder, CO). Although the follicular fluid samples analyzed in
this study were not grossly contaminated with blood from the follicle wall, a small
pellet of erythrocytes at the bottom of the centrifuge tube was observed in
several samples after centrifugation. Nitric oxide is quickly oxidized to NO 3' in the
presence of hemoglobin (Moncada and Higgs, 1993). Because as little as 0.2
mmol of hemoglobin (4% of normal blood concentration) has been reported to
scavenge NO (Lancaster, 1997) to produce the metabolite NO 3', the follicular
samples were then analyzed for their NO 3' contents. Follicular NO 3' is converted
into NO when in contact with a satured solution of VCL 3 in 1N HCI. Intra- and
inter-assay coefficients of variation for the NO chemiluminescence assay were 9
% and 14.2 %, respectively.
Statistical Analyses
Concentrations of NO, P4 and E2 were analyzed by two-way analysis of
variance (SigmaStat 2.0, Jandel Corporation, San Rafael, CA). All data were
reported as mean

1

SEM of pmol concentrations. When the statistical model

showed significance, post-hoc tests (Tukey’s test) were conducted. Data that did
not pass the normality or equal variance tests were transformed into logarithms
for comparisons.
RESULTS
Identification of Mares in Estrus
The

combination

of

teasing

and

frequent

transrectal

ovarian

ultrasonography was an effective method to detect mares at the initial stage of
estrus. Ultrasonographic examination was also performed on the uterus,
revealing the presence and degree of endometrial edema, which is a landmark of
mares approaching or in estrus (Figure 3.1). Furthermore, follicular diameter was
measured at each examination and presumptive preovulatory follicles were
mapped at least 10 days before the aspiration procedure (Figure 3.2). Thus,
follicular growth status of ovarian follicles was ascertained after repeated
ultrasonographic examinations that accurately classified them regarding their
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state of dominance and progression to the preovulatory stage. Concentrations of
plasma P4 (less than 1 ng/ml) as determined by radioimmunoassay verified the
classification of mares in estrus.
Follicular Fluids
Follicular fluids from

control

mares

obtained

before

(0

h)

hCG

administration had lower concentrations of NO than those from control mares
obtained 36 h after hCG administration (58.3 ± 17.8 pmol vs. 340.4 ± 57.7 pmol;
respectively; P < 0.05; Figure 3.3). Similarly, lower concentrations of P4 were
detected in control follicles harvested before hCG administration than those
sampled 36 h after hCG (1.2 ± 0.4 pmol vs. 26.9 ± 4.2 pmol; P < 0.05; Figure
3.4). In control mares, E2 concentrations of follicles sampled before hCG
administration were higher than those sampled 36 h after hCG (0.41 ± 0 .1 pmol
vs. 0.23 ± 0.1 pmol; P < 0.05; Figure 3.5).
Intrafollicular concentrations of NO in L-NAME or AG-treated mares were
not different from control mares before hCG administration, but were significantly
lower than in control mares at 36 h post-hCG administration (P < 0.05; Figure
3.3). Intrafollicular NO concentrations of L-NAME-treated mares were greater
before hCG than 36 h after hCG administration, whereas intrafollicular NO
concentrations of AG-treated mares did not change overtime (Figure 3.3).
Intrafollicular concentrations of P4 in L-NAME- and AG-treated mares were
significantly lower those that of control samples before and 36 h after hCG
administration (P < 0.05; Figure 3.4). The E2 concentrations in follicles of mares
treated with L-NAME or AG did not differ between follicles sampled before and
36 h after hCG (P > 0 .10 ; Figure 3.5), whereas, E2 concentrations in follicles of
control mares were greater in those sampled before than 36 h after hCG
administration (P < 0.5; Figure 3.5).
The

P4:E2

ratios

were

calculated

based

on

the

intrafollicular

concentrations of these hormones determined in follicles of each treatment group
before and after hCG administration. Control mares had higher P4 :E2 ratios than
L-NAME- and AG-treated mares before and 36 h after hCG (Figure 3.6). The
diameter of follicles punctured before hCG administration did not differ among
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treatment groups (P > 0.10), however, follicles from L-NAME- and AG-treated
mares punctured at 36 h after hCG administration were significantly smaller than
follicles from time-matched control mares (Figure 3.7; P < 0.05). Although
hormonal concentrations in the follicular fluids among treatment groups showed
changes before and after hCG administration, plasma concentrations of P4 and
E 2 did not show these changes.
DISCUSSION
The results of the present study suggest that intrafollicular production of
NO in equine ovaries is up-regulated following administration of an ovulatory
dose of hCG. The concentration of NO in the follicular fluid of control mares was
significantly greater at 36 h after hCG administration than in mares sampled at
0 h (without hCG stimulation). This increase in NO concentration in follicles of
control

mares

paralleled

a

temporally

related

increase

in

intrafollicular

concentration of P4 and decrease in E2 concentration in relation to hCG
administration. These results suggest that the purported participation of NO in
the ovulatory process may also involve modulation of an intrafollicular shift in
steroidogenesis known to occur in response to an ovulatory stimulus (hCG) in
mares (Watson and Hinrichs, 1988; Watson and Sertich, 1991; Collins et al.,
1997; Kerban et al., 1999). The decrease in CYP450 aromatase activity has
been

shown to be one of the first biochemical changes

in follicular

steroidogenesis that characterizes the transformation of the preovulatory follicle
from a primarily E2-producing tissue into an active P4-secreting endocrine
structure. Nitric oxide has been shown to inhibit CYP450 aromatase activity in
human cultured granulosa cells (Snyder et al., 1996) and this may be one of
roles of hCG-induced

production of NO hereby documented

in equine

preovulatory follicles.
Nitric oxide also appears to inhibit steroidogenesis of in vitro cultured
granulosa cells (Snyder et al., 1996; Yamauchi et al., 1997). Addition of NOS
inhibitors to cultured luteinized granulosa cells of rats (Dave et al., 1997), cows
(Basini et al., 1998) and humans (Van Voorhis etal., 1994) invariably resulted in
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Figure 3.1 Ultrasonographic pictures depicting endometrial edema in the left and right uterine horns (a) and in the uterine
body (b) of a mare in estrus.
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Figure 3.3 Nitric oxide (NO) concentration (mean ± SEM) in follicular fluid before
and 36 h after hCG administration. Note the increase in NO concentrations in
control mares 36 h after hCG administration. Mares treated with the NO synthase
inhibitors NG-nitro-L-arginine methyl ester hydrochloride (L-NAME) or
aminoguanidine hemisulfate (AG) did not have a significant increase in NO
concentrations. Bars with different letters are significantly different; P < 0.05.
* See Table 3.1 for the number of animals in each group.
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Before hCG
Figure 3.4 Progesterone (P4) concentration (mean 1 SEM) in follicular fluid
before (left y-axis) and 36 h after hCG (right y-axis) of mares treated with saline
solution (Control), NG-nitro-l-arginine methyl ester hydrochloride (L-NAME) or
aminoguanidine hemisulfate (AG). Note the increase in intrafollicular P4
concentrations in control mares after hCG stimulation as compared with to the
modest increase noted in mares treated with L-NAME and AG. Bars with different
letters are significantly different; P < 0.05.
* See table 3.1 for the number of animals in each group.
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Figure 3.5 Estradiol (E 2) concentration (mean ± SEM) in follicular fluid before
and 36 h after hCG administration. There were no significant differences between
intrafollicular E2 concentrations before and 36 h after hCG in mares treated with
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME) or aminoguanidine
hemisulfate (AG). However, E2 concentrations of control mares were lower 36 h
after hCG than before hCG administration. Bars with different letters are
significantly different; P < 0.05.
* See table 3.1 for the number of animals in each group.

80

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Control
L-NAME

O «

»«
“
iu

*9
2
5

c

w•

Q . CO

36 h after hCG *

Before hCG *

Figure 3.6
Progesterone:estradiol (P4:E2) ratio (mean ± SEM) based on
intrafollicular P4 and E2 concentrations before hCG (see left y-axis) and 36 h after
hCG (see right y-axis) of mares treated with saline solution (Control), NG-nitro-Larginine hydrochloride (L-NAME) or aminoguanidine hemisulfate (AG). Note the
marked increase in ratios of control mares after hCG stimulation resulting both
from increased intrafollicular P4 production as well as decreased E2 production.
Bars with different letters are significantly different; P < 0.05.
* See table 3.1 for the number of animals in each group.
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Figure 3.7 Follicle diameter (mean ± SEM) determined immediately before
follicular aspiration performed before hCG or 36 h after hCG administration.
There were no differences in follicles sizes among the treatment groups when
aspiration was performed before hCG. Note, however, that follicles from mares
treated with NG-nitro-L-arginine hydrochloride (L-NAME) or aminoguanidine
hemisulfate (AG) did not increase in diameter after hCG stimulation and were
smaller than follicles from time-matched controls. Bars with different letters are
significantly different; P < 0.05.
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increased E2 production by the granulosa cells and little or no effect on P4
production, whereas, addition of NO donors into culture wells resulted in a
significant inhibition of steroidogenesis, primarily E2 production. Moreover,
decreased production of androstenedione was found in genetically altered mice
deficient in eNOS and iNOS (Jablonka-Shariff et al., 1999b). In the present study,
increased concentrations of NO in follicular fluid were associated with low
concentrations of E2 after hCG administration. Mechanisms mediating NOinduced inhibition of steroidogenesis involve direct inhibition of NO on CYP450
steroidogenic enzymes, mainly the CYP450 aromatase (Van Voorhis etal., 1994;
Snyder et al., 1996), and NO-stimulated activation of soluble guanylate cyclase
(Ishimaru ef al., 2001).
The administration of hCG to mares in estrus induces ovulation and
triggers biochemical events leading to preovulatory luteinization that translates
into augmented P4 production and diminished E2 production by equine granulosa
cells. The declining intrafollicular E2 concentrations found in hCG-stimulated
equine

preovulatory follicles

reflect hCG-induced

regulation

of CYP450

aromatase that involves dual regulation of promoter II- and promoter 1f-derived
transcripts in granulosa cells. A switch in the expression of these two promoters
has been suggested (Boerboom et al., 1999). Administration of hCG downregulates promoter ll-derived P450 mRNA transcripts and induces promoter
1f-derived transcripts in the granulosa cells. Loss of CYP450 aromatase activity
derived from down-regulation of promoter II is evident within 24 h post-hCG
administration.
Furthermore, down-regulation of CYP450 17a-hydroxylase mRNA in theca
cells at 33 h post-hCG is likely a result of theca interna cell degeneration. Loss of
CYP450 17a-hydroxylase activity is coincidental with the loss of steroidogenic
acute regulatory protein mRNA in cells of the theca intema and accounts for the
scarcity of androgen substrates for aromatization. One might consider that
changes in follicular steroidogenesis induced by hCG may be perceived as antisteroidogenic but, in reality, hCG only steers the potential for follicular
steroidogenesis toward P4 production. Molecular regulation of these complex
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mechanisms controlling the steroidogenesis shift after hCG stimulation may be
well modulated, at least in part, by NO and NO-derived nitrosothiols with
biological action. Therefore, the role of NO as an anti-steroidogenic molecule
needs to be redefined.
Accordingly, results from research using the in vitro ovarian perfusion
model or human follicular fluid analysis have suggested that the relationship
between NO and follicular steroidogenesis may be more complex than just
classifying NO as an anti-steroidogenic molecule. For example, in addition to
providing evidence that NOS inhibitors blocked hCG-induced ovulation in
perfused rat ovaries, it has been also reported that addition of L-NAME to the
perfusion system resulted in decreased E2 production by the perfused ovary
(Bonello et al., 1996). In another study using the perfused rat ovary model,
addition of a nonspecific NOS inhibitor (N-monomethyl-l-arginine) and AG did
not alter the pattern of steroid production as compared with ovaries perfused with
saline solution (Mitsube et al., 1999). However, stimulation of steroidogenic
activity was evident, because the addition of a diazeniumdiolate NO donor agent
(spermine NONOate) to the perfusion medium resulted in a significant increase
in P4 secretion by the perfused ovary.
in the present study, mares treated with L-NAME or AG did not experience
the

expected

decrease

in

intrafollicular

E2

concentrations

after

hCG

administration. These findings suggest that inhibition of NO may have served to
presen/e CYP450 aromatase activity despite the luteinizing action of hCG
administration. Conversely, intrafollicular P4 concentrations of NOS inhibitortreated mares modestly increased over time after hCG administration suggesting
a partial hCG-induced action in follicular luteinization of these treated mares.
However, the hCG-induced increase in intrafollicular P4 concentrations of NOS
inhibitor-treated mares were significantly lower than the increase noted in follicles
from control mares.
In contrast to the results of the present study, NO metabolites (NO 3 and
N 0 2) were positively correlated with E2 concentration in follicular fluid obtained
from women undergoing in vitro fertilization (IVF) procedures (Anteby et al.,
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1996). Unfortunately, P4 concentrations in the follicular fluid were not measured
in that study. In subsequent study study, no differences were found in NO
concentrations in human follicular fluid samples aspirated from large, medium
and small follicles 34h after hCG administration (Sugino et al., 1996). Similar
results were reported in a subsequent study (Tao et al., 1997), where no
correlation was found between NO metabolites and steroids (P 4 and E2)
measured in human follicular fluid obtained from follicles classified as primary or
secondary follicles (based on size). It is important to note that these studies in
human subjects used follicular fluids from hCG-stimulated follicles of various
sizes and stages of follicular maturation.
Because hCG administration is known to induce pivotal processes leading
to follicular maturation and ovulation (Watson and Hinrichs, 1988; Watson and
Sertich, 1991; Collins etal., 1997; Kerban etal., 1999; Chaffin etal., 2000), we
feel that a better model to investigate the relationship between NO and follicular
dynamics or maturation would utilize follicles either undergoing growth or atresia,
before and after hCG administration. In that aspect the human IVF model is
limited and offers constraints to providing meaningful information on these
follicular dynamics variables.
However, using mares in studies of follicular dynamics is an attractive
model because palpation per rectum and ultrasonography of ovaries can be
performed repeatedly throughout the estrous cycle and more information can be
gained for a given time frame. Collectively, the results of previous studies
exemplify how different experimental approaches may lead to discrepant
conclusions about the involvement of NO in follicular steroidogenesis, for
example, inhibition of steroidogenesis (based on granulosa cell culture studies),
stimulation of steroidogenesis (in vitro ovarian perfusion studies) or absence of
correlation between NO and variables of follicular dynamics and maturation
(IVF-derived follicular fluid studies).
Much evidence exists suggesting the participation of NO in the ovulatory
process in mice (Jablonka-Shariff et al., 1999b), rats (Shukovski and Tsafriri,
1994; Mitsube et al., 1999), rabbits (Hesla et al., 1997; Yamauchi et al., 1997)
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and mares (Pinto et al., 2000). If expression and up-regulation of NO were truly
necessary for ovulation to occur, what would its role be in relation to follicular
steroidogenesis,

specifically

in

regard to

the

hCG-induced

preovulatory

luteinization? In the present study, preovulatory luteinization as evidenced by
increased intrafollicular concentrations of P4 and decreased E 2 was accompanied
by a significant increase in intrafollicular NO concentrations after hCG
stimulation.
This

increase

in

P4

was

partially,

but

significantly

blocked

by

administration of L-NAME or AG, which disrupted the expected hCG-induced
pattern of steroid production and increased NO concentrations in follicular fluids
as detected in follicles of control mares. W e failed to detect any difference in
intrafollicular E2 concentrations in both groups of animals treated with L-NAME
(a nonspecific inhibitor) or AG (an iNOS specific inhibitor) and before and after
hCG administration, suggesting that inhibition of NO likely contributed to
preserving CYP aromatase activity. Furthermore, intrafollicular P4 concentrations
in these treatment groups were significantly lower than those of control mares
after hCG stimulation, indicating that both eNOS and iNOS isoforms may be upregulated following hCG administration in mares.
The effects of the administration of systemic NOS inhibitors, L-NAME and
AG, in the present study contrast with those from our granulosa cell culture study
(Chapter 4) where it was noted that L-NAME and AG affected the P4 :E2 ratio
primarily by increasing E2 production by equine granulosa cells and not P4. In the
present study, systemic administration of NOS inhibitors likely resulted in
vascular changes in the ovaries, effects obviously absent in the granulosa cell
culture study. Differences in these two experimental approaches may explain the
discrepancy between the results reported herein and Chapter 4. However, a
common conclusion that is drawn from these studies is that NOS inhibitors
prevented or partially inhibited the normal pattern of hCG or LH-induced
luteinization of the granulosa cells, as evidenced by the decreased P4: E2 ratio
documented in the equine granulosa cell culture study and in the present study.
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Using the equine model, repeated ovarian ultrasonography showed the
initiation of development of specific follicles toward their state of dominance and
progression to the preovulatory stage. Moreover, each follicle aspiration
procedure was performed in a way to minimize blood contamination of follicular
fluid samples and, because oocyte searches were not a goal of this study
(in contrast to a human IVF clinical setting), follicular fluid samples were
minimally exposed to room atmosphere and samples were rapidly processed and
stored in the freezer. This experimental approach likely enabled us to detect
significant up-regulation of NO production in the follicular fluid in response to an
hCG stimulus, a phenomenon not yet reported in any other species.
In summary, results of the present study suggest the presence of an NOgenerating system in the equine ovary that is up regulated following an
intravenous ovulatory dose of hCG. Increases in intrafollicular concentrations of
NO

after

hCG

administration

paralleled

the

hCG-induced

preovulatory

luteinization, providing a conciliatory explanation for the purported role of NO in
ovulation and the seemingly conflicting NO-induced inhibition of steroidogenesis
in cultured granulosa cells (Dave et al., 1994; Ahsan et al., 1997; Basini et al.,
1998).
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CHAPTER 4
EVIDENCE FOR A NITRIC OXIDE-MEDIATED MODULATION OF
EQUINE GRANULOSA CELL STEROIDOGENESIS
INTRODUCTION
Several recent studies suggest the existence of a nitric oxide-generating
system in the ovaries of quail (Van Nassauw et al., 1999), small laboratory
animals (Van Voorhis et al., 1995; Chatterjee et al., 1996; Zackrisson et al.,
1996; Hesla et al., 1997), cows (Basini et al. 1998), humans (Van Voorhis et al.,
1994) and horses (Pinto et al., 2000). Nitric oxide (NO) is synthesized as a result
of the conversion of L-arginine into citrulline, a reaction catalyzed by the enzyme
nitric oxide synthase (NOS). The expression and regulation of NOS have been
suggested to be under gonadotropin control during the reproductive cycles of rats
(Jablonka-Shariff and Olson, 1997; Nakamura etal., 1999), rabbits (Hesla etal.,
1997) and humans (Anteby etal., 1996; Rosselli etal., 1994a). Both the inducible
(iNOS) and the endothelial (eNOS) isoforms of NOS have been implicated in
mechanisms regulating follicular dynamics. It appears that NO, a small gas
molecule with an ultra short half life, modulates follicular growth and atresia
through apoptotic mechanisms (Chun et al., 1995) and also acts as an important
signaling molecule in the ovulatory process of mice, rats and rabbits (Tsafriri and
Reich, 1999).
The role of NO in the ovulatory process of rats is, at least in part,
attributed to its vascular effects in the ovary such as increased blood flow that is
characteristic of preovulatory follicular physiology (Shukovski and Tsafriri, 1994;
Anteby et al., 1996; Kerban et al., 1999). However, nonvascular effects of NO on
ovulation in rats have also been suggested (Bonello et al., 1996). In the latter
study, administration of N°-nitro-L-arginine methyl ester (L-NAME) to in vitro
perfused rat ovaries caused a 46% decreased flow rate in the perfusion system
and a significant decline in ovulation rate. Artificially adjusting the flow rate of
ovaries perfused with luteinizing hormone (LH) and interleukin-1 p to that same
extent did not suppress the ovulation rate thereby, showing that the L-NAME-

88

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

induced inhibition of ovulation was not caused solely by decreased perfusion. In
addition L-NAME treatment caused a reduction in estradiol (E 2) secretion by LHtreated perfused ovaries.
However, most studies that exposed cultured granulosa cells of rats,
rabbits and humans to (NOS) inhibitors or NO donors suggest that NO modulates
steroidogenesis by inhibiting cytochrome P450 (CYP450) aromatase activity
(Snyder et al., 1996). Van Voorhis et al. (1994) noted that when NOS inhibitors
were added to a

human granulosa cell culture,

E2 production by the

granulosa cells was significantly increased, whereas, no change resulted in
progesterone (P4) production. The addition of an NO generator, S-Nitroso-Lacetyl penicillamine (S-NAP), caused a significant inhibition of both E2 and P4
production; however, the E2 production was inhibited more than P4 production.
Similar findings of NO-induced inhibition of follicular steroidogenesis have been
reported in rats (Dave et al., 1997; Dunnam et al., 1999), rabbits (Yamauchi et
al., 1997) and cultured bovine granulosa cells (Basini etal., 1998).
Follicular steroidogenesis is essential to the dynamics of ovarian
functioning in response to hypothalamic and hypophyseal hormonal signals. In
mares, the theca interna and granulosa cells are thought to act in unison to
balance the production of progesterone, androgens and estrogens depending
upon the stage of follicular growth or maturation and atresia (Sirois et al., 1990;
Gerard and Monget, 1998). After an ovulatory stimulus, granulosa cells of the
equine preovulatory follicle start to increase P4 production while the production of
E2 decreases. This shift in steroidogenesis increases the P4:E2 ratio in the
follicular fluid and has been used as a marker of mature follicles approaching
ovulation (Watson and Sertich, 1991; Collins etal., 1997).
In this study, cultured equine granulosa cells were exposed to NOS
inhibitors or an NO generator. Accordingly, AG, a relatively specific iNOS
inhibitor, L-NAME, a non specific NOS inhibitor, or SNP, an NO generator, were
added to cultured equine granulosa cells and E2 and P4 concentrations in the
media were determined after 24 h of incubation. Our hypothesis was that the
addition of NOS inhibitors to equine granulosa cells would result in greater
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steroidogenesis output than similar granulosa cells cultured without the addition
ofL-NAME, AG or SNP.
MATERIALS AND METHODS
Experimental Aoents and Culture Medium
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), aminoguanidine
hemisulfate (AG) and sodium nitroprusside (SNP) were purchased from Sigma
Chemical Company (St. Louis, MO). Cell culture media were prepared using
TCM-199 (Gibco, Grand Island, NY) in combination with 5% fetal bovine serum,
2% SerXtender™ (Irvine Scientific, Santa Ana, CA), 10 ng/ml FSH (Sigma, St.
Louis, MO), 1 pg/ml LH (Sigma, St. Louis, MO), 10'7 M androstenedione (Sigma,
St. Louis, MO), and 1% (v/v) antibiotic-antimycotic (100 IU penicillin, 100 mg
streptomycin, 0.25 pg amphotericin-B (Sigma, St. Louis, MO). All media used in
this study were filtered through a

0 .2

pm filter.

Preparation of Equine Granulosa Cells (EGC)
Ovaries utilized in this study were obtained from cycling mares that were
euthanized for reasons unrelated to reproductive problems. Mares were palpated
before the euthanasia, and the stage of the estrous cycle was estimated based
on transrectal ultrasonography of the ovaries and uterus. Only ovaries from
mares with a follicle >30 mm and well-developed uterine edema were used in this
study. Post-mortem examination of the uterus (presence of well-developed
uterine edema), ovaries (large preovulatory follicle and absence of the corpus
luteum) and plasma P4 concentrations <1.0 ng/ml confirmed the antemortem
ultrasound findings.
Equine granulosa cells were obtained from follicles that were classified as
preovulatory follicles from three estrual mares. Only one follicle was harvested
per mare and cultures of EGC were completely separately for each mare. Using
careful dissection, follicles were isolated from the ovarian stroma and mural
granulosa cells were obtained by gently scraping the inside of the follicle wall
with a scalpel blade. Granulosa cells were placed into a 15-ml centrifuge tube
with 10 ml of TCM-199, but without hormones, and centrifuged at 600 x g. After
10

min, the supernatant was replaced with fresh medium and the tube was
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centrifuged for an additional 10 min. After centrifugation, EGC were counted
using a hemacytometer and cell viability was assessed using 0.4% trypan blue
dye exclusion technique.
Experimental Desion
Granulosa cells (500,000 cells/well) were placed into a multiwell plastic
culture dish (24 wells/dish; Costar, Cambridge, MA) with 1,000 pi of culture
medium. A minimum of three wells was allotted for each of the treatments for
each of the three follicles used in this study. Once in the culture wells, cells were
exposed to one of the following treatments: control (no additional agents added),
L-NAME (10 -4 M), AG (10 -4 M) and SNP (10^ M). After 24 h in culture (38°C,
humidified 5% C 0 2 in air), media were collected and stored at -20°C until
hormonal analyses were performed. Immediately after removal of the medium,
the EGC were trypsinized and the percentage of viable cells was determined.
Statistical Analyses
Medium

from

each

well

was

analyzed

for

P4

and

E2,

using

radioimmunoassay techniques previously described (Thompson et al., 1983).
Samples were directly analyzed without extraction. Concentrations of P4 and E2
and P4 :E2 ratios were analyzed by analysis of variance (ANOVA). All data were
reported as mean ± SEM per 100,000 cells. Whenever the statistical model
showed significance, a Tukey’s test was conducted. Data that did not pass the
normality or equal variance tests were transformed into logarithms. Intra-assay
coefficients of variation for P4 and E2 were 7.2% and 6.5%, respectively. The
inter-assay coefficients of variation for P4 and E2 were 9.8% and 11.5%,
respectively.
RESULTS
Progesterone concentrations produced by control and treated EGC were
not different (P > 0.10, Figure 4.1). Estradiol concentrations were significantly
greater in L-NAME and AG-treated cells than in control cells, whereas SNPtreated cells had a lower concentration than control cells ( P < 0.05; Figure 4.2).
The P4 :E2 ratios were calculated for each well and analyzed. The P4 :E2 ratios
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Figure 4.1 Progesterone (P 4) concentration (mean ± SEM) in medium from
equine granulosa cells cultured for 24 h. Each treatment group was run in
triplicate in three different and independent experiments. There were no
significant differences in P4 concentrations among media of control cells and of
cells treated with NG-nitro-L-arginine methyl ester hydrochloride (L-NAME),
aminoguanidine hemisulfate (AG) or sodium nitroprusside (SNP). (P > 0.10).
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Figure 4.2 Estradiol (E 2) concentration (mean ± SEM) in medium from equine
granulosa cells cultured for 24 h. Each treatment group was run in triplicate in
three different and independent experiments. Medium of cells treated with the
nitric oxide synthase inhibitors NG-nitro-L-ariginine methyl ester (L-NAME) or
aminoguanidine hemisulfate (AG) had significantly higher E2 concentrations than
medium of control cells. Medium of cells treated with sodium nitroprusside (SNP)
had lower E2 concentrations than that of control cells. Bars with different letters
are significantly different; P < 0.05.
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Figure 4.3 Progesterone:estradiol ( P ^ ) ratio (mean ± SEM) in medium from
equine granulosa cells cultured for 24 h. Each treatment group was run in
triplicate in three different and independent experiments. Medium of equine
granulosa cells treated with the nitric oxide synthase inhibitors NG-nitro-L-arginine
hydrochloride (L-NAME) or aminoguanidine hemisulfate (AG) had lower ratios
than control cells, whereas, medium of equine granulosa cells treated with the
nitric oxide donor agent sodium nitroprusside (SNP) had greater P4:E2 ratio than
control cells. Bars with different letters are significantly different; P < 0.05.
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from SNP-treated cells were significantly greater than those of the control
granulosa granulosa cells ( P < 0.05). The L-NAME treated cells and the AGtreated cells P4:E2 ratios were three-fold lower than control ratios (P < 0.05,
Figure 4.3).
Cell viability was not different among EGC obtained from each mare (mare
1, 73%; mare 2, 80%; mare 3, 68%; P = 0.15). Similarly, percentage values of
cell viability (mean ± SEM) before and after a 24-h culture interval for the
treatment groups were not different (before: 73.7 ± 3.5%; after: L-NAME, 73.7 ±
3.3%; AG, 63.3 ±4.2% ; SNP, 68.0 ±4.1% ; P > 0.10).
DISCUSSION
The results of the present experiment suggest that NO can modulate
equine granulosa cell steroidogenesis. In addition, the results of the present
study are in agreement with other studies that found the NO-mediated inhibition
of ovarian steroidogenesis in rats and rabbits to be primarily directed to E2
production (Van Voorhis et al., 1994). The addition of a nonspecific (L-NAME) or
a specific (AG) NOS inhibitors, or an NO generator (SNP) did not affect P4
concentration when compared with that of control cells. However, E2 production
was significantly lower in SNP-treated ceils than in control and L-NAME or AGtreated cells.
Estradiol production in L-NAME or AG-treated cells was three-fold higher
than control cells. Moreover, E 2 concentrations in media of L-NAME and AGtreated cells were not different from each other. These results suggest that both
iNOS and eNOS isoforms modulate equine granulosa cell steroidogenesis,
especially in regard to E2 production. However, findings from recent research
using the rat model show that the effects of NO in steroidogenesis still do not
present unequivocal evidence as to which NOS isoform (endothelial, inducible or
both) plays a major role in ovarian physiology and follicular dynamics (Jablonka
and Olson, 1998; Faletti et al., 1999).
The absence of significant effects on P4 production by the EGC resulting
from the addition of NOS inhibitors or an NO generator is in agreement with
studies in rats, rabbits and humans that reported a more significant NO
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modulation of ovarian steroidogenesis targeted to E2 production and minor or
insignificant effects on P4 production (Van Voorhis et al., 1994; Olson et al.,
1996; Yamauchi et al., 1997; Dunnam et al., 1999). Mitsube et al. (1999)
reported that the addition of NOS inhibitors (AG and NG-monomethyl-L-arginine)
to an ex-vivo perfused rat ovary system did not affect steroid concentrations,
whereas the addition of an NO generator (spermine NoNoate) increased P4
production in the perfusion medium.
In a study performed in rabbits, Yamauchi et al. (1997) reported that
ovaries perfused with AG or L-NAME had significantly increased E2 production,
but not P4 production. In that study, addition of SNP reversed the AG-induced
increase in E2 production, but perfusion with SNP alone did not affect the basal
production of P4 and E2. Another NO generator (S-NAP), when added to ovarian
explants derived from NO-deficient rats (Dunnam et al., 1999), not only failed to
inhibit

P4,

but also

increased

concentrations of ovarian

P4, following

administration of equine and human chorionic gonadotropins (eCG and hCG).
Estradiol production was, however, significantly decreased by the addition of SNAP to the perfusion medium.
Scientific publications on NO and its role in ovulation and steroidogenesis
are conflicting. Most authors agree that NO plays a role in ovulation, but its role
in P4 and E2 production by ovarian steroidogenic cells remains controversial. For
example, Boneilo et al. (1996) reported that L-NAME reduced the ovulation rate
in rats in vivo and in vitro; however, L-NAME decreased the secretion of E2 but
not of P4 in perfused ovaries. The same authors ruled out the possibility that this
effect could be attributed to blood flow changes. It was then suggested that there
is a role for NO in ovulation, but not in follicular luteinization. However,
preovulatory follicular luteinization is a well-documented phenomenon intrinsically
related to the ovulatory process (Collins et al., 1997, Kerban et al., 1999).
Therefore, a unifying hypothesis for the role of NO in ovulation and follicular
steroidogenesis, specifically regarding the process of preovulatory luteinization,
is lacking.
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The global hypothesis of the present study was that NO, in addition to its
participation in the ovulatory process, modulates, at least in part, the process of
follicular luteinization. Evidence linking NO to the ovulatory process as well as to
follicular steroidogenesis cannot be overlooked. If NO is essential for ovulation to
occur, what would its role be in follicular steroidogenesis before ovulation? To
answer this question hypothetically, the hormonal events within the preovulatory
follicle wall must be understood. First, in most domestic species, it has been
documented that after an ovulatory stimulus (e.g., hCG or gonadotropin-releasing
hormone administration) granulosa cells start to luteinize regardless of whether
ovulation will occur or not (Abel et al., 1975; Edwards and Steptoe, 1975;
Oieleman et al, 1983; Watson and Hinrichs, 1988). This phenomenon is further
supported by studies showing hCG-induced changes in steroidogenic acute
regulatory protein (StAR) and aromatase activity in follicles of rats, cows and
mares (Voss and Fortune, 1993; Kerban et al., 1999). Moreover, hormonal
analyses of follicular fluid samples obtained from equine preovulatory follicles
after hCG administration demonstrated increasing concentrations of P4 and
decreasing E2 concentrations as evidence of proximity and readiness for
ovulation (Watson and Hinrichs, 1988; Watson and Sertich, 1991; Collins e ta /.,
1994).
This shift in steroidogenesis also is accompanied by up-regulation of
cyclooxygenase-2 (COX-2) induced by hCG. The hCG-induced COX-2 upregulation is highly conserved among species (e.g., rats, cows, horses,
monkeys), usually occurring approximately 10 h before expected ovulation (Sirois
eta!., 1992; Sirois, 1994; Sirois and Dor6, 1997; Duffy and Stouffer, 2001). A link
between NO and follicular prostaglandin production also has been suggested by
several authors (Yamauchi etal., 1997; Ahsan et al., 1997; Falletti et al., 1999).
Thus, it is conceivable that NO may be a key signaling molecule (actively or
permissively) mediating important hormonal events preparatory for ovulation,
such as the increase in follicular blood flow, up-regulation of follicular
prostaglandins and inhibition of aromatase activity. As discussed in Chapter 3,
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NO concentrations in preovulatory follicles of mares in estrus increase after hCG
administration, paralleling the increasing intrafollicular P4 concentrations.
In conclusion, results of the present study show that addition of an NO
generator to cultured equine granulosa cells resulted in higher P4:E2 ratios,
whereas culture cells treated with L-NAME or AG had lower P4 :E2 ratios than
control cells. The altered P4:E2 ratios noted in medium harvested from cells
treated with NOS inhibitors (L-NAME or AG) or an NO donor (SNP) appear to be
derived mainly from effects on E2 production than on P4 production. W e propose
that an involvement of NO in the process of preovulatory follicular luteinization in
the equine ovary is conceivable in light of its purported role in ovulation and
inhibition of E2 production by in vitro cultured granulosa cells in the experiment
reported herein.
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CHAPTER 5
EFFECTS OF Ng-NITRO-L-ARGININE METHYL ESTER
(A NONSPECIFIC NITRIC OXIDE INHIBITOR) ON BOVINE
FOLLICULAR DYNAMICS AND STEROIDOGENESIS
INTRODUCTION
Soon after nitric oxide (NO) was found to have properties identical to the
endothelial-derived relaxing factor its role in other biological systems became
evident (Moncada eta!., 1991; Rosselli et al., 1998;. The biochemical properties
and the complex molecular regulation of nitric oxide synthases (NOS), which are
enzymes that catalyze the production of NO, account for NO participation in most
physiological and pathobiological processes in mammals (Moncada etal., 1991;
Alderton et al., 2001). In the reproductive system, NO was found to modulate
important biological processes involving hypothalamic, hypohyseal and gonadal
functions (McCann and Rettori, 1996b; Rosselli etal., 1998; Tsafriri and Reich,
1999).
In the ovary, NO was found to be a molecule that promotes ovulation
because inhibition of NO production resulted in inhibition of ovulation, whereas,
administration of a NO donor agent induced ovulation in a fashion similar to
human chorionic gonadotropin (hCG; Shukovski and Tsafriri, 1994, Powers etal.,
1995; Yamauchi et al., 1997). Different experimental approaches confirmed this
regulatory role of NO in mammalian ovulation in several species including mice
(Powers etal., 1995), rats (Shukovski and Tsafriri, 1994, Falletti etal., 1999) and
rabbits (Hesla et al., 1997, Yamauchi et al., 1997). Studies using granulosa cell
culture systems as an experimental approach to investigate the role of NO in
ovarian steroidogenesis also provided circumstantial evidence of a role for NO in
ovulation in cows (Basini etal., 1998) and humans (Van Voorhis etal., 1994).
Accordingly, administration of NOS inhibitors to mice, rats and rabbits
showed that inhibition of NO inhibited or significantly impaired ovulation in
gonadotropin-stimulated animals, whereas, administration of NO donor agents
produced ovulation rates comparable with those noted in animals that were
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administered

hCG.

Parameters

of ovarian

response

such

as

follicular

development, ovulation rates, ovarian steroidogenesis and estrous cycle
regularity were also altered when rats were chronically administered NOS
inhibitors added to drinking water offered ad libitum (Dunnam et al., 1999) or
when mice were genetically engineered to lack the gene for eNOS (Drazen et al.,
1999; Jablonka-Shariff etal., 1999b) oriN O S (Jablonka-Shariff etal., 1999b).
Pregnancy rates and litter size were reduced in mice made genetically
deficient for genes encoding for both constitutive (nNOS and eNOS) and
inducible (iNOS) NOS isoforms (Klein ef al., 1998; Jablonka-Shariff et al., 1998;
Drazen et al., 1999; Jablonka-Shariff et al., 1999b). However, the relative
importance of a given NOS isoform for ovarian function is yet to be unequivocally
demonstrated as evidence exists that favors greater participation of the iNOS
(Falletii et al., 1999) or eNOS (Jablonka-Shariff et al., 1999b) as the main isoform
related to NO production during the ovulatory process.
Although the participation of NO in follicular dynamics has been relatively
well documented in laboratory animals, evidence suggesting a role for NO in
ovarian physiology of other domestic animals and humans is limited. Information
on the role of NO in ovarian physiology of cows (Basini et al., 1998) and women
(Van Voorhis et al., 1994) has been derived from studies investigating the effects
of

NOS

inhibitors

and

NO

donor

agents

in

cultured

granulosa

cell

steroidogenesis. These reports seem to agree that NO is an anti-steroidogenic
molecule. Addition of NOS inhibitors to cultured bovine and human granulosa
cells increased the production of estradiol (E2) and progesterone (P4), whereas,
the addition of an NO donor agent inhibited the production of both steroids.
Inhibition of cytochrome P450 (CYP450) aromatase activity has been shown to
be one of the mechanisms whereby NO inhibits steroidogenesis whereas other
investigators have suggested that the cyclic GMP pathway is involved in the NOmediated inhibition of steroidogenesis (Van Voorhis et al., 1994; Snyder et al.,
1996). Analyses of human and bovine follicular fluid were inconclusive in
providing meaningful information on the role of NO in ovarian dynamics. Taken
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together, the major finding reported for NO in human and bovine ovarian
dynamics is that NO acts mainly as an anti-steroidogenic molecule.
The finding that NO appeared to be an anti-steroidogenic molecule was
apparently discrepant and did not contribute to explaining the purported role of
NO in ovulation. Nitric oxide has been shown to up regulate the cyclooxygenase
pathway (COX) in several systems including hCG-stimulated production of
prostaglandins (Yamauchi etal., 1997; Falletti etal., 1999). The confusion arises
when one examines the scientific literature that shows that indomethacin (COX
inhibitor) and epostane (3(3-hydroxysteroid dehydrogenase inhibitor) inhibited
ovulation and impaired follicular steroidogenesis (Tanaka etal., 1991).
Thus, the information that NO production is temporally related to
intrafollicular prostaglandin production along with the evidence that NO has
strong anti-steroidogenic activity is not congruent in elucidating its role in
mammalian ovulation. Therefore, scientific evidence is missing that links the role
of NO in promoting ovulation based on in vivo studies with its inhibitory effect on
steroidogenesis based on granulosa cell culture studies. The only report that
presented data suggesting a role for NO as an autocrine modulator of bovine
granulosa cell function used serum-free culture medium, thus, effects of NO on in
vitro luteinization of granulosa cells could not be examined (Basini etal., 1998).
Luteinization of bovine granulosa and theca interna cells after the
luteinizing hormone (LH) surge is a marker of follicle maturation and proximity of
ovulation. In the last follicular wave occurring during the late stages of bovine
diestrus, a group of follicles is selected to grow and at least one reaches a stage
of dominance reflected by comparatively increased follicle diameter and greater
steroidogenic output (Ginther et al., 1997; Fortune et al., 2001). The dominant
follicle and, therefore, the presumptive preovulatory follicle, produces a relatively
large amount of E2 that eventually triggers an endogenous LH surge (Voss and
Fortune, 1993; Komar et al., 2001). One of the first biochemical events triggered
by endogenous LH (or exogenous hCG) noted in functions of the preovulatory
follicle is a shift in the character of steroidogenesis production from E2 to P4
production (Voss and Fortune, 1993; Liu et al., 1997)). During proestrus, the
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preovulatory follicle is predominantly a steroid-producing endocrine gland that
changes to predominantly P4 production after hCG stimulation. Therefore, hCGinduced preovulatory luteinization is initiated before ovulation (follicular rupture)
occurs and, consequently, before definite morphological transformation of bovine
granulosa and theca interna cells into luteal cells is established (Komar et al.,

2001).
Administration of GnRH (Kot and Ginther, 1999), LH (Quintal-Franco et
al., 1999) or hCG (Schmitt et al., 1996) induces ovulation in cows. Based on this
information, I decided to investigate the role of NO in bovine hCG-induced
ovulation in vivo. In the present study, cows in proestrus were administered the
NOS synthase inhibitor L-NAME, an L-arginine analogue that competitively and
nonspecifically binds to NOS, therefore, blocking NO production. Ovarian
response parameters to hCG administration such as follicular dynamics and
ovulation pattern were examined by transrectal ovarian ultrasonography. Plasma
P4 concentrations before and after ovulation were also measured by RIA
analyses. It was hypothesized that cows treated with L-NAME would have altered
follicular growth and ovulation patterns when compared with control cows
receiving saline solution vehicle.
MATERIAL AND METHODS
Experimental Animals and Estrus Synchronization
Cycling multiparous Holstein cows in good health were grouped in a
15-acre pasture and supplemented with a 12% crude protein ration at
1.2 kg./cow/day and free choice Gulf rye grass. Cows were subjected to an
estrus synchronization protocol that involved administration of PGF2Q, GnRH and
hCG. Estrus synchronization was conducted in two phases during the spring of
2000. The first phase, pre-synchronization, was comprised of administration of
PGF2„ (25 mg Lutalyse®, Pharmacia & Upjohn, Kalamazoo, Ml; im) twice 14 d
apart to bring the cows into an approximate similar stage of the luteal period after
the second PGF2q injection. The second phase of the synchronization was
carried out using a modification of a protocol known as OVSYNCH (Pursley et
al., 1995) that does not rely on estrus detection before artificial insemination. The
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OVSYNCH

synchronization

protocol

consists

of an

injection

of GnRH

administered in any stage of the estrous cycle, an injection of PGF2a 7 d later,
and a second injection of GnRH 48 h after the PGF2a injection. In the present
study, hCG was substituted for the second injection of GnRH. All cows were
treated with GnRH im (100 pg Cystorelin®, Rhone Merieux, Athens, GA) 12 d
after the second injection of PGF2Q. At 7 d following injection of GnRH cows were
treated with PGF2Qagain. At 48 h following PGF2a injection, all cows were treated
with hCG iv (2,000 i.u. Chorulon®, Intervet, Millsboro, DE) to induce ovulation.
Experimental Design
Cows (n = 16) were randomly allotted to two groups that were treated with
three injections of either saline solution (n =

10,

matched volume, iv, q

NG-nitro-L-arginine methyl ester hydrochloride (L-NAME; n =

6

12

h) or

, 148 pmol/kg, iv,

q 12 h) starting 12 h before hCG administration. Most cows (n =13) were not
lactating, whereas, 3 cows were at least beyond 45 d postpartum. Two of these
lactating cows were allotted to the control (saline solution) group and the
remaining cow to the treatment (L-NAME) group.
Palpation per rectum and transrectal ovarian ultrasonography were
conducted once daily during the estrus synchronization protocol, twice daily after
the last injection of PGF2a, every

6

h starting 24 h post-hCG administration until

ovulation, and once daily 1, 3, 7,11 and 16 d after ovulation. Transrectal ovarian
ultrasonography was performed using an ultrasound scanner (Sonovet 600,
Universal Ultrasound, NY, NY) equipped with a 5-MHz linear-array transrectal
transducer. Care was taken to minimize manipulation of the ovaries and uteri of
cows being palpated and scanned. Ovaries were examined during each
ultrasonography session for the presence of corpora lutea and follicles.
Regression of corpora lutea as well as follicular development after PGF2Q
injection

was

documented

by

ovarian

ultrasonography.

Ovarian

follicle

measurements are the average of two diameters taken at right angles to each
other.
Blood samples were collected immediately before each ultrasound
examination during the estrus synchronization protocol, treatments and post-
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ovulation examinations. Blood was collected by venipuncture of the coccygeal
vein into heparinized tubes and placed on ice until centrifugation. Plasma was
separated

and

stored

at -2 0

°C

until assayed

for P4

using

routine

radioimmunoassay techniques (Thompson etal., 1983).
Statistical Analyses
All experimental data were expressed as mean ± SEM. Follicle diameters
(mm) and plasma P4 (nmol) were analyzed by two-way repeated measures
analysis of variance using a general linear model (SigmaStat 2.0, Jandel
Corporation, San Rafael, CA). Time to ovulation after hCG administration was
analyzed by Fischer’s exact test. Differences in the mean values between
treatment groups were considered significant when a probability < 5% was
accepted as an indication that the differences that occurred could not be
attributed to random variability.
RESULTS
Estrus Synchronization and Plasma Progesterone Concentrations
All cows had plasma P4 concentrations greater than 7 nmol at the time of
the administration of the PGF2q injection following GnRH administration (Figure
5.1). Luteolysis was achieved in all cows as plasma P4 concentrations were less
than 2.1 nmol when hCG was administered. At 4 d after hCG, concentrations of
plasma P4 in L-NAME-treated cows were lower than control cows, whereas, no
differences were noted in plasma P4 concentrations of both groups at d 11 or d
16 after ovulation (Figure 5.1).
Follicular Dynamics and Ovulation
Follicle diameters were not different between treatment groups when final
luteolysis was induced with PGF2a (Figure 5.2). Similarly, no difference in follicle
diameter was found between groups at the start of treatments 12 h before hCG
injection as well as between follicle diameters measured at the last ultrasound
scanning before detection of ovulation (Figure 5.2).
All control cows (100 %) had ovulated by 30 h after hCG administration,
whereas, three L-NAME-treated cows (50%) ovulated by 30 h and the remaining
3 cows by 36 h (50%) after hCG. Statistical analysis using Fisher's test detected
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significant differences in the proportion of cows ovulating at 30 or 36 h post-hCG
administration (Figure 5.3). Ovulation and formation of corpora hemorrhagica
were unremarkable as examined by transrectal ovarian ultrasonography. Mature
corpora lutea in either group did not show marked morphological differences
upon ultrasonography, showing echotexture similar to those previously described
(Kotand Ginther, 1999).
DISCUSSION
Estrus Synchronization
In the present study, cows underwent an estrus synchronization protocol
to minimize random variability that could have originated from environmental
conditions, such as season of the year, pasture and experimental factors (source
of chemical agents, preparations of intravenous solutions). Using estrus
synchronization likely reduced individual variability owing to the phenomenon of
follicular waves.

Two

major modifications were

applied

to

the

estrus

synchronization protocol employed in the present study known as OVSYNCH
(Pursley et al., 1997), a protocol that does not rely on estrus detection before
artificial insemination.
The OVSYNCH protocol consists of an injection of GnRH randomly
administered during any stage of the estrous cycle, an injection of PGF2„ 7 d
later, and a second injection of GnRH 48 h after the PGF2a injection. The first
modification adopted in the present study was the inclusion of a presynchronization with 2 injections of PGF2q performed before the beginning of the
OVSYNCH. The first GnRH injection was administered 12 d after the second
PGF2q injection when cows were thought to be between d 5 and d 10 of diestrus,
which has been suggested to be a better period to start the synchronization
program (Vasconcelos et al., 1999; Moreira et al., 2000; Thatcher et al., 2001).
The second modification was the substitution of hCG for the second injection of
GnRH. In summary, the use of a pre-synchronization treatment with PGF2a and
the use of hCG instead the second injection of GnRH resulted in a uniform
synchronization of the estrous cycles before treatments were applied.
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Figure 5.1 Plasma progesterone (P4) concentration (mean ± SEM) of controls
(n = 10) and cows treated with the nitric oxide synthase inhibitor NG-nitro-Larginine methyl ester hydrochloride (L-NAME; n = 6 ). Each time point was named
in relation to an ovulatory dose of hCG. Note that -48 h refers to the day when
PGF2a was administered. Experimental treatments were administered at -1 2 h,
0 h and 12 h in relation to the hCG injection. Note that the L-NAME-treated cows
had lower concentrations of plasma P4 at d 4 post-hCG than control cows but no
differences were detected between control and treated cows at mid cycle (d 1 2 to
17 post-hCG). Bars with different letters are significantly different; P < 0.05.
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-1 2 h hCG
At ovulation

Control

L-NAME

Figure 5.2 Follicle diameter (mean ± SEM) of controls (n = 10) and cows treated
with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME; n = 6 ). Follicle sizes were determined by averaging two
measurements obtained at right angles from images stored during transrectal
ovarian ultrasonography. Note that follicle measurements were recorded at the
time of PGF2a injection (48 h before hCG), first treatment administration ( 1 2 h
before ovulation) and at the last ultrasonographic examination before ovulation
was detected (at ovulation). Bars with different letters are significantly different;
P < 0.05.
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Figure 5.3 Number of cows treated with saline solution (n = 10) or Nc-nitro-Larginine methyl ester hydrochloride (L-NAME; n = 6 ) that ovulated by 30 or 36 h
post-hCG administration. Note that all control cows (n = 10) ovulated by 30 h
after hCG administration. Delayed ovulation was noted in L-NAME-treated cows.
P < 0.05.
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The pre-sycnhronization protocol provided that cows at initiation of the
OVSYNCH were at the same stage of the estrous cycle, i.e., between d 5 and
d 10 of the estrous cycle (Thatcher et al., 2001). Synchronization of estrous cycle
and ovulation using OVSYNCH has been shown to vary if treatment is initiated
on different days of the estrous cycle in dairy cows (Vasconcelos et al., 1999;
Moreira et al., 2000). This variation of synchronization is associated with
increased rates of premature ovulation in relation to the timing of artificial
insemination and reduced fertility rates (Vasconcelos etal., 1999).
Pre-synchronization using two PGF2a injections

resulted

in higher

pregnancy rates than that obtained from cows not pre-synchronized before
OVSYNCH (Thatcher et al., 2001). The plasma P4 concentrations and absence
of significant differences in follicle diameters evidenced the success of such
synchronization in the present study when animals were randomly allotted to the
experimental groups. All cows had low P4 plasma concentrations at the time of
hCG administration. The tight synchronization of ovulation documented in control
animals further reaffirmed the success of the synchronization protocol.
Accordingly, premature ovulation or anovulation after hCG was not noted in the
present study as all control cows ovulated between 24 and 30 h post-hCG
administration.
Follicular Dynamics and Ovulation
There were only 16 cows were used in the present study. This relatively
low number could have posed a problem to detecting statistical differences
between control and treated cows. As the power of the study was compromised,
the risk of failing to reject the null hypothesis was increased. However, because
all cows were subjected to a pre-synchronization protocol before mOVSYNCH
that resulted in adequate synchronization of ovulation in control cows, the
probability of detecting significant differences between control and L-NAME
treated cows was likely enhanced.
The results of the present study suggested that treatment with the
nonspecific NOS inhibitor agent L-NAME delayed ovulation in dairy cows
subjected to an estrus synchronization protocol. Furthermore, as we have noted
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with mares treated with L-NAME (Chapter 2), none of the preovulatory follicles of
treated cows underwent follicular atresia and anovulation. The L-NAME-induced
delayed ovulation in cows, as we have previously suggested for mares treated
with NOS inhibitors, likely resulted from NO inhibition in the ovary bearing the
preovulatory follicle. Potential effects of NO inhibition in the hypothalamichypophyseal axis (McCann and Rettori, 1996) were likely circumvented by
administration of hCG that acts locally in the ovary.
If the original OVSYNCH protocol had been used, that includes an
injection of GnRH to induced ovulation, then any alteration in the ovulation
pattern could have been attributed to central effects of NOS inhibition in the brain
in addition to ovarian effects. It remains to be investigated in a subsequent study
whether the administration of L-NAME in the proestrus stage would alter the
endogenous LH surge, resulting in a more prolonged inhibition of ovulation than
that documented in the present study. Inhibition of ovulation resulting in cystic
follicles has been reported following administration of estradiol valerate
(Nadaraja and Hansel, 1976) or P4 (Sirois and Fortune, 1990) in late diestrus that
resulted in lowered LH secretion and altered E2 and P4 plasma concentrations.
When L-NAME was administered to mares in estrus, a significantly lower
growth rate of preovulatory follicles in treated mares was noted as compared with
that of control mares. In contrast to the equine study, no significant differences in
follicle growth rate or follicle size at the time of hCG administration and ovulation
were noted between cows treated with L-NAME or saline solution. Administration
of experimental drugs started 36 h after luteolysis was induced with PGF 2Q. The
mean diameter of presumptive preovulatory follicles was

already at a

preovulatory size (Control, 15.3 ± 0.8 mm; L-NAME 15.8 ±1.1 mm) and likely at
a stage of development that the effects of NOS inhibition on follicle growth could
not have been perceived. In the equine study (Chapter 2), administration of NOS
inhibitors started at the very beginning of estrus and follicles had not yet reached
preovulatory diameters (27 to 29 mm). This fact in association with a relatively
longer estrus period in mares likely contributed to more noticeable effects of NOS
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inhibition of the growth rate of preovulatory follicles in mares than was noted in
cows.
The reported inhibition of ovulation following administration of NOS
inhibitors in small laboratory animals (Shukovski and Tsafriri, 1994, Powers etal.,
1995; Bonello et al., 1996; Hesla et al., 1997) has been suggested to involve
vascular and nonvascular effects of NO in the ovulatory process. At least two
studies (Powers et al., 1995; Bonello et al., 1996) provided evidence that NO
may modulate ovarian blood flow regulation. Increase in diameter of the
preovulatory follicle is more evident at the proestrus and estrus stage when
increased hyperemia is present in the presumptive preovulatory follicle.
Exacerbation of follicular hyperemia and the appearance of edema in the cells of
the theca interna and externa are apparent after endogenous the LH surge or
exogenous hCG administration when preovulatory follicles of cows and mares
experience a final spur of growth. Thus, increased blood flow to the preovulatory
follicle is associated with dynamic follicular growth.
As previously discussed, no differences were noted in follicular growth in
the present study, yet ovulation was significantly delayed in cows treated with
L-NAME. Therefore, it is likely that the delayed ovulation induced by L-NAME
documented in the present study was not primarily related to altered blood flow
induced by L-NAME-induced inhibition of ovarian NO. Consequently, one might
speculate that L-NAME-induced delayed ovulation involved another important
aspect of mammalian ovulation that NO may modulate, that is follicular
steroidogenesis (Van Voorhis et al., 1994; Yamauchi et al., 1997; Falletti et al.,
1999).
In addition to hCG-induced vascular effects in the ovary and preovulatory
follicle, a steroidogenesis shift from E2 to P4 production by the granulosa-theca
interna cell complex is noted after an ovulatory stimulus (Voss and Fortune,
1993; Komar et al., 2001). This favored intrafollicular P4 production is a result of
decreased CYP450 aromatase activity (Voss and Fortune, 1993; Tian et al.,
1995). Analysis of intrafollicular fluids of cows and horses at different times after
hCG stimulation has shown a gradual increase in P4 concentrations as ovulation
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approaches (Edwards, 1974; Dieleman et al., 1983). The participation of NO in
steroidogenesis events between hCG stimulation and ovulation are presently
unknown, but a role for NO modulation of granulosa cell steroidogenesis has
been suggested (Van Voorhis et al., 1994; Yamauchi et al., 1997; Falletti et al.,
1999). However, most reports agree that NO inhibits steroidogenesis, primarily
E 2 production and, to a lesser extent, P4 production. One might ask how to
reconcile the anti-steroidogenic activity of NO with the proposed role in promoting
ovulation?
A conciliatory answer to this question came from results of a subsequent
study investigating the role of NO on bovine granulosa cell in vitro luteinization
(Chapter 6 ). In that study, addition of L-NAME to bovine granulosa cells cultured
for 72 h had lower P4:E2 ratios than control cells that displayed increased ratios
over time. The lower P4:E2 ratio noted in L-NAME-treated cells was mainly
attributed to a significantly higher E2 production at 48 and 72 h while maintaining
P4 production at levels that did not differ from control cells. The conclusion was
that one of the mechanisms of NO participation in the ovulatory process might
involve modulation of the steroidogenesis shift that occurs in response to an
ovulatory stimulus. This hypothesis is supported by a previous research showing
that NO inhibits CYP450 aromatase by directly inhibiting the enzyme activity and
also by decreasing CYP450 aromatase mRNA (Van Voorhis eta l., 1994; Snyder
et al., 1996). Therefore, the anti-steroidogenic NO activity may actually be
directed to aromatase activity, thus, being permissive to enhanced P4 production
by bovine granulosa cells after hCG administration.
The suggestion that L-NAME may have disrupted the pattern of hCGinduced follicular steroidogenesis and, therefore, delayed ovulation, was further
reinforced by observing lower plasma P4 concentrations in L-NAME treated cows
than in control cows 3 d after ovulation. No differences in P4 concentrations were
noted at mid cycle. The pattern of follicle evacuation in both treatment groups
was unremarkable as were the ultrasonographic features of early corpora
hemorrhagica of both control and L-NAME-treated cows. Therefore, the lower
plasma P4 concentrations of L-NAME treated cows at the beginning of diestrus
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were likely attributed to effects of NO inhibition on the process of preovulatory
and postovulatory luteinization. A prolonged effect of L-NAME, a compound that
has a very short half life, may be expected in cows because it is known in rats
(Pfeiffer et al., 1996) and horses (Chapter 7) that L-NAME is rapidly metabolized
to NG-nitro-L-arginine (L-NNA), a compound with a longer half life than L-NAME
(~ 20 h in horses). Thus, inhibitory effects of L-NAME on NO production could
have been present at the time most L-NAME-treated cows had ovulated or were
in the process of completing ovulation.
Although L-NAME was shown to prolong diestrus when administered in
late diestrus to cows (Jaroszewski and Hansel, 2000) and, thus, denoting a role
for NO in the luteolytic process, it is likely that NO inhibition at the very initial
stages of luteinization may impair it. In that regard, NO biological function in the
ovary may be comparable to that of prostaglandins, which have been shown to
participate both in the ovulatory process (Liu et al., 1997) and luteolysis (Tian
etal., 1994). All cows in the present study had plasma P4 concentrations greater
than 7 nmol at d 17 post-hCG administration suggesting that none of either
control or L-NAME-treated cows experienced shortened diestrus and likely
resumed normal cyclicity.
In summary, results of the present study suggest that up-regulation of the
NO pathway may be necessary for ovulation and luteinization to occur
uneventfully in cows, as indicated by L-NAME-treated animals displaying delayed
ovulation and lower metestrus plasma P4 concentrations than time-matched
control cows. Vascular effects resulting from L-NAME administration were likely
not involved in the phenomenon of delayed ovulation documented in the present
study. Follicular growth, an event dependent on normal blood flow to the ovary,
proceeded unaltered in both control and L-NAME-treated cows.
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CHAPTER 6
EFFECTS OF NITRIC OXIDE INHIBITORS ON BOVINE
GRANULOSA CELL STEROIDOGENESIS
INTRODUCTION
After nitric oxide (NO) was associated with the cyclic events of the human
menstrual cycle (Rosselli et al., 1994a), thus suggesting a potential relationship
between NO and ovarian physiology, researchers started to investigate what role
NO may have in ovarian physiological functions. In 1994, two reports described
evidence that linked NO to the process of ovulation in rats (Shukovski and
Tsafriri, 1994) and a role for NO-induced modulation of human granulosa cell
steroidogenesis (Van Voorhis et al., 1994).
The

results of studies

investigating

the

role of NO

in ovarian

steroidogenesis pointed out a strong anti-steroidogenic activity of NO in
granulosa cell function. That NO inhibits estradiol (E 2) and progesterone (P4)
production has been shown by studies using rat (Olson et al., 1996), mouse
(Jablonka-Shariff et al., 1999b), rabbit (Yamauchi etal., 1997), swine (Masuda et
al., 1997; Grasselli et al., 2001), bovine (Basini et al., 1998) and human (Van
Voorhis et al., 1994) granulosa cells. A few studies, however, found that NOS
inhibitors decreased only E2 production in perfused rat ovaries (Bonello et al.,
1996) or reported an absence of significant effects on steroidogenesis (Yamauchi
etal., 1997).
Conclusive evidence relating the biological significance of the role of NO
in ovarian steroidogenesis is lacking. The apparent discrepancy that arises from
reports stating that NO increases, decreases or has no effect at all on
steroidogenesis may derive from differences in experimental approaches using
granulosa cell cultures or ovarian perfusion systems. Furthermore, whereas,
most investigators elected to assay the spent media or ovarian perfusate for P4
and E2 , others only assayed for P4 (Dave et al., 1994). However, most reports
agree that NO affects steroidogenesis by preferentially inhibiting E2 production
(Vega etal., 1998).
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Enzymes of the cytochrome P450 (CYP450) superfamily are abundant in
several steps of the steroidogenic pathway (Voss and Fortune, 1993) and are
speculated to be another mechanism which NO utilizes to exert its inhibitory
action on steroidogenesis (Snyder et al., 1996; Hanke et al., 1998). Inhibition of
human CYP450 aromatase activity was the first mechanism suggested by which
NO may inhibit steroidogenesis (Van Voorhis et al., 1994; Snyder et al., 1996).
Inhibition of CYP450 aromatase activity was shown to be at the transcriptional
and post-translational levels (Snyder et al., 1996). Other studies suggested that
NO-induced inhibition of steroidogenesis might involve stimulation of guanylate
cyclase and consequent cyclic GMP activation (Grasselli et al., 2001).
However, if NO is essential for ovulation how does the NO antisteroidogenic activity fit in the ovulatory process? Before we hypothetically
consider the answer to this question, well established aspects of bovine ovarian
physiology should be considered. Follicular dominance of the presumptive bovine
preovulatory follicle is established in late diestrus and early proestrus and is
evidenced by increased follicular diameter over the subordinate follicles, as well
as, by pronounced steroidogenic activity. Relatively high levels of folliclestimulating hormone (FSH) that stimulate CYP450 aromatase activity and
luteinizing hormone (LH) receptors in the granulosa cells support increased
follicular steroidogenic activity.
As follicular growth proceeds unabated throughout proestrus, high plasma
E2 concentrations trigger the LH surge that marks the onset of estrus. The LH
surge or exogenous administration of human chorionic gonadotropin (hCG)
initiates a cascade of biochemical and morphological events in the preovulatory
follicle in the period preceding ovulation that leads to follicle and oocyte
maturation, ovulation and the commencement of transformation of the granulosatheca cell complex into luteal cells. One of the primary changes induced by LH is
the shift in steroidogenesis from E2 to P4 production by the granulosa-theca
intema cell complex. This conversion in steroidogenesis is a result of decreased
activity of CYP450 17a-hydroxylase and CYP450 aromatase that accounts for
diminished availability of aromatizable androgens and decreased aromatization
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of E2 precursors. The temporal regulation of down-regulation of these two
important CYP450 cytochrome enzymes may vary among species, but it has
been suggested that in cattle, androgen production and the capacity of granulosa
cells for aromatization is coordinately and synchronously decreased after the LH
surge (Voss and Fortune, 1993; Komar et al., 2001). Therefore, luteinization of
granulosa and theca interna cells is initiated before ovulation is completed by
follicular rupture (Murphy, 2000).
Bovine granulosa cells spontaneously luteinize when placed in culture and
exposed to fetal bovine serum (Edwards, 1974; Luck et al., 1990; Legault e ta t,
1999). The degree of luteinization can be evident morphologically as cells adhere
to the culture plate and more importantly, through determination of increased P4
production that causes an increase in the P4 :E2 ratio (Norman and Greenwald,
1971). The increase in P4 :E2 ratios is even more evident when cells are treated
with LH and FSH. The addition of FSH to cultured bovine granulosa cells
stimulates adenylate cyclase activity that generates cyclic AMP (Legault et al.,
1999). The increase in cyclic AMP up regulates FSH and LH receptors, thus
amplifying steroidogenic activity. Addition of serum to the culture increases
granulosa cell responsiveness to LH stimulation (Dain et al., 1995). The
phenomenon of in vitro luteinization of bovine granulosa cells may therefore be
considered as a model for endocrine events induced by endogenous LH surge
(or exogenous administration of hCG) in vivo. Because the current scientific
literature has only reported the effects of NO on granulosa cell steroidogenesis
using serum-free culture systems, the effects of NO on the phenomenon of in
vitro luteinization are presently unknown.
In the present study, bovine granulosa ceils were placed in a culture
system containing fetal bovine serum to promote luteinization of granulosa cells
for 72 h. Cultured bovine granulosa cells were then treated with NOS inhibitors
L-NAME and AG, and SNP, an NO donor agent. The E2 and P4 concentrations
produced by treated and control bovine granulosa cells were measured at 24, 48
and 72 h of incubation. It was hypothesized that addition of NOS inhibitors
(L-NAME and AG) would disrupt the pattern of in vitro granulosa cell luteinization
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as evidenced by the analysis of P4 :E2 ratios in treated and control granulosa cell
cultures over 72 h of incubation, whereas, ceils treated with SNP would have
P4 :E2 ratios similar to that of control cells.
MATERIAL AND METHODS
Experimental Procedures
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), aminoguanidine
hemisulfate (AG) and sodium nitroprusside (SNP) were obtained from one
commercial source (Sigma Chemical Company, St. Louis, MO). Cell culture
media were prepared using TCM -199 (Gibco, Grand Island, NY) in combination
with 5% (v/v) fetal bovine serum (FBS), 2% (v/v) SerXtender™ (Irvine Scientific,
Santa Ana, CA), 10 ng/ml FSH (Sigma, St. Louis, MO), 1 pg/ml LH (Sigma, St.
Louis, MO), 10'7 M androstenedione (Sigma, St. Louis, MO), and 1% (v/v)
antibiotic-antimycotic

(100

IU

penicillin,

100

pg

streptomycin,

0.25

pg

amphotericin-B; Sigma, St. Louis, MO). Ail media used in this study were filtered
through a

0 .2

pm filter.

Bovine granulosa cells (BGC) were obtained from follicles > 4mm in
slaughterhouse ovaries by follicular puncture with a

6 -ml

plastic syringe

containing 2 ml of aspiration medium (TCM-199 , 1% FBS, 20 lU/ml sodium
heparin and 1% antibiotic-antimycotic) connected to a 22-gauge needle. After
aspiration, BGC were placed into 15-ml centrifuge tubes and passed twice
through a 25-gauge needle to disperse the BGC. Bovine granulosa cells were
placed into a 15-ml centrifuge tube with 10 ml of aspiration medium and
centrifuged at 600 x g. After 10 min, the supernatant was replaced with fresh
medium and the tube was centrifuged for an additional 10 min. After
centrifugation, BGC were counted using a hemacytometer and cell viability was
assessed using 0.4% trypan blue dye exclusion technique.
Experimental Design
Granulosa cells (1,000,000 viable cells/well) were placed into a multiwell
plastic culture dish (24 wells/dish; Costar, Cambridge, MA) with 1,000 pi of
culture medium. A minimum of three wells was allotted for each of the
treatments. Each experiment was repeated three times in an independent
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experimental setting. Once in the culture wells, BGC were exposed to one of the
following treatments: control (no additional agents added), L-NAME (10 *4 M), AG
(10 -4 M) and SNP ( If f 4 M). At 24, 48 and 72 h in culture (38°C, humidified 5%
C 0 2 in air), media were collected and stored at -20°C until hormonal analyses
were performed. Fresh media with respective treatment agents were added
immediately after collection of spent media at each time point. Immediately after
removal of media after 72 h of incubation, the BGC were trypsinized and the
percentage of viable cells was determined as described above.
Statistical Analyses
Medium

from

each

well

was

analyzed

for

P4

and

E2,

using

radioimmunoassay techniques previously described (Thompson et al., 1983).
Samples were directly analyzed without extraction. Concentrations of P4 and E2
and P4 :E2 ratios were analyzed by two-way analysis of variance (ANOVA) having
time as one factor and treatment as the other factor. All data were reported as
mean ± SEM per 1,000,000 viable cells. Whenever the statistical model showed
significance, a Tukey’s test was conducted. Data that did not pass the normality
or equal variance tests were transformed into logarithms. Intra-assay coefficients
of variation for P4 and E2 were 5% and 7%, respectively. The inter-assay
coefficients of variation for P4 and E2 were 7.5% and 10.5%, respectively.
RESULTS
The P4 concentrations in spent media of control cells and those treated
with the NOS inhibitors, L-NAME or AG, were not different at 24 (Figure 6.1), 48
(Figure 6.2) and 72 h (Figure 6.3) of incubation, whereas, cells treated with the
NO donor agent SNP had lower P4 concentrations throughout the culture period.
The E2 concentrations in spent media of L-NAME-treated cells at 24 (Figure 6.4)
and 48 h (Figure 6.5) were higher than those of time-matched control cells.
Although no significant differences in E2 concentrations were detected at 72 h
among the treatment groups, L-NAME-treated BGC had E 2 concentrations 2-, 3and 4-fold greater than control, AG- and SNP-treated cells, respectively (Figure
6 .6 ).

Combined production of P4 (Figure 6.7) and E2 (Figure

6 .8 )

were different
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among treatment groups. The P4 .E 2 ratios of control and AG-treated cells were
significantly greater than ratios of L-NAME or SNP treated cells (Figure 6.9).
Cell viability of BGC before experimental agents were added into culture
was not different for the three independent experiments (Table 6.1), among
treatment groups after 72 h of incubation and within a treatment group for the
three experiments (Table 6.2).
Table 6.1 Bovine granulosa cell viability determined before experimental agents
for the different treatment groups were applied. No significant differences in cell
viability were detected among the three independent experiments. (P > 0.10).

Experiment 1
Experiment 2
Experiment 3
Mean ± SEM

Cell Viability (%)
75
62
66
67.7 ± 3.8

Table 6.2 Cell viability of control, L-NAME (NG-nitro-L-arginine methyl ester
hydrochloride)-, AG (aminoguanidine)- and SNP (sodium nitroprusside)-treated
bovine granulosa cells after 72 h of incubation for each experiment. No
significant differences in cell viability were noted among groups or within a group
at 72 h of incubation for the three independent experiments. (P > 0.10).

Experiment 1
Experiment 2
Experiment 3
Mean ± SEM

Control
71
69
69
70 ± 1 .2

L-NAME
67
71
66
68.1 ± 2.8

AG
67
65
68
66.7 ± 4 . 4

SNP
64
66
63
64.7 ±2.3

DISCUSSION
The results of the present study suggest that NO modulates the regulation of
bovine granulosa cell steroidogenesis and point to a participation in the process
of in vitro luteinization of granulosa cells. This finding is important as it may
provide a conciliatory explanation for the apparent discrepant scientific evidence
that implicates NO as a key player in the ovulatory process (Shukovski and
Tsafriri, 1994) and as an anti-steroidogenic molecule (Van Voorhis et al., 1994).
Although several studies have found a major participation of NO in the ovulatory
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Figure 6.1 Progesterone (P4) concentration (mean ± SEM) in spent media of
cultured bovine granulosa cells collected at 24 h of incubation. Cells were treated
with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor
agent sodium nitroprusside (SNP). Bars with different letters are significantly
different; P < 0.05.
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Figure 6.2 Progesterone (P4) concentration (mean ± SEM) in spent media of
cultured bovine granulosa cells collected at 48 h of incubation. Cells were treated
with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor
agent sodium nitroprusside (SNP). Bars with different letters are significantly
different; P < 0.05.

121

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

■ H

Control

g » g | SNP

72 Hours of Incubation
Figure 6.3 Progesterone (P4) concentration (mean ± SEM) in spent media of
cultured bovine granulosa cells collected at 72 h of incubation. Cells were treated
with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor
agent sodium nitroprusside (SNP). Bars with different letters are significantly
different; P < 0.05.
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Figure 6.4 Estradiol (E 2) concentration (mean 1 SEM) in spent media of cultured
bovine granulosa cells collected at 24 h of incubation. Cells were treated with the
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride (LNAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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Figure 6.5 Estradiol (E 2) concentration (mean ± SEM) in spent media of cultured
bovine granulosa cells collected at 48 h of incubation. Cells were treated with the
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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Figure 6.6 Estradiol (E2) concentration (mean l SEM) in spent media of cultured
bovine granulosa cells collected at 72 h of incubation. Cells were treated with the
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium
nitroprusside (SNP). L-NAME-treated cells had E2 concentrations 2-, 2.5- and
4-fold higher than control, AG- and SNP-treated cells, respectively. (P < 0.05).
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Figure 6.7 Total progesterone (P4) concentration (mean ± SEM) in spent media
of cultured bovine granulosa cells incubated for 72 h. Cells were treated with the
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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Figure 6.8 Total estradiol (E2) concentration (mean ± SEM) in spent media of
cultured bovine granulosa cells incubated for 72 h. Cells were treated with the
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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Figure 6.9 Progesteroneiestradiol (P 4:E2) ratio (mean ± SEM) in spent media of
cultured bovine granulosa cells calculated at 24, 48 and 72 h of incubation. Cells
were treated with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl
ester hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor
agent sodium nitroprusside (SNP). Bars with different letters are significantly
different; P < 0.05
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process, the relationship between the apparent anti-steroidogenic activities of NO
in relation to its role in ovulation remains unexplained.
The phenomenon of luteinization of granulosa cells in vitro is useful as an
experimental

approach

for studying

biochemical events associated

with

preovulatory follicular luteinization, because LH or hCG administration to cultured
bovine granulosa cells evokes similar changes in cell function as it does in vivo
(Channing, 1970). Accordingly, the endogenous surge of LH has also been
shown to trigger significant increases in bovine follicular P4 concentrations within
24 h concomitantly with decreased E2 concentrations (Sirois, 1994; Liu et al.,
1997). In comparison, bovine granulosa cells spontaneously luteinized in vitro
when cultured in serum-supplemented medium (Davis etal., 1988).
Furthermore, administration of hCG to cows in estrus induced the
expression of cyclooxygenase-2 (COX-2) and prostaglandin E synthase - 10 h
before ovulation (Liu et al., 1997; Filion et al., 2001). Administration of hCG to
spontaneously luteinized bovine granulosa cells in vitro induced the expression
of PGF2a receptor mRNA and COX-2 mRNA via activation of cyclic AMP
production (Tsai and Wiltbank, 2001). Similarly, hCG administration to cultured
bovine granulosa cells up-regulated COX-2, PGF2a receptor and PGE receptor
mRNA (Tsai et al., 1996). Taken together, these studies indicate that in vitro
tissue culture systems using bovine granulosa cells can serve as experimental
research

models to study regulation of biochemical events evoked

by

gonadotropins and then applied to in vivo conditions.
Studies that demonstrated the NO-induced inhibition of granulosa cell
steroidogenesis have failed to elucidate what would be the biological significance
of the anti-steroidogenic activity of NO for the physiological function of the ovary.
Undoubtedly, the suggestion that a molecule acts to promote ovulation but also
strongly inhibits steroidogenesis is puzzling, and poses a challenge for
reproductive biologists.
The steroidogenic capability of ovarian follicles is high during the
periovulatory period when expression of specific regulatory genes is induced by
FSH to promote maximum follicular growth and other genes, induced by LH, are
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expressed to promote follicular maturation and ovulation (Richards, 2001).
Before the LH surge, E2 is the predominant hormone whereas P4 concentrations
in the follicular fluid increase remarkably after the LH surge. If NO is truly
necessary for ovulation to occur, then participation of NO in the phenomenon of
preovulatory follicular luteinization might, at least partially, serve that function.
Thus, it seemed logical to investigate what role NO would have on in vitro
luteinization of granulosa cells. Therefore, the ultimate goal of the present study
was to investigate NO-induced modulation of steroidogenesis (especially in
relation to luteinization) in cultured bovine granulosa cells to further relate it to
NO role in ovulation.
Immunohistochemistry studies have identified NOS isoforms in the
mammalian ovary (Van Voorhis et al., 1994; Chatterjee et al., 1996; Zackrisson
etal., 1996; Hesla etal., 1997; Basini e ta i, 1998). Researchers still disagree on
which NOS isoform (or isoforms) is primarily involved during ovulation and the
initial stages of luteinization. Although some studies point to a preferential
involvement of eNOS in ovulation and steroidogenesis (Jablonka-Shariff et al.,
1999; Mitsube et al., 1999), others suggest that iNOS is the primary isoform
involved in the ovulatory process and biochemical events occurring in the
preovulatory follicle such as the up-regulation of follicular prostaglandins
(Shukosvi and Tsafriri, 1994; Faletti etal., 1999). Unlike the results of the equine
granulosa cell study, the administration of AG to bovine granulosa cells in the
present study did not significantly increase E2 production over hours as L-NAME
treatment did. Actually, granulosa cells treated with AG displayed a high degree
of luteinization demonstrated by increased production of P4 and temporally
related decrease in E2 production by treated cells. Further work will be needed to
investigate the mechanisms underlying this difference in the expression of NOS
activity between bovine and equine granulosa cells.
Immunohistochemistry of granulosa cells or follicle walls of equine and
bovine preovulatory follicles might help to elucidate species-specific differences
in the expression of ovarian NOS isoforms. Another approach would be to
pharmacologically design a specific inhibitor for iNOS devoid of secondary
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effects unrelated to iNOS inhibition. In that regard, AG has been known as an
inhibitor of diamine oxidase before NO was even discovered as a cell-signaling
molecule (Schuler, 1952) and, thus, before AG was known as a NOS inhibitor.
Administration of AG into serum-supplemented tissue culture systems has been
used to inhibit diamine oxidase, a key enzyme in the process of degradation of
polyamines. Catabolism of polyamines present in serum-supplemented tissue
culture systems might potentially lead to a build up in the concentration of toxic
aldehydes that could be deleterious for the cell viability in the culture system.
Thus, it should be considered that administration of AG in the present study
could have promoted a beneficial effect on the process of luteinization that
overrode inhibition of iNOS-derived NO.
Another possibility for the absence of significant differences between
L-NAME and AG effects is based on the fact that the culture system employed in
the present study was adequate for luteinization as indicated by marked
increases in P4 concentrations over time, both in control and NOS inhibitortreated cells. Perhaps attenuation of factors favorable for luteinization used in the
present study would allow luteinization of control bovine granulosa cells to be
conducted at a slower rate or less intensively, thus allowing effects of NOS
inhibitors in preventing luteinization more evident.
The original hypotheses of the present study stated that the P4:E2 ratios in
cells treated with SNP would be similar to those noted in control cells, indicating
that NO is permissive to the process of luteinization through its inhibitory effects
on steroidogenesis, primarily E2 production. This hypothesis was based on
strong evidence that suggests an important role for NO in the ovulatory process.
Preovulatory luteinization is an important LH-induced biochemical change
resulting from the intrafollicular shift in steroidogenesis from E2 to P4 as
previously discussed. Moreover, analysis of follicular fluid of mares before and
after stimulation with hCG showed that intrafollicular concentrations of NO were
higher after hCG stimulation, paralleling the temporally related increase in
intrafollicular P4 concentrations (Chapter 3). Taken together, these results led to

131

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

the hypothesis that addition of a NO donor agent to cultured granulosa cells
would favor, or be permissive to, in vitro luteinization of granulosa cells.
However, addition of SNP to cultured bovine granulosa cells in the present
study seemed to have suppressed production of E 2 and P4 but without
significantly affecting cell viability. It is likely that excessive NO generation
resulted in generalized binding of NO with CYP450 enzymes that are regulatory
for the steroidogenesis pathway.
Preliminary data analyzing samples from spent media of the present study
showed that concentrations of NO in spent media of SNP-treated cells were five
fold greater than that of control cells. Interestingly, the NO concentrations in
spent media of control cells increased over time, thus paralleling in vitro
luteinization of bovine granulosa cells in a somewhat analogous fashion noted in
intrafollicular NO concentrations in hCG-stimulated mares. The bovine granulosa
cells were treated with a dose of SNP based on previous studies and also on a
concentration that did not significantly affect cell viability but likely exceeded the
ability of cultured cells to utilize the NO produced at a physiological rate.
Retrospectively, the use of lower concentrations of SNP probably would have
enhanced the chances of detecting a beneficial effect of SNP toward in vitro
luteinization of granulosa cells.
Initial results from studies investigating the effects of NO on granulosa cell
steroidogenesis used serum-free culture medium (Basini et al., 1998) or short
term culture (Van Voorhis et al., 1994). Therefore, NO-induced modulation of
steroidogenesis during the process of in vitro luteinization could not be
determined.
The apparent NO-induced anti-steroidogenic activity was in agreement
with contemporaneous research investigating NO-induced regulation of rat luteal
function that found production of basal NO was significantly higher than that
produced by ovarian cells obtained at various stages of follicular development
(Olson et al., 1996). Thus, it was concluded that the relatively high amount of
basal production of NO maintained the E2 production by luteal cells at low
concentrations because addition of AG to the culture luteal cells produced a
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dose-dependent increase in E2 but not in P4 production (Olson et al., 1996).
Again, the latter study placed emphasis on the fact that inhibition of NO by AG
resulted in increased E2 production but did not discuss another seemingly
important finding, which was that control rat luteal cells produced a relatively high
amount of NO as well as high concentrations of P4 (Olson et al., 1996).
Subsequent studies using human (Frid6n et al., 2000; Vega et al., 2000)
and rat (Motta etal., 1999) luteal cells began to emphasize NO anti-steroidogenic
activity as the basis for a potential luteolytic action in the corpus luteum. In
Holstein heifers at mid-diestrus, intraluteal administration of L-NAME using a
microdialysis system provoked significant increases in P4 concentrations in the
perfusate but not in the peripheral blood (Jaroszewski and Hansel, 2000). When
heifers were perfused at the end of the diestrus period, the luteal activity was
prolonged as shown by the maintenance of P4 above 3 ng/ml from d 19 through
25 in three of the four treated heifers. It was concluded that NO had a direct role
on luteal regression.
However, in many aspects the NO pathway shares similarities with the
prostaglandin pathway and, therefore, still fails to provide the last word on the
molecular mechanisms regulating luteal regression. For example, a dichotomy is
present in the way prostaglandins interact with luteal cells, as is the seemingly
paradoxical relationship of NO with the luteinization process. Although PGF2a is
luteolytic in vivo, hCG-stimulated in vitro luteinization of bovine granulosa ceils is
accompanied by up-regulation of prostaglandin receptor mRNA for PGE and
PGF2a, as well as up-regulation of COX-2. Furthermore, PGF2a in vitro did not
inhibit basal P4 production by bovine large luteal cells and, interestingly,
significantly stimulated P4 production by small luteal cells. Therefore, the
evidence of the present study suggesting that NO is involved in the process of
bovine granulosa cell luteinization in light of evidence showing that NO might
regulate luteal regression should not be alarming if we consider the lessons from
prostaglandin research. Accordingly, a recent report discussed a potential dual
effect of NO on P4 production by luteal cells, that is, NO stimulating P4 production
in the functional mid-cycle corpus luteum and mediating PGF2a-induced luteolysis
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(Motta et al., 2001). In agreement with a possible luteotrophic role of NO are the
results of studies that showed that addition of NO donor agents to rat ovaries that
were simply incubated (Dong et al., 1999) or placed in a perfusion chamber
(Mitsube et al., 1999) increased the concentration of P4 in a dose-dependent
manner.
In summary, results of the present study showed that addition of a
nonspecific NOS inhibitor (L-NAME) to bovine granulosa cells cultured in vitro
decreased the P4:E2 ratios of treated cells over time, thus altering the pattern of
in vitro luteinization as compared with control cells. Treatment of cells with AG, a
specific iNOS inhibitor, did not differ from control cells, suggesting lack of
involvement of iNOS in the process of in vitro luteinization. However, beneficial
effects of AG, as a diamine oxidase to serum-supplemented tissue culture
systems should not be overlooked. The findings of the present study provide a
new conciliatory insight into the matter of NO participation in the ovulatory
process, in consideration with its anti-steroidogenic activity. It is proposed that
NO, along with its vascular effects in the preovulatory follicle, has a permissive
role on the phenomenon of LH-induced preovulatory luteinization, likely mediated
by inhibition of CYP450 aromatase.
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CHAPTER 7
PHARMACOKINETICS OF Ng-NITRO-L-ARGININE METHYL
ESTER (L-NAME) AFTER AN INTRAVENOUS BOLUS
ADMINISTRATION IN CONSCIOUS HORSES
INTRODUCTION
Nitric oxide (NO) has in its diatomic molecule equimolar amounts of two of
the most abundant gaseous elements known, nitrogen and oxygen (Fukoto,
1995). Until recently, NO was primarily known as a pollutant present in the
atmosphere derived from car combustion and even from cigarette smoke
(Weitzberg and Lundberg, 1998). Thus, it was as surprising as well fascinating
the information that the endothelial-derived relaxing factor was undistinguishable
from NO (Ignarro et al., 1987). Later, it was found that endogenous NO was
synthesized from the amino acid L-arginine in the presence of O 2 and NADPH,
and releasing an equimolar amount of citrulline as a co-product (Moncada et al.,
1991). The reaction was shown to be catalyzed by a family of enzymes known as
nitric oxide synthases (NOS; Alderton et al., 2001). These initial discoveries
launched an avalanche of intensive research trying to elucidate molecular
mechanisms of NO regulation and function.
Nitric oxide was initially discovered as a molecule controlling vasodilator
tone (Ignarro et al., 1987; Aisaka et al., 1989), but soon after its discovery NO,
was also found to be involved in several physiological and pathophysiological
processes such as neurotransmission (Sanders and Ward, 1992), macrophage
activity (Stuehr and Marietta, 1985; Abu-Soud et al., 1995) and hormonal
modulation (Adams et al., 1992). Accordingly, researchers began to turn their
attention to novel uses for old drugs, such as nitroglycerin, which had been used
for over 100 years to treat angina pectoris. Preterm labor is a serious condition
that affects women and nitroglycerin has been used to prevent or stop early labor
(Lees et al., 1994; Buhimschi et al., 1996). Other areas that were believed to
potentially benefit from treatment with NO donor agents are infectious diseases
(Burgner et al., 1999), parasitism (Garcia et al., 1999), pain management
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(Moncada et al., 1991) and, more recently, ovarian function (Rosselli et al.,
1998). However, an excess of NO can be as harmful in some instances as the
lack of adequate NO production. Thus, when it was found that one NOS isoform
(inducible isoform; iNOS) was expressed primarily in pathological, life-threatening
conditions (e.g., septicemia, septic shock, infections), researchers soon realized
that selective inhibition of iNOS during these critical conditions could potentially
ameliorate vital conditions that were altered by iNOS-derived NO overproduction.
The design and investigation of agents that inhibited NOS activity received as
much attention as did the research on NO-generating agents.
It was determined that the nonspecific NOS inhibitor NG-nitro-L-arginine
methyl ester (L-NAME) was shown to inhibit acetylcholine-stimulated relaxation
of rat aortic rings (Hutcheson and Griffith, 1991). Because of its high solubility
L-NAME was preferred as an experimental agent in NO research (Griffith and
Kilbourn, 1996). Because of its ester form, L-NAME is quickly hydrolyzed to
L-NNA by abundant cellular esterases (Pfeifer et al., 1996). The free acid L-NNA
is likely responsible for L-NAME NOS inhibition. This hypothesis was supported
by studies that showed that physiological effects denoting that NOS inhibition far
exceeded the short L-NAME half life. It has been suggested that L-NAME rapidly
enters the cell, is hydrolyzed and then becomes restricted inside the cell where it
exerts its physiological effects.
Subsequent studies have shown the potential of L-NAME for therapeutic
use. Administration of L-NAME resulted in reduction of plasma exudation (Perez
etal., 1997), neuroprotection following cerebral ischemia (C oertetal., 1999), and
restoration of normal systemic blood pressure following iatrogenic (Bone et al.,
1998) and naturally occurring (Kiehl et al., 1997; Avontuur et al., 1998)
endotoxemia.
However, no information has been published on characteristics of
L-NAME

pharmacokinetics following

systemic administration

in domestic

animals. Because of its solubility, tissue distribution, and effects on NOS
blockade, L-NAME is a potentially useful drug for experimental or clinical use.
Knowledge of its pharmacokinetics is crucial to pursuing research investigating
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the role of NO in equine physiologic and physiopathological processes. However,
dosages of L-NAME administered to horses in previous studies were not based
on pharmacokinetic studies but rather extrapolated from dosages from other
species or empirically from pilot studies (Mills et al., 1997; Manohar and Goetz,
1998). Therefore, in the present study plasma L-NAME concentrations and
kinetics were investigated after bolus intravenous administration of L-NAME
hydrochloride to conscious horses. The plasma L-NAME and L-NNA (major
L-NAME metabolite) concentrations were determined using high-performance
liquid chromatography system (HPLC).
MATERIAL AND METHODS
Experimental Procedures
Six clinically normal adult horses (4 Quarter Horses, 1 Thoroughbred, 1
Paint) and in good health were acclimatized to stand unrestrained in stocks
without chemical sedation and were accustomed to handling and the presence of
personnel and research equipment at close proximity. There were 2 sexually
intact females and 4 geldings. The horses weighed (mean ± SEM) 518.94 ±
11.58 kg and were 11.0 ± 1.15 years old. Horses were fed a commercial grain
ration (4 kg/horse) twice daily in addition to ad libitum access to Alicia hay and
water. All horses were housed in individual stalls for the duration of the
experiment (Fall 1999 and Spring 2000).
NG-nitro-L-arginine methyl ester (L-NAME) hydrochloride and N°-nitro-Larginine (L-NNA) were purchased from Sigma Chemical Company (St. Louis,
MO). This study was approved by the Institutional Animal Care and Use
Committee of Louisiana State University.
Instrumentation
Two 14-gauge, 13.3 cm Teflon catheters were aseptically inserted
percutaneously into the right and left jugular vein, and were used for the drug
administration and blood collections. A 10% (w/v) solution was freshly prepared
immediately before the experiment commenced by dissolving L-NAME into 0.9 %
(w/v) saline solution. The L-NAME solution (40 mg/kg) was injected in the left
jugular vein over 2 min. Blood samples (10 ml) were drawn from the right jugular
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vein immediately before and at 1, 2, 5 ,1 0 ,1 5 , 20, 25, 30, 40, 50 ,60 , 75, 90,105
min and at 6, 12, 24, 30, 36, and 48 h after L-NAME administration. A 30-ml
syringe was used to draw 20 ml of blood from the catheter and only then a 12-ml
plastic syringe was used to collect fresh blood that, likely, did not contain heparin
saline solution (0.9%, w/v), which was used to prevent catheter occlusion. The
first 20 mi of blood was then infused back to the jugular vein and catheters were
immediately flushed with heparinized saline solution. Blood samples (10 ml) were
immediately placed in tubes coated with lithium heparin, placed on ice and
centrifuged (2,000 x g for 10 min) within 15 min after collection.
Because hyperthermia has been detected (Mills et al., 1997) in horses
receiving L-NAME (by mechanisms not yet fully elucidated), fans were
maintained in the stalls for the duration of the study. Plasma samples were
stored at -7 0 °C until analysis for determination of L-NAME and L-NNA using
HPLC.
Sample Preparations and HPLC Analyses
Frozen plasma samples were thawed at room temperature (20 to 23 °C).
Once samples were thawed and vortex mixed for 45 sec, 0.5 ml of sample was
transferred into 5-ml conical glass tubes containing 3 ml of ethanol, which
resulted in plasma deproteinization. After vortex mixing the tubes for 45 sec, 1.5
ml was transferred into microcentrifuge tubes and centrifuged at 16,000 x g for
10 min. After centrifugation, 100 pi of supernatant was diluted with 400 pi of
HPLC water, passed through a 0.45 pm nylon filter and loaded into the HPLC
system for automated injection (50 pi per sample) and analysis.
A standard curve was determined immediately before each run using
freshly prepared standard solutions. The L-NAME and L-NNA standard solutions
were

made

using

L-NAME- and

L-NNA-free

pooled

horse

plasma

at

concentrations of 100, 50, 25 ,10 , 5, 1, and 0 pg/ml. The use of horse plasma to
dilute L-NAME and L-NNA was previously validated against standard solutions
made with HPLC water. A new calibration curve was prepared daily before
samples were analyzed. A method (made with HPLC water) and horse plasma
blank (obtained from horses that were not treated with L-NAME) controls
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containing no chemicals were included in each run. Linear calibration curves with
an t2 value a 0.99 were used for analysis. The limit of quantification for L-NAME
and L-NNA was 0.05 pg/ml.
Plasma concentrations of L-NAME and L-NNA were determined using an
ion exchange HPLC system (HP 1090 Agilent Technologies, Wilmington, DE)
equipped with a nucleosil SA column (length = 250 mm; internal diameter = 4.6
mm, Machery-Nagel,) and a column guard (length = 7.5 mm; internal diameter =
4.6 mm, Machery-Nagel). The nucleosil SA is a sulfonic acid-based strong cation
exchanger with an ion exchange capacity of approximately 1 meq/g. The particle
diameter was 5 pm. The nucleosil SA column was chosen because it is stable
when exposed to mobile phase of low pH, such as the one used in the present
study to detect L-NAME and L-NNA.
The mobile phase was composed of 90% of an aqueous phase containing
NaH 2P 0 4 /H 3Po4 (1:1 ratio; 200 mM; pH * 2.3) and 10% of an organic phase
containing MeOH run at (1.5 ml/min). A diode-array light detector for the UV
signal was set at a wavelength of 268 qm. The mobile phase solutions were
degassed with helium for 20 min before each run. The run time was 19 min (stop
time = 14 min; post-time = 5 min). A PC computer equipped with software
designed for HPLC analysis was connected to the HPLC equipment to collect
data.
Statistical and Pharmacokinetic Analyses
Plasma L-NAME and L-NNA concentrations of six horses were used to
calculate pharmacokinetic parameters. Experimental data was further analyzed
using standard methods and equations performed by computer software
designed to analyze pharmacokinetic data (WinNonlim®, Scientific Consulting
Inc., Cary, NC).
RESULTS
In general, no signs of discomfort or colic were noticed in horses receiving
L-NAME. However, It seemed that, overall, all horses were not as alert after the
beginning of the experimental procedures including L-NAME infusion, whereby a
submissive demeanor was observed. Five of six horses were eating and drinking
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normally within the first 12 h after L-NAME administration. Only one horse
developed hyperthermia (104 to 106 °F) and loss of appetite for 48 h following
L-NAME administration. Blood chemistry and complete blood count analyses
were within normal limits. At the end of the study (48 h), the horse was still
depressed and was treated with fluids. Recuperation to normal health and
behavior was uneventful.
The mean (± SEM) values of plasma L-NAME and L-NNA concentrations
for each time point were calculated (Table 7.1) and used to estimate
pharmacokinetic parameters. Experimental data from analyses for detection of
L-NAME suggested that a two-compartment model (Figure 7.1) was adequate for
analyses, whereas a one-compartment model (Figure 7.2) was used to derive
pharmacokinetic parameters from plasma L-NNA concentrations over time. Both
one- and two-compartment models were used based on intravenous bolus input
and first-order output.
Determination of L-NAME and L-NNA in the same sample by HPLC was
reliable because the peaks for each compound were identified at different
retention times. Retention time for L-NAME was ~ 7 min, whereas, the retention
time for L-NNA was - 3 min. Plasma concentrations of L-NAME and L-NNA were
plotted against time (Figure 7.3 and 7.4, respectively) and pharmacokinetic
parameters were calculated (Tables 7.2 and 7.3).
The overall biologic half life (K10-HL) for L-NAME was 3.7 min, whereas,
the K10-HL for L-NNA was 19.5 h. The plasma L-NAME concentrations were
highest after 1 min and declined rapidly over the next 30 min, stabilizing at - 1
Mg/ml until the last time point (t = 48 h). The plasma L-NNA concentrations never
peaked and concentrations determined at the first time point (1 min) were the
beginning of a plateau (30 to 35 ug/ml) that ended 12 h after L-NAME
administration when the first significantly different L-NNA concentration was
noted (18.81 ug/mi). Defined as the average amount of time a compound
remains in the body, the mean residence time (MRT) was 14.4 min and 28.2 h for
L-NAME and L-NNA, respectively.
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Table 7.1 Plasma concentrations (mean ± SEM) of NG-nitro-L-arginine methyl
ester (L-NAME) and NG-nitro-L-arginine (L-NNA) after an intravenous bolus
administration of L-NAME hydrochloride (40 mg/kg).

Time point (h)
0.017
0.033
0.083
0.167
0.250
0.330
0.417
0.500
0.667
0.83
1.0
1.3
1.5
1.8
6.0
12.0
24.0
30.0
36.0
48.0

L-NNA(ug/ml)
35.35 ± 2.8
30.87 ± 3.3
33.25 ± 1 .7
35.45 ±1.1
36.33 ± 1 .5
33.35 ± 2.3
35.31 ±1.1
35.27 ± 1 .3
34.66 ± 1 .0
32.92 ± 1 .2
32.17 ± 0 .8
31.51 ± 1 .3
31.54 ± 0 .5
31.29 ± 0 .8
26.38 ± 3.0
18.81 ± 1 .9
14.21 ±2.1
12.58 ± 1 .8
10.52 ± 2 .0
8.40 ± 0.6

L-NAME (ug/ml)
233.94 ± 17.8
151.37 ±12.8
99.07 ± 6.0
42.95 ± 2.2
22.93 ± 1.8
12.76 ± 1.1
9.32 ± 0.9
6.15 ± 0.4
3.55 ± 0.5
2.35 ± 0.5
1.62 ± 0.4
1.58 ± 0.5
1.03 ± 0.3
0.60 ± 0.3
1.26 ± 0.4
0.87 ± 0.1
1.65 ± 0.3
1.35 ± 0.3
1.38 ± 0.2
0.99 ± 0.1
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Bolus iv
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Figure 7.1 Two-compartment model with intravenous bolus input and first order
of elimination rate used to calculate pharmacokinetic parameters from
administration of NG-nitro-L-arginine methyl ester hydrochloride (L-NAME; 40
mg/kg corresponding to 34.6 mg/kg of L-NAME). K10 * Elimination rate; K12 =
Transfer rate from compartment 1 to 2; K21 = Transfer rate from compartment 2
to 1.

Bolus iv

K10
1

Figure 7.2 One-compartment model with intravenous bolus input and first order
of elimination rate used to calculate pharmacokinetic parameters of NG-nitro-Larginine (L-NNA) following administration of NG-nitro-L-arginine methyl ester
hydrochloride (L-NAME; 40 mg/kg) corresponding to 32.6 mg/kg of L-NNA. K10 =
Elimination rate.
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Figure 7.3 First-hour plot of plasma concentration versus time of NG-nitro-Larginine methyl ester (L-NAME) and NG-nitro-L-arginine (L-NNA) derived from
mean values obtained from 6 horses that were administered an intravenous
bolus injection of L-NAME hydrochloride (40 mg/kg).
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TABLE 7.2 Pharmacokinetics of NG-nitro-L-arginine methyl ester hydrochloride
(L-NAME) after an intravenous bolus administration (40 mg/kg) to six adult
horses.
Parameters
AUC
K10-HL
Alpha
Beta
Alpha-HL
Beta -H L
A
B
Cmax
CIB
Non-compartmental
AUMC
MRT
Vss

Units
pg.h.mr1
h
h'1
h‘1
pg.ml'1
pg.ml*1
Mg.ml'1
pg.ml'1
Mg.ml*1
ml.kg .h

Estimate (± SEM)
27.57 ±1.41
0.06 ± 0.01
25.95 ± 8.41
3.20 ± 0.77
0.04 ± 0.01
0.26 ± 0.04
271.86 ±31.51
53.30 ± 58.27
325.08 ±47.21
1.27 ± 0.06

M g.fr.m r
h
ml.kg'1

7.08 ± 1.6 7
0.20 ±0.01
0.25 ± 0.02

Estimate of pharmacokinetic parameters were calculated from mean values of
plasma L-NAME concentrations from six horses.
Intravenous bolus dose = 40 mg/kg (corresponding to 34.6 mg/kg free L-NAME).
AUC = Are under the curve.
K10-HL = Overall biologic half life in relation to the elimination rate.
Alpha = Distribution rate constant.
Beta - Elimination rate constant.
A = Distribution extrapolated zero time concentration.
B = Elimination extrapolated zero time concentration.
Cmax = Maximum plasma concentration.
CIb = Total body clearance.
AUMC = Area under the moment curve.
MRT = Mean residence time.
Vss = Volume of distribution at steady state.
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TABLE 7.3 Pharmacokinetics of NG-nitro-L-arginine (L-NNA) as a product of
hydrolysis of L-NAME administered intravenously as a bolus injection (40 mg/kg)
to six adult horses.

Parameters
AUC
K10-HL
Cmax
CIb
Non-compartmental
AUMC
MRT
Vss

Units
pg.h.ml'1
h
Mg.ml*1
ml.kg .h

Estimate ( l SEM)
961.6
19.5
34.1
33.8

pg.h2.ml'1
h
ml.kg*1

27117.7
28.2
953.4

Estimate of pharmacokinetic parameters were calculated from mean values of
plasma L-NNA concentrations from six horses.
L-NAME hydrochloride intravenous bolus dose = 40 mg/kg (corresponding to
34.6 mg/kg free L-NAME).
AUC = Are under the curve.
K10-HL = Overall biologic half life.
Cmax = Maximum plasma concentration.
CIb = Total body clearance.
AUMC s Area under the moment curve.
MRT = Mean residence time.
Vs, = Volume of distribution at steady state.
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DISCUSSION
The estimates of pharmacokinetic parameters determined for L-NAME in
the present study were in agreement with previous studies in rats (Brouillet et al.,
1995), rabbits (Schwarzacher and Raberger, 1992), dogs (Krejcy et al., 1993)
and humans (Klein and Dudenhausen, 1996; Avontuur etal., 1998) that reported
plasma L-NAME concentrations increased shortly after intravenous infusion and
decreased rapidly as a result of hydrolysis yielding L-NNA. However, different
half lives for L-NAME have been found for different species: rats = 2 min; rabbits
= 7.5 min; dogs = 222 min; humans = 19.2 min and horses (present study) = 3.7
min. NG-nitro-L-arginine methyl ester hydrochloride were added to blood plasma
of dogs (Krejcy et al., 1993) and humans (Klein and Dudenhausen, 1996),
whereas, in other studies

L-NAME was administered to live rats (Brouillet et al.,

1995) and humans (Avontuur et al., 1998), as it was performed in the present
study with horses. Therefore, different experimental approaches and speciesspecific differences likely accounted for the different reported half life (3.6 min).
In contrast, the estimates of pharmacokinetic parameters determined for
L-NNA in the present study were in agreement with the half life and MRT
estimated values reported for rats (Piotrovskij etal., 1993; Piotrovskij etal., 1994;
Tabrizi-Fard and Fung, 1994) and humans (Avontuur et al., 1998). In general,
L-NNA has a relatively long half life of - 20 h (19.5 h in the present study) and a
long MRT of around 28 h (28.2 h in the present study). The Vss of L-NNA
suggests that, despite being a low lipophilic compound (Piotrovskij et al., 1994), it
might be formed intracellularly by the action of cellular esterases breaking down
L-NAME (Pfeifer etal., 1996). The L-NNA distribution along with its relatively low
plasma clearance (CIb) accounted for the relatively long half life documented for
L-NNA in the present study.
The fact that L-NAME administration has been associated with clinical
effects that exceeded its long half life led to the hypothesis that inhibition of NOS
activity was probably accomplished by its free acid, L-NNA (Schwarzacher and
Raberger, 1992; Brouillet ef al., 1995; Avontuur et al., 1998). In addition, L-NAME
hydrolysis to the free acid L-NNA has been suggested to be a requirement for
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L-NAME-induced inhibition of NOS isoforms (Pfeifer et al., 1996). Accordingly,
results of the present study suggested that L-NAME is rapidly hydrolyzed to
L-NNA, which was detected in plasma samples obtained 1 min post-L-NAME
administration. Brouillet et al. (1995) noted that L-NAME decomposition was
concomitant with increases in rat plasma L-NNA concentrations. However, a
more careful analysis of that data and estimates obtained in the present study
revealed that L-NAME hydrolysis is not correlated with plasma L-NNA
concentrations. The plasma L-NNA concentrations reached a plateau soon after
L-NAME administration that was not correlated with continuously declining
plasma L-NAME concentrations. Similar results were reported for anesthetized
rabbits treated with L-NAME, but specific estimates for L-NNA pharmacokinetic
parameters were not given (Schwarzacher and Raberger, 1992).
Pfeifer et al. (1996) reported that when L-NAME was incubated in rat
plasma or physiological buffer, hydrolysis of L-NAME occurred resulting in a
proportional formation of L-NNA over time. Surprisingly, when L-NAME was
added to total rat blood, hydrolysis occurred at a more rapid rate, but no
correlation was found between L-NAME hydrolysis and formation of the free acid
L-NNA. It was concluded that L-NAME must have entered the blood cells.
In a preliminary study in our laboratory, equine plasma samples obtained I
min after the administration of L-NAME were left at room temperature for up to 8
h and analyzed by HPLC at 3-h intervals. The resulting L-NAME and L-NNA
concentrations were inversely proportional, thus, contrasting with the pattern of
hydrolysis noted in plasma samples analyzed by HPLC in the present study.
Therefore, one might consider that the rapid L-NAME disappearance in equine
blood plasma noted in the present study may not be solely explained by
complete hydrolysis of L-NAME into L-NNA, but rather may suggest that L-NAME
is rapidly transferred to the intracellular compartment where it is subjected to
hydrolysis by intracellular esterases. Hence, some researchers have suggested
that studies using in vivo experimental approaches should not use L-NAME
(Schwarzacher and Raberger, 1992), however, this may deprive studies from
benefiting from L-NAME’s solubility and its rapid distribution to target cells.
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Brouillet et al. (1995) raised another concern related to the potential
therapeutic use of L-NAME in that methanol is formed as a by-product of
L.-NAME hydrolysis. They noted that radioactive labeled [11C] L-NAME as
detected by positron emission tomography entered the brain of nonhuman
primates in less than 30 sec. Because an injection of unlabelled L-NAME was
unable to displace L-NAME in a previous study (Roeda et al., 1995), it was
hypothesized that methanol was a candidate for L-NAME hydrolysis by-product.
Because methanol was found to be one important metabolite of L-NAME
biodegradation in addition to L-NNA, the authors of that study elected not to
perform pharmacokinetic studies in primates and dogs as initially planned
(Brouillet et al., 1995). Furthermore, it was advised to use caution if L-NAME is to
be used in a clinical situation involving humans or domestic animals. The
apparent half life of cerebral methanol was 17.6 h. Methanol is not toxic per se,
but under the catabolic activity of alcohol dehydrogenase, methanol is converted
to formaldehyde and formic acid, which exert neurotoxicity (Wexler, 1998).
However, in the present study no signs of neurotoxicity were noted in
horses following L-NAME administration. Furthermore, the amount of injected
L-NAME (148 pmol/kg) would have yielded only 2.5 g of methanol in a horse
weighing 500 kg. It is noteworthy to mention that the LD50 for methanol observed
in rats, rabbits and monkeys is approximately 5 g/kg, 14.4 g/kg and 7 g/kg,
respectively (Wexler, 1998). Although plasma concentrations of methanol
associated with toxicity are not well established for horses, the potential amount
of methanol resulting from L-NAME administration in the present study likely
would have been insufficient to cause neurotoxicity
In summary, the results of the present study provide for the first time
information on the pharmacokinetics of L-NAME and L-NNA following an
intravenous bolus administration to conscious horses suggested the following:
1) L-NAME has a short half life (3.6 min); 2) L-NNA is rapidly detectable in
equine plasma following L-NAME administration with a half life of 19.5 h; and 3)
hydrolysis of L-NAME does not correlate with plasma L-NNA concentrations.
Furthermore, horses administered L-NAME did not develop signs of neurotoxicity
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that could have been associated with L-NAME-derived methanol formation. The
pharmacokinetic profile of L-NAME administration in horses documented in the
present study will be beneficial to developing pharmacological regimens for
experimental or therapeutic purposes
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CHAPTER 8
HEMODYNAMIC EFFECTS ASSOCIATED WITH AN
INTRAVENOUS BOLUS ADMINISTRATION OF NG-NITRO-LARGININE METHYL ESTER (L-NAME) IN CONSCIOUS HORSES
INTRODUCTION
There have been three major nitric oxide synthase (NOS) isoforms
identified presently that catalyze the formation of nitric oxide (NO) from i-arginine
(Palmer et al., 1988; Bredt et al., 1991; Alderton et al., 2001). The endothelial
(eNOS) and the neuronal (nNOS) NOS isoforms are constitutively expressed,
whereas, a third NOS isoform (iNOS) has its catalytic activity induced in
response to cytokines and lipolysaccharides (Moncada etal., 1991). It has been
shown that nitric oxide (NO) derived from eNOS activity exerts control over basal
vascular tone to maintain normal blood pressure and organ blood flow.
Conversely, increased production of NO produced by iNOS activity during sepsis
and endotoxemia results in a remarkable vasodilation, which accounts for
hypotension and organ hypoperfusion during septic or endotoxic shock (Moore
and Seahorn, 1997; Mirza et al., 1999). The iNOS-derived NO produced in these
life-threatening conditions also contributes to extensive tissue damage observed
in diabetes mellitus, rheumatoid arthritis, and other inflammatory disorders via
production of reactive oxygen species such as peroxynitrite (a powerful oxidant;
Beckman and Crow, 1993). Administration of NOS inhibitors may cause
neurotoxicity as seen in focal cerebral ischemia caused by middle cerebral artery
occlusion (Coert etal., 1999)
One approach to study the multifaceted aspects of the action of NO in
pathophysiological mechanisms is to use drugs that block the production of NO
or the expression of nitric oxide synthase. Analogues of L-arginine, including NGnitro-L-arginine (L-NNA) and its methyl ester, NG-nitro-L-arginine methyl ester
(L-NAME) can inhibit the production of NO (Moncada et al., 1991). Accordingly,
L-NAME enantiomerically induces competitive reversible inhibition of NOS in vitro
and in vivo (Griffith and Kilboum, 1996). Although inhibition of NOS by L-NAME
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has not yet been fully characterized, L-NAME has been extensively used as a
pharmacological tool to study NOS blockade in tissue homogenates, intact cells,
animals, and humans (Southan and Szabo, 1996). However, studies have
disregarded the investigation of its biodistribution and metabolism kinetics.
It has been reported that L-NAME has less affinity for NOS than L-NNA,
being comparatively a less potent NOS inhibitor than L-NNA (Griffith and
Kilbourn, 1996). However, L-NAME is quickly hydrolyzed to L-NNA in the
presence of intracellular esterases. It has been shown that L-NAME is far more
soluble than L-NNA allowing better intracellular distribution where it undergoes
intensive hydrolysis to form L-NNA (Griffith and Kilboum, 1996). Estimated half
life of L-NAME in vivo has been documented in rabbits (7.5 min; Schwarzacher
and Raberger, 1992), humans (19.2 min; Avontuur et al., 1998), rats (2 min;
Brouillet et al., 1995), and in vitro in dogs (222 min; Krejcy et al., 1993) and
sheep (250 min; Whiting et al., 1994). The half life of the metabolite L-NNA has
been reported to be several hours (3 to 24 h; Piotrovskij et al., 1994; Brouillet et
al., 1995). Because L-NNA has far greater affinity for NOS than L-NAME,
inhibition of NOS activity following L-NAME administration is apparently L-NNAmediated (Pfeifer et al., 1996). These few studies addressing the kinetics of
L-NAME have contributed to a more rational design of therapeutic regimens and
experimental investigations in these species.
As with humans, dogs, and laboratory animals (Durakbasa et al., 1998),
NO may play a role in the pathophysiology of diseases of horses involving the
gastrointestinal (Moore and Seahorn, 1997; Mirza et al., 1999) and respiratory
systems (Costa et al., 2001). Thus, a potential therapeutic use for L-NAME would
be to counteract the overproduction of NO in cases of acute or chronic
inflammation of the gastrointestinal tract, including ischemic and inflammatory
intestinal diseases (Moore etal., 1994), and inflammatory lung disease (Seahorn
et al., 1997; Costa et al., 2001). It has also been demonstrated that loss of
endothelial cell integrity of equine digital palmar vessels may impair NO
production after carbohydrate overload (Schneider et al., 1999). The resulting
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decrease in digital blood flow contributes to the pathophysiology of laminitis
(Allen etal., 1990; Schneider etal., 1999).
Results of studies investigating effects of L-NAME administration to
horses demonstrated that NO regulates pulmonary blood pressure and body
temperature during exercise in horses following intravenous L-NAME injection
(Mills et al., 1997). Thus, NO may play a role in pulmonary hypertension and heat
intolerance during exercise. The presence of the NO pathway in the development
of pulmonary hypertension has been suggested (Adnot etal., 1991) after NO was
identified as being the endothelium-derived relaxing factor (EDRF; Ignarro et al.,
1987).
Pulmonary hypertension is directly a result of increased vascular
resistance and decreased compliance owing primarily to severe injury to
endothelium

of

pulmonary

vessels

followed

by

extensive

remodeling

(mesenchymal proliferation). Expression of NOS activity is elevated in the
pulmonary vasculature of animals used in experimental models of pulmonary
hypertension. The consequent NOS-stimulated production of NO has been found
to be protective to the lung at initial stages of the disease. However, sustained
NO production may amplify pulmonary vascular endothelial injury in more chronic
forms of pulmonary hypertension (Hampl and Herget, 2000). Thus, with selective
reduction of pulmonary vascular tone by inhaled NO has been shown as a
therapeutic alternative to treat pulmonary hypertension in newborn humans
(Weinberger et al.,1999) and foals (Lester et al., 1999), the inhibition of
pulmonary NO and

NO-related production of oxygen

radicals maybe more

advantageous in some forms of chronic pulmonary hypertension (Hampl and
Herget, 2000). It is

probable that modulation of NO concentration by NOS

inhibitors such as L-NAME may be beneficial

to treat

a number ofdiseases

especially to overcome detrimental iNOS-derived overproduction of NO.
Because of its solubility, tissue distribution, and effects on NOS blockade,
L-NAME is a potentially useful drug for experimental or clinical use. Knowledge
of its pharmacokinetics is crucial to pursue research investigating the role of NO
in equine physiological and pathophysiological processes. Therefore, the aims of
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the present study were to examine the effects of an intravenous bolus
administration of L-NAME on hemodynamic variables including systemic arterial
blood pressure, pulmonary arterial blood pressure, right atrial pressure, heart
rate and rhythm, and clinical signs. I hypothesized that the administration of
L-NAME (40 mg/kg) would cause an increase in systemic and pulmonary arterial
blood pressure while maintaining unaltered clinical signs. I also hypothesized that
the L-NAME induced hypertension would parallel plasma concentrations of
L-NAME (Chapter 7).
MATERIAL AND METHODS
Experimental Procedures
Six clinically normal adult horses (4 Quarter Horses, 1 Thoroughbred, 1
Paint) and in good health were acclimatized to stand unrestrained in stocks
without chemical sedation and were accustomed to handling and the presence of
personnel and research equipment at close proximity. There were 2 sexually
intact females and 4 geldings. The horses weighed (mean ± SEM) 518.94 ±
11.58 kg and were on average 11.0 ± 1.15 years old. Horses were fed a
commercial grain ration (4 kg/horse) twice daily in addition to ad libitum access to
Alicia hay and water. All horses were housed in individual stalls for the duration
of the experiment.
N°-nitro-L-arginine methyl ester (L-NAME) hydrochloride was purchased
from Sigma Chemical Company (St. Louis, MO). This study was approved by the
Institutional Animal Care and Use Committee of Louisiana State University.
Instrumentation
Instrumentation of animals was performed on average 3 h before L-NAME
administration. Horses were sedated with xylazine (0.25 mg/kg of body weight,
iv). Subcutaneous infiltration of mepivicaine hydrochloride (0.5 to 1.0 ml) was
used to desensitize the skin prior to the insertion of intravascular catheters. Two
14-gauge, 13.3 cm Teflon catheters were used for the drug administration and
blood collections. The polyethylene tubing was inserted into a catheter in the
jugular vein and was positioned into the main pulmonary artery to measure mean
pulmonary artery pressure. Another polyethylene tubing was positioned into the
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right atrium for measurement of mean right atrial pressure. The position of the
catheters was verified by characteristic pressure waves. To measure arterial
blood pressure a 20-gauge, 5.1 cm Teflon catheter was placed into the facial
artery. The hair was clipped from the paralumbar fossa and an electronic
stethoscope (Escope, Card ionics, Houston, TX) was secured using tape.
Right atrial, pulmonary artery, and facial artery catheters were interfaced
with pressure transducers (Ohmeda Medical Devices, Madison, W l) and an
amplifier and recorder (Grass, AstraMed, Warwick, RT) pressure transducers
were placed at the height of the point of the shoulders. Intestinal sounds detected
by the electronic stethoscope were interfaced with the driver amplifier of the
Grass recorder.
Hemodynamics and Clinical Signs
A bolus dose of L-NAME (40 mg/kg, iv, 10%, w/v, dissolved in saline
solution) was infused into the left jugular vein over 2 min. Arterial, right atrial and
pulmonary arterial pressures, heart rate and rhythm, clinical signs, and intestinal
sounds were monitored continuously 20 min before and for 3 h after the
intravenous injection of L-NAME. During these initial 3 h animals were kept in
stocks and thereafter moved into a stall in the bam. Blood samples (10 ml) were
drawn from the right jugular vein immediately before and at 1, 3, 6, 24 and 48 h
after L-NAME administration. Blood samples (10 ml) were immediately placed in
tubes coated with lithium heparin, placed on ice and centrifuged (2,000 x g for 10
min) within 15 min after collection.
Rectal temperature, respiratory rate, capillary refill time and skin tent were
monitored every hour for the duration of the experiment (48 h). Because
hyperthermia has been reported (Mills et al., 1997) in horses receiving L-NAME
intravenously (by mechanisms not yet fully elucidated), fans were maintained in
the stalls for the duration of the study. W e did not administer L-arginine to reverse
L-NAME action because clinical examination of horses did not indicate that such
intervention was necessary.
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Statistical Analyses
All data were expressed as mean ± SEM. The data were analyzed by one
way repeated measures analysis of variance using a general linear model
(SigmaStat 2.0, Jandel Corp., San Rafael, CA). All data were evaluated for
normality using Kolmogorov-Smimov test (with

Lilliefors' correction) and

transformed when appropriate. When statistical differences were detected using
a P < 0.05, post hoc comparisons were made using Tukey’s test.
RESULTS
Intravenous administration of L-NAME to six conscious horses resulted in
an immediate increase in systemic arterial pressure that returned to normal
baseline values at 6 h post-L-NAME administration. Mean right atrial pressure
was increased significantly between 20 and 30 min, whereas, mean pulmonary
arterial pressure was not significantly affected by L-NAME administration (Table
8.1). Mean values for heart rates were not significantly different from the baseline
values

(Table 8.1).

No significant differences were detected for rectal

temperature, heart rate, respiratory rate, capillary refill time and skin tent among
the 6 horses throughout the experiment (data not shown).
In general, no signs of discomfort or colic were noticed in horses receiving
L-NAME. However, it seemed that all horses were not as alert after L-NAME
infusion compared to prior to administration; a submissive demeanor was
observed as early as early as 15 min post-L-NAME administration. Five of six
horses were eating and drinking normally within the first 12 h after L-NAME
administration. Only one horse (gelding) experienced hyperthermia and loss of
appetite for 48 h following L-NAME administration. Blood chemistry and complete
blood count analyses were within normal limits. At the end of the study (48 h),
this horse remained depressed and was treated with fluids administered
intravenously. Recuperation to normal health and behavior was uneventful.
DISCUSSION
An intravenous bolus administration of L-NAME hydrochloride (40 mg/kg)
to conscious horses quietly standing in stocks significantly increased mean SAP
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Table 8.1

Mean (± SEM) values of systemic arterial blood (SAP), pulmonary

artery (PAP) and right atrial (RAP) pressures, and heart rates (HR) of conscious
horses at rest following an intravenous bolus administration of NG-nitro-L-arginine
methyl ester (L-NAME) hydrochloride (40 mg/kg).

Time (h)a

SAP (mm Hg)

PAP (mm Hg)

RAP (mm Hg)

HR (beats/min)

0 (baseline)

156.3 ± 6 .1 6

32.0 ± 2.0

11.4 ±1.2

39.0 ±1.3

0.017
0.033
0.083
0.167
0.25
0.33
0.41
0.50
0.67
0.83
1
1.25
1.5
1.75
2
2.5
3

186.4
203.7
224.7
225.7
242.2
243.5
242.4
240.7
240.1
241.8
244.2
239.7
239.2
238.2
231.9
223.7
219.1

39.9
42.0
46.3
42.4
45.7
44.4
41.8
42.1
39.4
39.4
38.0
39.1
42.1
39.4
37.2
41.3
38.4

19 4
20.5
23.1
23.9
24.9
27.3
27.2
26.3
22.8
21.4
23.8
20.1
21.7
22.3
17.9
18.5
12.9

33.0
33.0
33.0
36.5
37.5
36.8
36.8
37.2
37.2
38.1
37.3
37.3
37.8
39.2
38.2
38.5
37.2

6

154.5 ±

±19.1
± 22.8 *
± 19.2*
± 16.0 *
± 17.4 *
±19.4*
± 23.2 *
± 16.6 *
±15.8*
± 15.3*
± 11.7*
±10.9*
± 12.4 *
± 7 .7 *
± 9 .5 *
±10.4*
±13.6*
5.3

± 5.8
±6.7
± 6.9
± 6.7
± 7.7
±9.1
±8.5
± 9.0
±6.7
± 6.7
± 5.8
±5.0
±7.8
± 6.6
± 5.7
±7.0
±4.8

33.2 ± 2.6

± 3 .0
± 3.9
± 2 .8
±3.1
± 6.1
± 5.9 *
± 5.3 *
± 4.9 *
± 5.9
±5.1
± 6.6
± 6. 2
±4.8
± 5.4
± 4 .8
± 5 .4
± 3.9

12.0 ± 2 . 2

± 0.9
± 0. 9
± 0.9
± 2.4
± 3.9
± 3.9
±4.8
±6.0
±4.9
±4.7
±4.8
±4.8
± 3.5
± 4.3
±4.5
±4.6
± 3.5

36.7 ± 2.7

* Time in relation to L-NAME administration.
’ P < 0.05 as compared with baseline values.
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Figure 8.1 Systemic arterial (SAP), pulmonary artery (PAP) and right atrial
(RAP) mean (± SEM) pressures obtained from six conscious horses after
administration of NG-nitro-L-arginine methyl ester (L-NAME; 40 mg/kg). Note that
mean SAP increased significantly by 2 min and returned to baseline values by
6 h after L-NAME injection. The mean RAP was significantly increased between
20 and 30 min post-L-NAME administration, whereas, no significant alterations
were noted for mean PAP throughout the study. * P < 0.05 as compared with
baseline values before L-NAME administration, was considered significant.
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as early as 2 min post-L-NAME administration, and returning to normal baseline
values by 6 h after infusion. No significant differences were noted in mean PAP,
whereas the mean RAP was significantly increased between 20 and 30 min postL-NAME administration. It is interesting to note that these alterations in
cardiovascular variables were not related to plasma concentrations of L-NAME or
its metabolite L-NNA (Chapter 7). The estimates for L-NAME and L-NNA half
lives were 3.7 min and 19.5 h, respectively. The lack of correlation between
L-NAME plasma concentrations and effects on systemic blood pressure suggests
that more information has to be gained on the mechanism of L-NAME
biochemistry before adequate dosage regimens can be adequately designed for
L-NAME therapeutic use.
Specifically, the knowledge of intracellular L-NAME metabolism and
pattern of tissue distribution would likely help to clarify the L-NAME mechanism
of action. Moreover, the plasma L-NNA concentrations did not show a correlation
with hypertension in horse in the present study. Overall, results of present study
suggested that even using relatively higher doses than those used in horses
before, undesirable side effects, such as hypertension were transient in horses
but significantly more prolonged than previously reported (Manohar and Goetz,
1998).
Increased mean SAP noted in the present study is in agreement with
previous studies that demonstrated induction of acute (Aisaka et al., 1989;
Fernandez et al., 1993) or chronic (Baylis et al., 1992; Manning et al., 1993)
hypertension following L-NAME treatment in guinea pigs, rats and dogs,
respectively. The L-NAME-induced hypertension, once thought to be exclusively
a result of decreased eNOS-derived NO production (Aisaka et al., 1989), has
also been shown to involve inhibition of nNOS-derived NO pathway (Sander et
al., 1995; Kagiyama etal., 1998). The nNOS-derived NO has been hypothesized
to mediate neurotransmission of the sympathetic vasoconstrictor control of
arterial blood pressure in the brain stem and L-NAME treatment has been
reported to augment sympathetic vasoconstriction in rats (Sander et al., 1997;
Kagiyama etal., 1998) and humans (Sanderetal., 1999). In addition to L-NAME-
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induced

inhibition

of endothelial-dependent vasodilation

and

augmented

sympathetic vasodilation, the hypertension documented in horses in the present
study could have been, at least in part, attributed to nonspecific effects of
L-NAME on vasomotor tone. It has been shown that the alkyl ester moiety has
affinity for muscarinic receptors in vitro suggesting a possible anti-muscarinic
effect for L-NAME (Buxton et al., 1993). However, no evidence of muscarinic
receptor antagonism was found following administration of L-NAME in vivo
(Koss, 1997; Sander et al., 1997), thus, potential hypertension attributed to
L-NAME treatment remains speculative.
Few studies have investigated the effects of L-NAME administration on
exercised-induced pulmonary hypertension in horses (Mills etal., 1996; Manohar
and Goetz, 1998; Kindig etal., 2000) and there have discrepancies in the results.
Mills et al. (1996) and Kindig et al. (2000) reported that L-NAME induced an
increase in mean pulmonary arterial pressure when horses were exercised on a
treadmill, whereas no changes were noted in horses exposed to similar
conditions in another study (Manohar and Goetz, 1998). These investigators
used a similar L-NAME dose (20 mg/kg) in their studies; however, Mills et al.
(1996) infused the drug in the pulmonary artery, whereas others used the
intravenous route (Manohar and Goetz, 1998; Kindig etal., 2000).
Only one research group (Manohar and Goetz, 1998; Manohar et al.,
2001) has reported the effects of L-NAME (20 mg/kg) on horses at rest, and that
was a rapid onset of increased mean PAP, RAP and HR noted during the first 10
min post-L-NAME administration. Cursory evaluation and comparison of the
results of the present study appear to be in contradiction with those from the
study of Manohar and Goetz (1998) and Manohar et al. (2001) because we failed
to detect any statistical difference in mean PAP and mean RAP was only
increased between 20 and 30 min post-L-NAME administration. Furthermore, we
did not detect any statistical increase in HR after L-NAME infusion. However, if
our data were analyzed in the current study only for the first initial 10 min as
Manohar and Goetz (1998) did, we would have found a statistically significant
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difference between mean SAP, PAP, RAP and HR as compared with baseline
values.
Although apparently discrepant, conclusions drawn from these studies
likely differ because different experimental designs were used. Results of the
present study actually expand the previous information that hemodynamic
variables were increased during the first 10 min after L-NAME infusion by
showing that recorded mean SAP and RAP were increased for up to 6 h and
between 20 and 30 min, respectively, in a 6-h monitoring period. In agreement
with the results of the present study are the findings that administration of NOS
inhibitors to conscious cats (DeWitt et al., 1997) and dogs (Nishiwaki et al., 1992)
did not appear to regulate basal pulmonary vasomotor tone. Absence of L-NAME
effects on mean PAP were noted in normal rats chronically treated with L-NAME
(Hampl et al., 1993). In contrast, experimental studies using sheep have
invariably reported L-NAME-induced pulmonary hypertension (Koizumi et al.,
1994; Bone etal., 1998).
In one study, three of five horses were treated with L-NAME hydrochloride
(20 mg/kg) and subjected to exercise on a treadmill (Gallatin et al., 1999). Shortly
after runs were completed, the three fastest horses showed weakness and ataxia
(Gallatin, 1999). Two horses developed anorexia, which resulted in constant
weight loss that lasted weeks. Because the other two horses that ran at slower
speeds did not show any alteration in their health combined with the absence of
severe side effects noted in the horses in the present study (treated with 40
mg/kg) suggest that animals being treated with L-NAME, experimentally or
therapeutically should have restricted exercise. Furthermore, exercise-induced
sweating

in

horses

has

been

shown

to

decrease

following

L-NAME

administration (Mills etal., 1997), a phenomenon that could aggravate the health
condition of horses, including hyperthermia, being treated with L-NAME and
exposed to intensive exercise. It is noteworthy to mention that 30 horses were
treated with L-NAME in studies reported in this dissertation and all but one had
no signs of altered clinical parameters. Perhaps the absence of forced exercise
in our experiments prevented horses from developing unusual clinical signs
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following L-NAME administration associated with hypertension and altered
thermoregulation.
In summary, results of the present study suggest that intravenous bolus
administration of L-NAME hydrochloride (40 mg/kg) induced systemic arterial
hypertension for up to 6 h following intravenous administration. No significant
alterations were noted in the pulmonary vascular system or in heart rate or
cardiac rhythm. Furthermore, no significant altered clinical signs in treated horses
were noted in association with L-NAME treatment, but a mild change in
demeanor, depression and temporary anorexia were observed that subsided
within 12 h after L-NAME treatment.
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CHAPTER 9
SUMMARY AND CONCLUSIONS
Nitric oxide has emerged in the last decade as one of the most versatile
and ubiquitous cell-signaling molecules. These attributes likely reflect its gaseous
nature and ability to react with oxygen species. One of the most striking
biological functions of NO is related to its production by endothelial cells to
promote vasodilator tone. Although the participation of NO in controlling
cardiovascular functions are remarkable, other systems have been found to
utilize the NO pathway. For example, NO participation in the female reproductive
system has been shown at all levels of the hypothalamic-hypophyseal-gonadal
axis.
Nitric oxide modulation of ovarian function has been suggested by studies
reporting an NO-mediated anti-steroidogenic activity in granulosa and luteal cells.
In general, addition of nitric oxide synthase (NOS) inhibitors to cultured granulosa
cells invariably resulted in higher estradiol (E 2) production than that of untreated
granulosa cells. A less pronounced effect of NOS inhibition on steroidogenesis
was noted regarding progesterone (P4) production. Van Voorhis et al. (1994) first
suggested that NO action on granulosa cell steroidogenesis was primarily
through inhibition of E2 production via NO-mediated inhibitory effects on CYP450
aromatase activity, a hypothesis later confirmed by Snyder et al. (1996).
Moreover, studies using granulosa cell cultures that measured only P4 in
conditioned media failed to detect a significant effect on P4 production by the
granulosa cells, thus providing additional evidence to support the hypothesis that
the inhibitory effect of NO on steroidogenesis is primarily through its effects on E2
production
Shukovski and Tsafriri (1994) first suggested a role for NO in ovulation
when

it was

noted that administration

of NOS

synthase

inhibitors to

gonadotropin-stimulated rats inhibited ovulation. Administration of NO donor
agents could reverse the inhibition caused by NOS inhibitors. Moreover,
administration of NO donor agents induced ovulation in a similar fashion to
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ovulation rates induced by administration of human chorionic gonadotropin
(hCG). A role for NO in ovulation was further suggested for mice and rabbits. It
has been demonstrated that NO participation in ovulation involved not only
vascular effects in follicles approaching ovulation (Powers etal., 1995; Bonello et
al., 1996), but also direct participation in hCG-induced up-regulation of follicular
prostaglandins (Falletti etal., 1999).
Another facet of the relationship of NO with prostaglandins and
steroidogenesis in ovarian function was initially suggested by Olson et al. (1996)
who noted that NO significantly decreased E 2 synthesis of luteinized rat ovarian
cells suggesting a possible role for NO in functional luteal regression.
Jaroszewski and Hansel (2000) provided direct evidence for NO participation in
luteolysis when it was noted that intraluteal administration of L-NAME to corpora
lutea of cycling Holstein heifers stimulated P4 and oxytocin secretion in the
microdialysis perfusing medium that prolonged the life span of the corpus luteum.
These initial experiments investigating the relationship between NO and
ovarian physiology clearly pointed to a role for NO in ovarian function, but failed
to provide a conciliatory hypothesis for the apparent discrepancy between
studies reporting a role for NO in ovulation and others suggesting a strong antisteroidogenic activity for NO. One might then ask: “How does the antisteroidogenic activity of NO relate to its role in ovulation?” Another question to
be answered was whether the character of inhibition of ovulation by NOS
inhibitors would be permanent, leading to follicular atresia, or temporary,
resulting in delayed ovulation. One of the primary objectives of the present study
was to design experiments that would answer these two critical questions to
inform what would be the physiological role of NO in ovulation and follicular
steroidogenesis.
Ovarian dynamics of domestic large animals such as mares and cows are
routinely examined by transrectal ovarian ultrasonography. The administration of
NOS inhibitors to mares and cows in estrus in the present study demonstrated
that inhibition of ovulation was temporary (delayed) and anovulation was not
detected in any of the experimental animals treated with NOS inhibitors.
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Therefore, modulation of NO production with NOS inhibitors offers a potential
alternative for controlling ovarian dynamics for experimental or therapeutic
purposes.
In a subsequent study, the concentrations of E 2 and P4 in the spent media
of cultured equine granulosa cells treated with NOS inhibitors and an NO donor
agent were determined. There was a significantly higher E2 concentration in
spent media from equine granulosa cells treated with NOS inhibitors than control
cells or cells treated with an NO donor agent. The overall calculated P4:E2 ratios
of spent media from cells treated with NOS inhibitors were lower than those from
control cells. Both NOS inhibitors AG, a specific inhibitor of iNOS, and L-NAME,
a nonspecific NOS inhibitor, showed similar effects on steroidogenesis, thus
demonstrating that both iNOS and eNOS isoforms are involved in the modulation
of granulosa cell steroidogenesis. It was concluded that the lower P4:E2 ratios
noted in cells treated with NOS inhibitors indicated a permissive role for NO in
functional luteinization.
This hypothesis was further supported by similar results obtained with
bovine granulosa cells cultured for 72 h. Bovine granulosa cells spontaneously
luteinize in vitro, especially when exposed to fetal bovine serum. This time, only
L-NAME altered the pattern of functional luteinization as evidenced by higher E2
concentrations over 72 h, whereas, AG-treated cells did not show a significant
difference from control cells. Potential effects of AG treatment unrelated to NOS
inhibition, such as the well known inhibitory effect on diamine oxidase may have
favored functional luteinization of bovine granulosa cells, thus masking effects on
NOS inhibition.
Because treatment of equine and bovine granulosa cells with NOS
inhibitors suggested a role for NO in functional luteinization, a subsequent
experiment investigated

the

relationship

between

NO

and

hCG-induced

preovulatory follicular luteinization. Accordingly, follicular fluid from mares in
estrus, treated with NOS inhibitors sampled before hCG administration and 36 h
after hCG, was analyzed for NO, P4 and E2 concentrations. In control mares,
there was an increase in follicular NO concentrations after hCG administration
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that paralleled the increase in follicular P4 concentration and decrease in follicular
E2 concentration. It was concluded that hCG stimulation up-regulates the NO
pathway along with the hCG-induced steroidogenesis shift, thereby increasing P4
and decreasing E2 concentrations as ovulation approaches. Treatment with NOS
inhibitors altered the pattern noted in control mares. In general, follicular
steroidogenesis as well as follicular growth was depressed in mares treated with
NOS inhibitors when compared with similar parameters in control mares.
However, it is important to note that E 2 concentrations in follicles of mares treated
with NOS inhibitors did not decrease after hCG treatment, as they did in control
mares, suggesting that CYP450 aromatase activity was preserved despite hCGinduced functional luteinization.
The pharmacokinetics and hemodynamics associated with an intravenous
bolus injection of L-NAME were also investigated in the present study. The
calculated half-lives for L-NAME and L-NNA, its major metabolite, were 3.6 min
and 19.5 h, respectively. Hypertension induced by L-NAME was not present by 6
h after administration. It was concluded that in vivo effects of L-NAME
administration on reproductive parameters investigated in this study are likely not
a result of altered systemic cardiovascular parameters. Furthermore, the major
metabolite L-NNA has a relatively long half life and partially accounts for effects
associated with L-NAME administration.
Results of the present study provide novel information in several aspects
of the relationship between NO and ovarian physiology: 1) administration of NOS
inhibitors delayed ovulation in horses and cows; 2) hCG administration to mares
in estrus not only induced preovulatory luteinization, but also up-regulated the
NO pathway; 3) NO has a permissive role in functional luteinization of equine and
bovine granulosa cells. Effects of administration of AG on ovulation, in vivo
follicular steroidogenesis and in vitro granulosa cell steroidogenesis suggested
that expression of iNOS in regard to ovarian functions is constitutively expressed.
In the female reproductive system, the constitutive expression of isoforms that
are primarily induced in other tissues suits the dynamic and cyclic character of
pivotal cellular and biochemical changes, a recurrent theme in female
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reproductive physiology. Lastly, this study also established for the first time
pharmacokinetic parameters for L-NAME in horses and hemodynamics of horses
at rest treated with L-NAME.
In summary, the knowledge that NO participates in the process of hCGinduced functional preovulatory luteinization will contribute to the understanding
of ovarian dysfunction such as cystic ovarian syndrome and unruptured
luteinized follicles, conditions that affect both domestic animals and humans. In
addition, the pharmacokinetics of L-NAME in horses will help to design
pharmacological therapies of NOS inhibitors for experimental or therapeutic
purposes.
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